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ABSTRACT 
 
The control of cell fate in neural progenitor/stem cells (NPCs/NSCs) is essential 
for central nervous system (CNS) development. NSCs are also found within the 
adult brain. In particular, NSCs in the subventricular zone (SVZ) migrate 
through the rostral migratory stream (RMS) and terminally differentiate in the 
olfactory bulb (OB). However, our understanding of mechanisms regulating cell 
migration during SVZ neurogenesis remains limited.  
Previous work from our lab showed that the promyelocytic leukaemia protein 
(PML), a growth suppressor inactivated in leukaemia, controls cell fate during 
corticogenesis, with implications for regulation of brain size. The main aim of 
the present work was to investigate the role of PML in the context of adult SVZ 
neurogenesis. Our findings show that PML loss leads to reduction of the more 
primitive NSC pool accompanied by expansion of transit-amplifying NPCs and 
neuroblasts. However, PML-deficient neuroblasts display impaired migratory 
capacity through the RMS, thus resulting in reduced number of terminally 
differentiated neurons and a smaller OB. These changes can be recapitulated 
in vitro, demonstrating an intrinsic defect of PML KO NSCs. Mechanistically, 
our findings suggest that PML controls NSC expansion and migration via 
Polycomb Repressive Complex-2 (PRC-2) - dependent suppression of a 
transcriptional programme involving the axon guidance genes Slit2/Robo1 and 
the key epithelial-to-mesenchymal transition (EMT) gene Twist1. Notably, 
Twist1 is part of an amplification loop for transcriptional induction of Slit2.  
I was also involved in work aimed at determining whether the PML/Slit axis is 
functional in neoplastic settings. In this respect, alterations of adult 
neurogenesis are believed to lead to glioblastoma multiforme (GBM), and 
tumour spreading through the brain parenchyma is one of key factors 
underlying GBM aggressiveness. Our work revealed that a PML/Slit axis 
controls cell migration also in GBM cells, suggesting that mechanisms 
underlying cell migration are common to normal and neoplastic cells in the 
CNS. 
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Overall, these findings have important implications for our understanding of 
adult neurogenesis and may provide novel insights into the process of 
oncogenesis in the CNS. 
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1 Introduction 
1.1 An overview 
It is well established that adult stem cells contribute to tissue homeostasis and 
tissue regeneration in different organs due to their landmark capabilities: self-
renewal and generation of mature progeny cells within a given tissue. Likewise, 
the existence of adult neural stem cells (aNSCs) is central to the persistence of 
adult neurogenesis and brain plasticity throughout life. In mammals, the fully 
developed central nervous system (CNS) comprises three differentiated neural 
cell types: neurons, astrocytes and oligodendrocytes. In adulthood, the 
production/replacement of these mature cells from aNSCs are essential for 
normal brain function as well as under hazardous conditions (e.g. injury). The 
maintenance of aNSCs pool, the production of desired cells and subsequent 
migration of cells to the destination in need are under tight control from both 
extrinsic and intrinsic programmes.  Importantly, alterations of these normal 
processes give rise to disease, including brain cancer. The key hallmarks of 
brain cancer are the ability to proliferate indefinitely and to invade through the 
brain parenchyma. Interestingly, normal neural cells and brain cancer cells 
migrate through the same routes (myelin, vessels, soma), suggesting similar 
underlying mechanisms.  
Key nuclear functions such as transcription and chromatin regulation are 
believed to play a crucial role in the orchestration of adult neurogenesis, and 
their deregulation can lead to brain tumourigenesis. In particular, our laboratory 
has a long-standing interest in an interchromatin subdomain called the 
Promyelocytic Leukaemia nuclear body (PML-NB), which has been implicated 
in various cellular functions as well as in tumour suppression. Notably, its 
essential component PML plays an important role in maintaining the stem cell 
pool in both normal and cancerous settings, indicating an oncogenic side of 
PML. Importantly, previous work from our group has implicated PML in 
regulation of cortex development via controlling cell cycle progression of NSCs, 
unravelling a novel role of PML in CNS neurogenesis and stem cell fate. 
Therefore, it was tempting to delineate its role in adult neurogenesis with 
potential implications for our understanding of brain tumour pathogenesis.  
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1.2 PML and PML-NB 
 
The promyelocytic leukaemia (PML) protein was originally identified in acute 
promyelocytic leukaemia (APL) of the reciprocal chromosomal translocation at 
the breakpoint t (15; 17). This results in the juxtaposition of most of PML and 
the retinoic acid receptor α (RARα) gene coding sequences, generating the 
oncogenic PML-RARα fusion gene (de The et al. 1991; Kakizuka et al. 1991; 
Grimwade and Solomon 1997). The PML-RARα fusion protein is the main 
oncogene of APL (Grimwade and Solomon 1997; Melnick et al. 1999) (further 
discussed below). Structurally, PML belongs to the tripartite motif (TRIM) family 
of proteins (TRIM19), characterized by a really interesting gene (RING) 
domain, two zinc-finger motifs B-boxes and a coiled-coil (CC) domain (RBCC) 
(Fig. 1.1A) (Jensen et al. 2001; Reymond et al. 2001). TRIM protein members 
have been implicated in a number of biological and physiological processes, 
many of which are achieved through their ability to form high molecular weight 
complexes by homo-multimerisation or hetero-multimersation (Reymond et al. 
2001; Borden 2002; Napolitano and Meroni 2012). Notably, the CC domain is 
responsible for the homo-multimerisation of TRIM proteins and is indispensable 
for the formation of high order protein complexes and subcellular 
compartments, both in the nucleus and in the cytoplasm (Reymond et al. 
2001).  
The human PML gene is located on chromosome 15q22, which consists of 
nine exons (Jensen et al. 2001). The N-terminal tripartite motif within exon 1 to 
exon 3 is highly conserved, while the C-terminal exons are subject to 
alternative splicing, resulting in seven PML isoforms (PML-I to PML-VII) 
(Jensen et al. 2001; Reymond et al. 2001). Most PML isoforms harbour nuclear 
localisation signal (NLS) in exon 6 (Condemine et al. 2006), which explains 
their predominant nuclear localisation. However, it has been reported that PML-
I contains a nuclear export sequence (NES) in exon 9 (Condemine et al. 2006) 
and its cytoplasmic form exerts crucial functions. In particular, a  
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Figure 1.1: The PML protein isoforms and functional diversity of PML-NBs. 
(A) Alternative splicing of PML C-terminus generates seven isoforms. All PML isoforms 
harbor the RBCC motif within the first three exons. A nuclear localisation signal (NLS) 
is located in exon 6 whereas PML-I harbors a nuclear export sequence (NES) in exon 
9. (B) The many functions regulated by PML-NBs are categorized into: protein 
identification and storage, post-translational modification of proteins and regulation of 
nuclear activities. Many of these functions require recruitment of other proteins onto 
this nuclear hub. R, RING domain; B, B-box; CC, coiled-coil domain; NLS, nuclear 
localisation signal. Adapted from (Bernardi and Pandolfi 2007).  
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study has shown that PML cytoplasmic isoform is an essential modulator of 
transforming growth factor β (TGF-β) signalling (Lin et al. 2004; Salomoni and 
Bellodi 2007). Notably, among all the isoforms, PML-I is the most evolutionarily 
conserved as it shares high homology with murine isoforms. In addition, it is 
also the most abundant isoform in vivo (Condemine et al. 2006; Salomoni et al. 
2008). 
PML is the essential constituent of a nuclear domain of the interchromatin 
space (see Table 1) termed the PML-nuclear body (PML-NB). These 
macromolecular structures were also known previously as Kremer bodies, 
nuclear domains-10 (ND-10) and PML oncogenic domains (PODs) (Bernardi 
and Pandolfi 2007; Lallemand-Breitenbach and de The 2010).  PML-NBs are 
nuclear spherical bodies, ranging from 0.3 to 1.0 μm in width and normally 
number 5-30 per cell in most mammalian cell types. However, the size and the 
number of PML-NBs depend on the cell type and cell cycle phase (Koken et al. 
1995; Dellaire and Bazett-Jones 2004; Dellaire et al. 2006; Bernardi and 
Pandolfi 2007). PML contributes to formation of PML-NBs in part due to its 
RBCC domain. For instance, the RING motif has been reported to carry E3 
ubiquitin ligase activity in the context of other proteins (Joazeiro and Weissman 
2000; Meroni and Diez-Roux 2005; Deshaies and Joazeiro 2009; Ikeda and 
Inoue 2012; Metzger et al. 2012), but whether PML can act as an E3 ligase 
remains to be formally demonstrated. Irrespective of its putative enzymatic 
function, mutations in the PML RING domain disrupt PML-NBs formation in 
vivo potentially due to its role in mediating protein-protein interactions (Borden 
et al. 1995). Moreover, mutants in the zinc fingers called B-boxes disrupt PML-
NBs in vivo but without affecting the multimerisation with wild-type PML in vitro 
(Borden et al. 1996). One mechanism by which B-boxes affect protein-protein 
interactions is via SUMOylation-dependent recruitment of PML-NB components 
(Zhu et al. 2005a) (further elaborated below). Additionally, the coiled-coil 
domain has been shown to be indispensible for PML-NBs formation and growth 
suppressor activity in vivo (Fagioli et al. 1998) (see also below). 
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Table 1: Summary of nuclear microdomains 
Nuclear domain Size (μm) Number/cell Major constituent 
Nuclear speckle 0.8-1.8 25-50 SRSF1/2, Malat1 
PML-nuclear body 0.3-1.0 5-30 PML 
Paraspeckle 0.5 10-20 
PSP1, p54nrb, 
Neat1 
Polycomb body 0.3-1.0 12-16 Bmi1, Pc2 
Nuclear stress body 0.3-3.0 2-10 HSF1, HAP 
Cajal body 0.1-2.0 0-10 Coilin, SMN 
Histone locus body 0.2-1.2 2-4 NPAT, FLASH 
Nucleolus 0.5-8.0 1-4 RNA Pol I 
Perinucleolar 
compartment 
0.2-1.0 1-4 PTB, CUGBP 
Clastosome 0.2-1.2 0-3 
19S, 20S 
proteasome 
*Adapted from (Mao et al. 2011) 
 
Phosphorylation and sumoylation are the two well-characterised post-
translational modifications (PTMs) of PML (Chang et al. 1995; Duprez et al. 
1999; Zhu et al. 2005a). For example, phosphorylation on Serine (Ser) and 
Tyrosine (Tyr) residues of PML (Chang et al. 1995) following stress conditions 
such as DNA damage contributes to PML-mediated tumour suppressive 
effects, for instance induction of apoptosis or sequestration of MDM2 (Yang et 
al. 2002). Importantly, sumoylation of PML is required for recruitment of 
essential components such as Sp100 and Death-associated protein 6 (DAXX) 
to PML-NBs (Ishov et al. 1999; Lallemand-Breitenbach and de The 2010). 
Indeed, the biogenesis of PML-NBs has been proposed as a multi-step event 
involving sumoylation: non-sumoylated PML proteins first dimerise via RBCC 
motif (coiled-coil domain) and subsequently multimerise to form primary PML-
NBs. Following PML sumoylation, a higher order of protein structures is 
formed, resulting in recruitment of SUMO binding motif-containing/sumoylated 
partners to the SUMO binding motif/sumoylated PML to generate mature PML-
NBs (Shen et al. 2006; Lallemand-Breitenbach and de The 2010) (see also 
below). It is important to note that the PML RING domain is required for PML 
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sumoylation, thereby generating PML-NBs (Shen et al. 2006), suggesting that 
PML may mediate its own sumoylation by acting as E3 ligase for SUMO. 
1.2.1 Different roles of PML-NBs 
As mentioned above, PML is believed to contribute to the recruitment of many 
proteins into PML-NBs either transiently or constitutively (Zhong et al. 2000; 
Shen et al. 2006), with functions including DNA damage response, apoptosis 
and tumour suppression (Shen et al. 2006; Lallemand-Breitenbach and de The 
2010) (Alcalay et al. 1998; Ishov et al. 1999; Li et al. 2000; Bernardi and 
Pandolfi 2007) (Fig. 1.1B and further elaborated below). Notably, PML has 
been implicated in nuclear aggregate degradation (Janer et al. 2006), in 
particular those implicated in neurodegenerative polyglutamine (polyQ) 
disorders. One of the PML isoforms, PML IV, contributes to the formation of 
nuclear bodies associated with proteasomal subunits (reminiscent of 
clastosomes, see Table 1), which in turn recruit soluble mutant ataxin-7 and 
trigger its proteasome-dependent proteolysis (Janer et al. 2006). 
Importantly, PML-RARα has been implicated in interacting directly or indirectly 
with chromatin remodellers (Hofmann & Salomoni 2016). For example, PML-
RARα (through PML moiety) interacts with histone H3K9-specific 
methyltransferase SUV39H1 (Carbone et al. 2006), in which PML-RARα 
binding facilitates H3K9me3 establishment at the promoter of RARβ2, a well-
established target of PML-RARα. Moreover, PML-RARα interacts with 
Polycomb repressive complex 2 (PRC2) components SUZ12, EED and EZH2 
(see below 1.5.2 for more detailed discussion on PRC complexes) and recruits 
PRC2 to the RARβ2 promoter leading to increased H3K27me3 repressive mark 
levels (Villa et al. 2007). In addition, the chromatin modifier DAXX (Hollenbach 
et al. 2002; Kuo et al. 2005) interacts with PML-RARα and is believed to 
contribute to neoplastic transformation (Zhu et al. 2005a; Zhou et al. 2006). 
Interestingly, PML-RARα affects the chromatin state indirectly through 
modulating expression levels of histone demethylases, including JMJD3 and 
SETDB1, all of which are PML-RARα targets (Martens et al. 2010). 
Notably, chromatin regulators have been found localised to PML-NBs. For 
instance, the histone acetyltransferase CREB binding protein (CBP) /p300 has 
		 23	
been proposed to be responsible for p53 acetylation through its localisation to 
PML-NBs (Pearson et al. 2000). Furthermore, the histone deacetylase I (HDAC 
I) and co-repressors c-Ski, N-CoR and mSin3A, have been reported to interact 
with PML, mediating transcriptional repression (Khan et al. 2001). Interestingly, 
PML positively regulates the expression of the stem cells factor Oct4 and is 
essential for an open chromatin state (more accessible) of the Oct4 promoter in 
stem cells in part by interacting with Brg1-dependent chromatin remodelling 
complex (BRGC) (Chuang et al. 2011). In addition, it has been reported that 
PML-NBs non-randomly associate with genomic regions where transcription is 
active and a histone-encoding gene cluster is strongly associated with PML-
NBs in S phase (Wang et al. 2004b; Ching et al. 2005; Dellaire et al. 2006). 
Another study has shown that PML interacts directly with SATB1, and the two 
proteins colocalise within PML-NBs. Moreover, SATB1/PML complex binds to 
matrix attachment region (MAR) and regulates formation of chromatin-loop 
structures (P et al. 2007). Interestingly, as mentioned above, DAXX is a 
component of PML-NBs and it has been recently identified as a novel histone 
chaperone for the histone H3.3 variant (Drané et al. 2010; Lewis et al. 2010a; 
Michod et al. 2012; Salomoni 2013)	 (also discussed also below). Despite these 
studies, the precise role of PML and PML-NBs in chromatin remodelling still 
needs to be fully elucidated.  
1.2.2 PML in cancer pathogenesis and stem cell / cancer stem cell 
regulation 
PML exerts a Yin and Yang fashion in the context of cancer. PML was first 
identified as a tumour suppressor in APL, where its normal function is disrupted 
via the dominant negative effects of the PML-RARα fusion protein (de The et 
al. 1991; Kakizuka et al. 1991; Grimwade and Solomon 1997; Mazza and 
Pelicci 2013) (Note: I will not cover here retinoic acid signalling but I will be 
happy to discuss this during the viva). A number of studies have revealed that 
PML exerts a tumour suppressive effect through regulation of the p53 and pRb 
tumour suppressors downstream of oncogenic RAS (Alcalay et al. 1998; Fogal 
et al. 2000; Guo et al. 2000; Pearson et al. 2000; Salomoni and Pandolfi 2002; 
Vernier et al. 2011; Acevedo et al. 2016) and by suppressing PTEN-PI3K-Akt-
mTOR pathway (Trotman et al. 2006; Song et al. 2008) (Fig. 1.2). Moreover, 
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mounting evidence suggests that PML expression is decreased or lost in 
several human cancers of multiple histologic origins, including lung cancer, 
prostate cancer, breast carcinoma, colon adenocarcinoma and nervous system 
tumours (Gurrieri et al. 2004; Dvorkina et al. 2016). Intriguingly, a recent study 
from our lab shows that low PML expression is strongly associated with tumour 
recurrence in neuroblastoma (Dvorkina et al. 2016). Mechanistically, the PML-I 
isoform (not PML-IV) contributes to tumour suppression via upregulation of 
thrombospondin-2 (TSP-2) to inhibit angiogenesis (Dvorkina et al. 2016). 
Furthermore, PML has also been implicated in antiviral response (Chelbi-Alix et 
al. 1995; Lavau et al. 1995; Chelbi-Alix et al. 1998; McNally et al. 2008; 
Geoffroy and Chelbi-Alix 2011). For instance, PML expression was induced by 
interferon along with the number and size of PML-NBs (Chelbi-Alix et al. 1995; 
Lavau et al. 1995; Chelbi-Alix et al. 1998). Of note, it has been proposed that 
viruses evade cellular resistance for viral infections by co-localising with PML 
and disrupt PML-NBs (Geoffroy and Chelbi-Alix 2011). Additionally, PML 
confers antiviral function by inducing p53-dependent apoptosis of infected cells 
(McNally et al. 2008). In this way, it has been proposed that PML eliminates 
infected cells as they are susceptible to oncogenic transformation.  
Although many studies have suggested that PML works via regulating the 
localisation of nuclear factors to PML-NBs (e.g. p53 (Ferbeyre et al. 2000; 
Pearson et al. 2000; Bernardi and Pandolfi 2003; Louria-Hayon et al. 2003); 
Fig. 1.2), there is also evidence of PML-NB-independent mechanisms. For 
instance, PML regulates p53 stability via sequestration of Mdm2 in the 
nucleolus after cellular stress (i.e. DNA damage), challenging the canonical 
model by which PML regulates p53 and adding additional layer of complexity 
on PML in tumour suppression.  
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Figure 1.2: Role of PML in regulating cell growth and apoptosis pathways. 
PML colocalises with pRb to the PML-NBs and activates pRb via PP1α-dependent 
dephosphorylation, thereby preventing cell cycle progression. Conversely, PML loss 
leads to pRb hyperphosphorylation, thus inhibiting E2F binding capacity and 
subsequent growth suppressive effect. PML also recruits p53 to the PML-NBs and 
regulates p53 through post-translational modifications, including acetylation (Ser 15) 
and phosphorylation (Lys 382). In addition, PML indirectly regulates p53 stability via 
Mdm2 sequestration, thus preventing Mdm2-dependent p53 degradation. Finally, PML 
inhibits Akt via protein phosphatase 2 (PP2A)-mediated dephosphorylation of Akt as 
well as by inhibiting mTOR. Additionally, PML inhibits PI3K/Akt pathway through 
sustaining PTEN, which acts as an inhibitor of PI3K/Akt pathway. Adapted from 
(Salomoni et al. 2012). 
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Interestingly, there is also evidence supporting PML oncogenic functions within 
established tumours (Ito et al. 2008; Carracedo et al. 2012; Ito et al. 2012) in 
part by maintaining the stem cell/cancer stem cell (CSC) pool of chronic 
myeloid leukaemia (CML). Specifically, PML is highly expressed in 
hematopoietic stem cells (HSCs) and leukaemia-initiating cells (LICs) and 
contributes to their maintenance. Interestingly, rapamycin treatment restores 
the phenotypes observed in PML-deficient HSCs and LICs, indicating PML 
maintains HSCs and LICs pool by suppressing mTOR activity (Ito et al. 2008). 
In addition, a recent study suggests that PML maintains HSCs via promoting 
fatty acid oxidation (FAO) by regulating PPAR-δ. As a result, PML loss (or 
inhibition of PPAR-δ expression or FAO) results in symmetric stem cell division, 
leading to loss of HSCs self-renewal capacities and exhaustion of HSCs (Ito et 
al. 2012). More specifically, PML negatively regulates PPAR-δ coactivator 1A 
(PGC1A) acetylation and actively regulates PPAR signalling and FAO, which 
promotes ATP production. Interestingly, a similar pathway was shown to 
control breast cancer cells survival (Carracedo et al. 2012). Accordingly, PML 
expression in breast cancer is correlated with poor prognosis (Carracedo et al. 
2012). In this respect, a previous study reported that PML controls mammary 
gland development, and its loss disturbs the balance of two distinct mammary 
luminal cell progenitor populations (Li et al. 2009b). It would be interesting to 
determine whether a similar FAO pathway (see above) is also involved in 
normal homeostasis and potential transformation in the mammary gland.  
These studies suggest that PML may represent a potential therapeutic target in 
a number of human neoplasms. In this respect, APL patients treated with 
arsenic trioxide (As2O3) alone have up to 70% cure rate and this is due to 
As2O3-induced degradation of the oncogenic fusion protein PML-RARα 
(Lallemand-Breitenbach et al.). Intriguingly, it has been shown that this 
degradation is in part mediated by direct binding of As2O3 cysteine residues 
within the RBCC motif of PML and further triggering PML oligomerisation and 
enhanced sumoylation-induced degradation (Zhang et al. 2010). Of note, 
As2O3-induced production of reactive oxygen species (ROS) promotes PML 
oligomerisation, which leads to cysteine oxidation to promote formation of 
covalent disulphide bonds and further results in PML ubiquitylation and PML-
NBs degradation (Jeanne et al. 2010; Zhang et al. 2010).  
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Collectively, these studies highlight the complex and multifaceted role of 
PML/PML-NBs in contributing to distinct cellular functions as well as in 
oncogenesis. Importantly, the emerging involvement of PML in stem cell 
biology has added another layer of complexity to its function (Fig. 1.3). On one 
hand, its targetting in cancer stem cells could limit tumour recurrence and/or 
resistance to therapy. On the other hand, increasing PML expression could be 
beneficial to support haematopoiesis as well as stem cell function in other 
tissues.  
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Figure 1.3: Emerging role of PML in stem cell/cancer stem cell maintenance. 
PML facilitates the maintenance of both cancer and non-cancerous stem cells. More 
specifically, PML maintains hematopoietic stem cells (HSCs) and leukaemia-initiating 
cells (LICs) via inhibition of mTOR. Notably, PML also maintains HSCs through 
regulating metabolism, by which PML facilitates deacetylation of PGC1A and resulting 
in PPARδ  activation and fatty acid oxidation (FAO) to enhance ATP production. 
PPARδ/FAO thus promotes asymmetric division of HSCs to repopulate the stem cell 
pool. PML also controls mammary gland development. It is unclear whether PML 
regulates mammary luminal progenitors through a similar metabolic pathway observed 
in HSCs.  
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1.3 Stem cells in adult tissues 
Small populations of somatic stem cells are required for tissue homeostasis 
and tissue regeneration in different organs throughout life (Weissman 2000; 
Barker et al. 2010; Biteau et al. 2011). It has also been proposed a model 
whereby these subpopulation of cells represent units of evolution (Weissman 
2000): based on this model, germline stem cells outcompete the “losers” for 
gonad niches in protochordate colonial tunicates and mice, and somatic 
hematopoietic stem cells (HSCs) in mice and humans also compete for bone 
marrow niches for clonal expansion (Weissman 2000; Weissman 2015). At the 
single cell level, stem cell are defined by their ability for self-renewal, which is 
to maintain/regenerate themselves over a long period of time, and the 
capability to differentiate into specialised cell types within respective tissues 
(Barker et al. 2010). Based on their potential to give rise to differentiated cell 
types, stem cells are classified hierarchically with descending order as: 
totipotent, pluripotent, multipotent, oligopotent and unipotent over 
developmental stages (Wagers and Weissman 2004), with unipotent cells only 
being able to generate one mature cell type. As such, adult stem cells are 
characterised by their abilities for self-renewal and multipotency. Contrary to 
the relatively quiescent stem cells, transit-amplifying cells, their direct progeny, 
are fast-cycling and will terminate as functional cells within the tissue after a 
limited rounds of cell division (Barker et al. 2010), with different 
kinetics/dynamics in physiological conditions versus in response to stimuli or 
injury (Charruyer et al. 2009). Importantly, the differentiation process needs to 
be tightly regulated as emerging evidence has shown that alterations of cell 
plasticity and cell fate/lineage specification due to oncogenic insult can lead to 
neoplastic transformation and cancer development (Hanahan and Weinberg 
2011). In particular, the fact that stem cells persist longer than other cells 
together with their proliferative potential make them susceptible to accumulate 
mutations throughout life, which can trigger oncogenic transformation and 
eventually result in cancer development (Reya et al. 2001; Li and Neaves 
2006). Several lines of evidence suggest the existence within established 
tumours (see also above) of a subpopulation of stem cell-like (cancer stem 
cells, CSCs) with the ability to self-renew, at least to partially differentiate to 
other cell types (tumour bulk) and disseminate and metastatise to distant 
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organs (Reya et al. 2001; Hanahan and Weinberg 2011; Nguyen et al. 2012). 
However, it is important to note that CSCs are not necessarily solely derived 
from transformation of normal stem cells, as restricted progenitor cells or 
mature cells may also become transformed to acquire the properties of CSCs 
(Reya et al. 2001). 
1.4 NSCs and adult neurogenic niches 
The existence of adult neural stem/precursor cells (aNSCs) in the mammalian 
brain has revolutionised our understanding of brain plasticity and has added an 
additional layer of complexity to brain functions (Reynolds and Weiss 1992; 
Bond et al. 2015). Like other somatic stem cells, NSCs are rare and exert the 
fundamental functions of stem cells: self-renewal and the ability to generate a 
heterogeneous cell progeny upon differentiation (multipotency) (Doetsch et al. 
1999b; Gage 2000; Bond et al. 2015). Upon activation, aNSCs undergo two 
modes of division: symmetric division that generates either two aNSCs or two 
progenitor cells, or asymmetric division give rise to one aNSC to maintain the 
stem cells pool and one progenitor cell (Morrison and Kimble 2006). In 
particular, aNSCs are able to give rise to neurons, the functional building 
blocks of information transmission, and glia cells (astrocytes and 
oligodendrocytes), which support the normal functions of neurons (Nait-
Oumesmar et al. 1999; Gage 2000; Picard-Riera et al. 2002; Menn et al. 2006; 
Gonzalez-Perez et al. 2009; Gage and Temple 2013; Ortega et al. 2013b; Lim 
and Alvarez-Buylla 2014; Xing et al. 2014; Bond et al. 2015).  
In the adult mammalian brain, there are two main neurogenic niches where 
aNSCs are found (Fig. 1.4A): the subgranular zone (SGZ) of the dentate gyrus 
(DG) within the hippocampus and the subventricular zone (SVZ; also termed as 
subependymal zone, SEZ) lining the lateral ventricles in the forebrain (Zhao et 
al. 2008; Urban and Guillemot 2014). In brief, SGZ NSCs within the DG named 
radial glial-like cells (RGL, type B cells) generate intermediate progenitor cells 
(IPCs, type D cells), which in turn produce neuroblasts after a limited 
expansion. Newborn neuroblasts undergo tangential migration along the SGZ 
and eventually integrate as dentate granule neurons (type G cells) in dentate 
granule cell layer (van Praag et al. 2002; Ehninger and Kempermann 2008; 
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Urban and Guillemot 2014). With regard to SVZ NSCs, it has been proposed 
recently that slow-dividing embryonic radial glial cells (RGCs) are the source of 
SVZ aNSCs (Fuentealba et al. 2015; Furutachi et al. 2015). SVZ aNSCs (type 
B cells) are able to produce transit-amplifying progenitor cells (TAPs, type C 
cells) upon activation. After a few divisions, type C cells in turn generate 
migrating neuroblast cells (type A cells), which form a chain ensheathed by 
glial cells and migrate anteriorly through the rostral migratory stream (RMS) 
using a chain migration mechanism. Once they reach the olfactory bulb (OB), 
they then migrate radially, further develop and integrate into the existing neural 
circuits as local interneurons (Temple and Alvarez-Buylla 1999; Alvarez-Buylla 
and Garcia-Verdugo 2002). More specifically, newborn inhibitory interneurons 
develop into granule cells (GCs) and periglomerular cells (PGCs) located in the 
granule layer and glomerular layer, respectively (Kosaka et al. 1995; Carleton 
et al. 2003; Nagayama et al. 2014). Moreover, GCs and PGCs can be further 
divided into several subtypes. Based on their localisation in granule cell layers 
and the expression status of calcium-binding protein calretinin (CalR+), GCs 
are subdivided into superficial GCs (superficial granule layer), deep GCs (deep 
granule layer) and CalR+ GCs (Price and Powell 1970; Orona et al. 1983; 
Jacobowitz and Winsky 1991; Alvarez-Buylla et al. 2008). In terms of PGCs, 
there are CalR+ PGCs, tyrosine hydroxylase-expressing (TH+) dopaminergic 
PGCs and calbindin (CalB+) PGCs (Kosaka et al. 1997; Parrish-Aungst et al. 
2007; Alvarez-Buylla et al. 2008). The existence of these subtypes highlights 
the extensive heterogeneity and complexity of OB neurons. Of note, this 
continual SVZ-RMS-OB chain migration serves as the fundamental basis of 
production/replacement of OB neurons throughout life in rodents.  
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Figure 1.4: Neurogenic niches in adult mammalian brain and cytoarchitecture of 
the subventricular zone.	
(A) A sagittal view of the two neurogenic niches in an adult mammalian brain, showing 
the subgranular zone (SGZ) along the dentate granule cell layer of the hippocampus 
and the subventricular zone (SVZ) in the forebrain lining the lateral ventricle. St, 
striatum; CC, corpus callosum; LV, lateral ventricle; OB, olfactory bulb; DG, dentate 
gyrus; RMS, rostral migratory stream; Hipp, hippocampus. Red: SVZ. Yellow: SGZ. (B) 
A coronal view of the organisation of the SVZ. Of note, ependymal cells have multiple 
cilia to contact the CSF where as type B1 cells make contact with CSF using single 
cilium.  B, SVZ astrocytes; C, transit-amplifying progenitor cells; A, migrating 
neuroblasts. Adapted from (Alvarez-Buylla and Garcia-Verdugo 2002; Bond et al. 
2015). 
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1.4.1 Rodent SVZ organisation/cellular composition 
The organisation of SVZ and its cytoarchitecture provide the environmental 
support for NSCs within this niche (Fig. 1.4B). The SVZ is positioned next to 
the ependymal cell layer, which splits the SVZ from the ventricle cavity 
(Alvarez-Buylla and Garcia-Verdugo 2002; Zhao et al. 2008). The composition 
of cells within the SVZ display heterogeneity that can be defined based on their 
morphology and molecular markers (see Table 2): ependymal cells (E cells) 
separate SVZ from the ventricular space, which is filled with cerebrospinal fluid 
(CSF) and the astrocytic stem cells (type B1 cells) undergo asymmetric 
divisions to produce transit-amplifying progenitor cells (type C cells). Notably, E 
cells have multiple cilia to contact the CSF whereas B1 cells make connection 
with the ventricular space via a single cilium (Doetsch et al. 1999b; Alvarez-
Buylla and Garcia-Verdugo 2002), resembling the neuroepithelial stem cells in 
the embryo (Cohen and Meininger 1987). Type C cells in turn give rise to 
migrating neuroblasts (type A cells), which are ensheathed by astrocytic type 
B2 cells thereby forming a cylindrical morphology. Of note, B2 cells do not 
connect to the CSF (Doetsch et al. 1999b; Imayoshi et al. 2008b; Bond et al. 
2015). Thus, the adult SVZ in rodents can be subdivided into three 
compartments: layer I contains the ependymal cells and the apical astrocytic B 
cells; layer II contains the type C and type A cells in conjunction with the cell 
body of B cells; layer III is composed of basal B cells adjacent to blood vessels 
(Alvarez-Buylla and Garcia-Verdugo 2002; Bond et al. 2015). 
Table 2: Cellular composition of SVZ and their molecular markers	
Composition of SVZ Molecular markers 
Ependymal cells (E cells) CD24; S100β; Nestin; Vimentin 
Astrocytes (B1 cells) CD133; GFAP; Nestin; Vimentin 
Astrocytes (B2 cells) GFAP; Nestin; Vimentin 
Transit-amplifying progenitor cells 
(C cells) 
Ascl1; Nestin; Dlx1 
Neuroblasts (A cells) DCX; PSA-NCAM; βIII-tubulin; Nestin 
*Adapted from (Capilla-Gonzalez et al. 2015) 
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It has been suggested that SVZ type B cells and type A cells are dividing in 
addition to type C cells (Lois and Alvarez-Buylla 1994; Menezes et al. 1995; 
Alvarez-Buylla and Garcia-Verdugo 2002). Moreover, there is evidence that 
type E ependymal cells function as neural stem cells in vivo and generate OB 
neurons (Johansson et al. 1999), although the stem cell nature of type E cells 
is being debated. These studies raise the question: what are the genuine 
aNSCs within SVZ? Interestingly, a study has shown that a mixture of B and C 
cells are capable to differentiate into A cells whereas no self-renewal of A cells 
was found when cultured in vitro (Lim and Alvarez-Buylla 1999; Alvarez-Buylla 
and Garcia-Verdugo 2002), suggesting A cells are not stem cells. Furthermore, 
another important study has shown that following the treatment of Ara-C, an 
antimitotic drug, C and A cells were eliminated. However, only the remaining B 
cells divide to repopulate C and A cells, indicating that SVZ B cells are indeed 
NSCs in vivo, further supported by the finding that they are able to grow as 
multipotent neurospheres in vitro (Doetsch et al. 1999a; Alvarez-Buylla and 
Garcia-Verdugo 2002).  
As mentioned above, there are several OB neuron subtypes developed via the 
SVZ-RMS-OB route. Interestingly, it has been proposed that the heterogeneity 
of OB interneurons stems from the heterogeneity of the SVZ NSCs (Merkle et 
al. 2007; Alvarez-Buylla et al. 2008; Merkle et al. 2014). Particularly, the spatial 
organisation of NSCs within SVZ contributes to their multifaceted 
developmental potential. As mentioned earlier, aNSCs derive from embryonic 
RGCs (Fuentealba et al. 2015; Furutachi et al. 2015). Likewise, this 
conservation is also true with respect to the adult SVZ region and the 
developing lateral ganglionic eminence (LGE), as a common pattern of 
transcription factors is found expressed in both regions, including Ascl1 and 
Pax6 (Stenman et al. 2003; Parras et al. 2004; Guillemot 2005; Kohwi et al. 
2005; Alvarez-Buylla et al. 2008).  
Notably, a landmark study utilising adenovirus-expressing Cre recombinase 
system targeting neonatal brain has shown that RGCs from different regions 
within the SVZ give rise to distinct types of OB neurons in vivo (Merkle et al. 
2007). For instance, the CalB+ PGCs are derived from ventrolateral SVZ, 
whereas dorsal subpallial SVZ predominantly give rise to superficial GCs. 
Intriguingly, this regional specification is shared by the aNSCs as aNSCs 
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generate similar OB neurons as RGCs targetted in the matching region (Merkle 
et al. 2007). Furthermore, grafting experiments relocating postnatal SVZ NSCs 
from one region to another demonstrate that SVZ NSCs possess regional 
specification and which is sustained in propagating cells in vitro (Merkle et al. 
2007), indicating location-based plasticity is established at an early stage 
during development and is maintained after birth (Alvarez-Buylla et al. 2008). 
Another study has reported that this regional specification seems to be retained 
in vitro under a defined monolayer based cell culture system mimicking entire 
events during SVZ neurogenesis (Scheffler et al. 2005). Furthermore, a recent 
study has reported four previously unknown OB interneuron subtypes (type 1-
4) that are derived from domains within the anterior ventral ventricular (V)-SVZ 
region, which accounts for less than 5% of the V-SVZ surface area. In addition, 
Nkx6.2+ and Zic+ aNSCs contribute to the generation of these interneuron 
subtypes, with their expression correlating with the spatial origin of these novel 
OB interneurons, indicating the complexity of aNSC heterogeneity even within 
restricted microdomains (Merkle et al. 2014). Collectively, these studies 
suggest that SVZ NSCs are not homogenous and they are the source of 
heterogeneous OB interneurons.   
1.4.2 Regulation of SVZ aNSC self-renewal and entry into differentiation 
As mentioned above, multipotent aNSCs should in theory be able to give rise to 
all the mature cell types, including neurons, astrocytes and oligodendrocytes. 
However, several recent studies challenged the multipotent nature of aNSCs 
(Bonaguidi et al. 2011; Ortega et al. 2013a; Bond et al. 2015; Calzolari et al. 
2015). There is one study utilising in vitro live imaging and single-cell tracking 
of cultured mouse adult SVZ NSCs and revealed that these NSCs generate 
either oligodendrocytes or neurons, but never both (Ortega et al. 2013a). 
Another study using in vivo clonal labelling of individual adult SVZ NSCs and 
found that the self-renewal rate of aNSCs and the diversity of OB interneuron 
subtypes generated from aNSCs decline with age (Calzolari et al. 2015). In 
addition, one in vivo study combining clonal-tracing and fate-mapping 
techniques has shown that SGZ NSCs give rise to neurons and astrocytes only 
(Bonaguidi et al. 2011). Collectively, these studies suggest that endogenous 
aNSCs have limited differentiation potential. Intriguingly, it has been speculated 
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that aNSCs are indeed multipotent, however, the neurogenic niches may 
suppress their lineage specification potential (Bond et al. 2015). Evidence 
supporting this came from in vitro studies showing that aNSCs from both SGZ 
and SVZ are able to give rise to all the neural lineages (Reynolds and Weiss 
1992; Palmer et al. 1997; Bond et al. 2015). However, SGZ aNSCs give rise to 
dentate granule neurons and astrocytes whereas SVZ aNSCs generate OB 
interneurons as well as corpus callosum oligodendrocytes in vivo (Bond et al. 
2015), suggesting that neurogenic niches may shape the lineage specification 
potential of adult NSCs.  
Indeed, the regulation of adult NSCs is orchestrated both extrinsically and 
intrinsically. Extrinsic cues from the niche have been reported to regulate 
aNSCs in a number of circumstances. For instance, E cells within the SVZ 
express Noggin, an antagonist of bone morphogenetic protein (BMP), to 
promote neurogenesis and neuronal differentiation by blocking endogenous 
BMP signalling (Lim et al. 2000). In addition, a recent study has shown that 
endothelial cells in the SVZ maintain aNSC quiescence by expression of 
ephrinB2 and Jagged1, which suppress cell-cycle progression and inhibit 
differentiation by inducing stemness genes. In vivo deletion of either gene 
results in aNSC depletion (Ottone et al. 2014). Another study has found that 
endothelial cells in mouse SVZ secrete neurotrophin-3, which is required for 
aNSC quiescence and maintenance (Delgado et al. 2014). Moreover, one 
study has shown that EGFR-expressing progenitor cells in mouse SVZ affect 
the number and self-renewal ability of aNSC via Notch signalling (Aguirre et al. 
2010), reinforcing the importance of cell-cell interaction within the niche in 
regulation of aNSCs. Intriguingly, one study has reported that GDF11 found in 
the blood of young mice contribute to vascular remodelling and promotes an 
increase in SVZ aNSC number and neurogenesis, which is linked to an 
improvement in olfactory discrimination in aged mice (Katsimpardi et al. 2014). 
This study highlights the significance of extrinsic systemic circulating factors 
that are able to affect aNSCs.  
Intrinsic programmes, such as transcription factor networks, underpin one of 
the most potent mechanisms involved in regulation of aNSC self-renewal and 
differentiation. For example, one study has shown that the SRY-box 
transcription factor 2 (Sox2) can be directly activated by arsenite-resistance 
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protein 2 (Ars-2) in order to promote aNSC self-renewal in adult SVZ (Andreu-
Agullo et al. 2012), suggesting an overlapping transcriptional role of Sox2 in 
regulation of aNSC homeostasis in both SGZ and SVZ. Interestingly, another 
paper has found that the basic helix-loop-helix (bHLH) transcription factor Olig2 
is expressed in SVZ aNSCs and is necessary to direct them toward astrocytic 
and oligodendrocytic differentiation patterns (Marshall et al. 2005). Another 
bHLH transcription factor, Ascl1, was found expressed in a subset of type B1 
cells in SVZ and Ascl1 is known to be essential for neuronal and 
oligodendroglial specification (Schuurmans and Guillemot 2002; Parras et al. 
2004; Kohwi et al. 2005). Moreover, Id1, also a bHLH family member, is highly 
expressed in B1 cells in adult SVZ. Of note, the level of Id1 seems to be crucial 
for aNSC self-renewal (Nam and Benezra 2009). Another transcription factor, 
FoxO3 has been reported to express in adult SVZ NSCs and have roles in 
preventing premature depletion of aNSCs thus contributing to aNSC 
maintenance (Renault et al. 2009). Finally, the orphan nuclear receptor Tlx has 
been reported to be expressed in adult SVZ B cells. Interestingly, Tlx ablation 
leads to complete abolishment of SVZ neurogenesis, indicating the crucial role 
of Tlx in adult SVZ NSCs homeostasis (Liu et al. 2008).  
Importantly, cell cycle regulators have been implicated in regulation of SVZ 
NSC self-renewal and differentiation (Salomoni and Calegari 2010). For 
instance, it has been shown that depletion of cyclin-dependent kinase inhibitor 
(CDKi) p21Cip1 results in SVZ NSCs exhaustion both in vivo and in vitro, 
suggesting p21Cip1 is necessary for NSCs life-long maintenance (Kippin et al. 
2005). Moreover, another recent paper has shown that p21Cip1 negatively 
regulates Sox2 expression through directly binding to its enhancer, therefore 
regulating adult SVZ NSCs expansion (Marques-Torrejon et al. 2013). This 
study also highlights the crosstalk between transcription factors and cell cycle 
regulators, implicating a dynamic regulation network of intrinsic modulators.  
1.4.3 Regulation of RMS migration 
As mentioned above, the continual migration of newly generated neuroblasts 
from SVZ via RMS underpins OB neurogenesis. It has been reported that at 
E15 in rodents, cells expressing neuronal markers are beginning to line up in 
chains, exhibiting the hallmark of postnatal RMS (Pencea and Luskin 2003). 
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Once established, this route from SVZ to OB is a 5mm long journey and is 
maintained throughout adulthood (Lois and Alvarez-Buylla 1994; Doetsch and 
Alvarez-Buylla 1996). Notably, similar to SVZ aNSCs, this chain migration is 
subject to dynamic regulations by intrinsic and extrinsic factors. Intrinsic factors 
have been implicated in regulating cell morphology and motility during SVZ-
RMS migration (Francis et al. 1999; Kappeler et al. 2006; Koizumi et al. 2006; 
Ocbina et al. 2006; Hirota et al. 2007; Mejia-Gervacio et al. 2011; Capilla-
Gonzalez et al. 2015). For instance, cyclin-dependent kinase 5 (CDK5), a 
serine/threonine kinase, has been implicated in regulation of neuronal 
migration (Dhavan and Tsai 2001). CDK5 conditional deletion in mice results in 
irregular chain formation and impairments in orientation and speed of 
neuroblast migration, which leads to an accumulation of neuroblasts in SVZ 
and RMS (Hirota et al. 2007). Ion transporter NKCC1 has been implicated in 
cell size control through its regulation of cellular volume (Lytle and Forbush 
1996; Strange 2004). Intriguingly, one study has shown that NKCC1 controls 
neuroblast migration in RMS in mice and its activity is required for normal 
migratory speed (Mejia-Gervacio et al. 2011). Another example is doublecortin 
(DCX), a microtubule-associated protein that is highly expressed in migrating 
neurons (Gleeson et al. 1999). An in vitro study has shown that DCX 
knockdown by RNA-interference reduced SVZ cell migration, while re-
expression of DCX after knockdown rescued migration (Ocbina et al. 2006). 
Moreover, DCX deletion in vivo results in decreased RMS migration as cells 
migrate in a disorganised manner in association with bipolar morphology 
(Kappeler et al. 2006; Koizumi et al. 2006).  
With regard to extrinsic programmes, mounting evidence has shown that 
multiple factors control RMS migration via cell-cell interaction and cell-
extracellular matrix (ECM) interaction (Bonfanti et al. 1992; Yang et al. 1992; 
Tomasiewicz et al. 1993; Cremer et al. 1994; Hu et al. 1996; Peretto et al. 
1997; Jacques et al. 1998; Mason et al. 2001; Hack et al. 2002; Emsley and 
Hagg 2003; Bonfanti 2006; Courtes et al. 2011; Mobley and McCarty 2011). As 
mentioned earlier, migrating neuroblasts are ensheathed by astrocytes termed 
gliotubes (Jankovski and Sotelo 1996; Peretto et al. 1997; Alvarez-Buylla and 
Garcia-Verdugo 2002). Although it has been reported that the chain migration 
is independent of astrocytes (Wichterle et al. 1997), these astrocytes may 
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secrete factors that facilitate neuroblast migration as well as provide pro-
survival and directional guidance to migrating neuroblasts (Mason et al. 2001; 
Alvarez-Buylla and Garcia-Verdugo 2002), highlighting the importance of cell-
cell interaction in the RMS. In addition, the polysialylated form of neural cell 
adhesion molecule (PSA-NCAM) has been reported to be expressed in 
migrating neuroblasts throughout RMS (Bonfanti and Theodosis 1994; Bonfanti 
2006). Notably, PSA-NCAM has been implicated in providing intercellular 
space between migrating neuroblasts and the ensheathed astrocytic gliotubes 
to stimulate their movement (Yang et al. 1992; Hu et al. 1996). Importantly, 
NCAM mutant (loss of NCAM-180, the long cytoplasmic domain) shows a 
decrease in RMS migration (Ono et al. 1994), and PSA-NCAM-deficient mice 
exhibit a reduction in overall brain weight and a profound decrease in OB size 
(Cremer et al. 1994).  
The cell-ECM interaction also contributes to the establishment of a pro-
migratory environment in RMS. For example, the transmembrane receptors 
integrins mediate interactions between the cytoskeleton and the extracellular 
matrix (Hynes 2002). Ablation of integrin β8 in mice results in aberrant chain 
migration and a reduced OB (Mobley and McCarty 2011). In addition, α6β1 
integrin has been shown to be essential for chain migration (Jacques et al. 
1998; Emsley and Hagg 2003). Furthermore, the ECM glycoprotein Reelin, 
functions as a detachment signal in the postnatal mouse brain. Specifically, 
cells detach from Matrigel in response to addition of exogenous Reelin, whilst 
in a Reelin mutant	 line, where secretion of the protein is impaired, the switch 
from tangential chain migration to radial migration in OB is abolished (Hack et 
al. 2002).  
Another part of this dynamic regulatory network is the presence of soluble 
factors and secreted proteins that act as chemoattractant or chemorepellent 
signals during RMS migration. The secreted protein Sonic hedgehog (Shh) 
displays various types of functions during development (Ingham and McMahon 
2001; Varjosalo and Taipale 2008), such as regulation of cell proliferation and 
differentiation. Interestingly, several studies have shown that in the adult 
mouse brain, Shh functions as chemoattractant in the context of chain 
migration (Angot et al. 2008; Hor and Tang 2010; Ihrie et al. 2011). In this 
respect, migrating neuroblasts in SVZ-RMS express Shh receptor Patched, 
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and blockage of Shh signalling impairs neuroblast migration (Angot et al. 
2008). Another example is the family of Netrin proteins, which regulate axon 
guidance in the developing nervous system (Kennedy et al. 2006). A recent 
study has shown that deletion of the Netrin receptor Neogenin, leads to 
accumulation of neuroblasts in the RMS accompanied by decreased migration 
to the OB, an effect that has been recapitulated in vitro (O'Leary et al. 2015). 
Importantly, the axon guidance regulators and chemorepellent Slits (Slit1-Slit3) 
and their receptors Robo proteins (Robo1-Robo4) (Brose et al. 1999; Long et 
al. 2004) have been implicated in CNS cell proliferation and RMS migration (Hu 
1999; Wu et al. 1999; Nguyen-Ba-Charvet et al. 2004; Kaneko et al. 2010; 
Borrell et al. 2012; Blockus and Chedotal 2014) (further discussed in the 
Results chapters). In particular, Slit1 and Slit2 are found expressed in the adult 
septum and have roles in orientating and inhibiting SVZ cell migration (Nguyen-
Ba-Charvet et al. 2004). Collectively, these studies highlight the crucial roles of 
intrinsic and extrinsic factors in controlling cell migration in the adult SVZ-RMS-
OB route.  
1.4.4 Migration upon injury 
It has long been believed that OB is the only destination for SVZ-RMS 
migration in adult rodents (Alvarez-Buylla and Garcia-Verdugo 2002). 
Intriguingly, there is evidence suggesting that migrating neuroblasts persist in 
RMS even after elimination of OB (Kirschenbaum et al. 1999), indicating that 
OB is not essential for RMS migration. Another study has revealed additional 
migratory pathways in which young neurons migrate from the SVZ to different 
forebrain areas, including cortex, striatum and nucleus accumbens (Inta et al. 
2008), suggesting the capability of these cells to migrate across the brain 
parenchyma in addition to the RMS/OB route. In this respect, there is a large 
body of literature proposing that SVZ-derived neuroblasts are able to migrate to 
injury sites and subsequently conduct repair processes in the adult brain 
(Arvidsson et al. 2002; Goings et al. 2004; Imitola et al. 2004; Sundholm-Peters 
et al. 2005; Liu et al. 2006a; Yamashita et al. 2006; Nait-Oumesmar et al. 2007; 
Del Carmen Gomez-Roldan et al. 2008; Kojima et al. 2010; Otero et al. 2012; 
Kang et al. 2013; Capilla-Gonzalez et al. 2014). Importantly, this aberrant 
migration upon injury is regulated by variety of different factors. For instance, a 
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number of growth factors have been implicated in this migration, including 
fibroblast growth factor-2 (FGF-2) (Lachapelle et al. 2002), epidermal growth 
factor (EGF) (Sundholm-Peters et al. 2005), insulin-like growth factor-1 (IGF-1) 
(Yan et al. 2006) and vascular endothelial growth factor (VEGF) (Wang et al. 
2007). Additionally, cytokines/chemokines also contribute to the recruitment of 
migrating cells to the damage sites upon injury (Imitola et al. 2004; Jaerve and 
Muller 2012; Capilla-Gonzalez et al. 2015). For example, following injury, SVZ 
neurogenesis is increased, and stromal cell-derived-factor-1 alpha (SDF-1) 
directs newly generated neurons migrate into the injury site (Imitola et al. 2004; 
Capilla-Gonzalez et al. 2015). Moreover, ECM-associated proteins have been 
found to function in injury-induced migration (Barkho et al. 2008; Courtes et al. 
2011). For example, matrix metalloproteinases (MMPs), which are known to 
regulate ECM remodelling during development (Vu and Werb 2000) have been 
implicated in injury-induced migration. In particular, a study has reported that in 
response to injury-induced factors (SDF-1 and VEGF), MMP-3 and MMP-9 are 
upregulated in neuroblasts mediating their migration, whereas blockage of 
either MMP-3 or MMP-9 impairs the differentiation capacity of aNSCs as well 
as the injury-induced migration (Barkho et al. 2008). Furthermore, one study 
has found that the ECM glycoprotein Reelin is upregulated in damaged sites, 
triggering the redirection of neuroblasts from RMS to the injury site (Courtes et 
al. 2011). 
Importantly, there is also evidence that aNSCs themselves can migrate to the 
site of injury (Faiz et al. 2015). In particular, in response to endothelin-1 and 
pial vessel disruption-induced stroke in the cortex, neurospheres with extended 
self-renewal capacity could be derived from the SVZ as well as from the site of 
injury in the cortex, but not from the uninjured cortex. Of note, NSCs isolated 
from the site of injury originated from SVZ aNSCs. In this respect, the same 
study provided some evidence that SVZ aNSCs themselves migrate to the site 
of injury and give rise to reactive astrocytes that facilitate scar formation and 
they could be converted into neurons by forced Ascl1 expression (Faiz et al. 
2015). This study sheds light on the intrinsic migratory ability of SVZ aNSCs 
upon injury. 
Collectively, these studies highlight the complexity of adult SVZ neurogenesis 
and in particular how two highly interconnected processes, differentiation and 
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migration contribute to continuous generation of neural cells during the lifespan 
of rodents in both physiological settings and upon injury. 
1.4.5 Human vs Rodent SVZ 
Given the plasticity of SVZ NSCs in rodents, it was tempting to investigate if 
this niche and the migration route are comparable in human, which may shed 
light on potential therapeutic strategies aimed at promoting tissue repair upon 
injury or in pathological conditions caused by neuronal loss (Trounson and 
McDonald 2015). However, the characterisation of adult human SVZ has 
revealed a considerable degree of difference compared to rodents (Fig. 1.5) 
(Quinones-Hinojosa et al. 2006; Gonzalez-Perez 2012). As described earlier, 
based on the spatial organisation and cellular compartment, the adult SVZ in 
rodents can be segregated into three layers. Intriguingly, using intraoperative 
and postmortem samples, it has been shown that the cytoarchitecture of the 
human SVZ is different from the mouse SVZ (Quinones-Hinojosa et al. 2006; 
Gonzalez-Perez 2012) and there are four layers: layer I contains ependymal 
cells; layer II is predominantly devoid of cells, generating a hypocellular gap; 
layer III is composed of a ribbon of astrocytes and layer IV is characterised as 
a transitional area adjacent to the brain parenchyma. 
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Figure 1.5: Cytoarchitecture of rodent and human SVZ. 
Schematic representation of coronal views of rodent and human SVZ. LV, lateral 
ventricle; SVZ, subventricular zone. Note that unlike rodent SVZ, in human SVZ there 
is a hypocellular layer, layer II, which separates the astrocytes ribbon layer III from the 
ependymal layer I. Adapted from (Capilla-Gonzalez et al. 2014). 
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Although extensive studies have well documented the existence of adult 
human DG neurogenesis (von Campe et al. 1997; Eriksson et al. 1998; Sahay 
and Hen 2007; Spalding et al. 2013), with regard to adult SVZ neurogenesis 
and RMS migration, a number of studies have drawn controversial conclusions. 
While some groups have reported adult neurogenesis/chain migration in the 
human brain (Curtis et al. 2007; Wang et al. 2011), there is a lack of strong 
evidence to support the existence of human SVZ-RMS-OB neurogenesis 
(Sanai et al. 2004; Quinones-Hinojosa et al. 2006; Sanai et al. 2011). 
Moreover, a recent study utilised carbon dating technique to investigate cell 
turnover rate in human OB and failed to provide evidence supporting the 
existence of neurogenesis in human OB (Bergmann et al. 2012). However, a 
subsequent study has reported the generation of striatal neurons from human 
SVZ and that this integration route into the striatum is devoid in rodents (Ernst 
et al. 2014), suggesting the existence of adult stem cells in the human SVZ. It 
is important to highlight that there is evidence suggesting that neuroblast-like 
cells (PSA-NCAM+) exist in human infant SVZ (less than one year old) 
(Weickert et al. 2000). Furthermore, another paper has shown that a marked 
rostral extension of neuroblasts of the lateral ventricle in human foetal brain 
was observed (Guerrero-Cazares et al. 2011). Of note, these migrating 
neurons appear to be developmental-dependent, where they persist in RMS in 
infants but gradually decrease with maturation (Sanai et al. 2011). Thus it has 
been proposed that chain migration is a transient process that only takes place 
during infant development in humans (Quinones-Hinojosa et al. 2006). 
Taken together, these studies suggest that aNSCs are present in both humans 
and rodents, but there are substantial differences in their capacity to 
differentiate depending on whether they are located in the SVZ or DG. Further 
research into this area is needed.  
1.5 Epigenetic mechanisms controlling neurogenesis 
During development, multicellular organisms require tight control on gene 
expression to achieve their biological and physiological tasks. At the cellular 
level, gene expression is controlled via coordination of various intrinsic and 
extrinsic stimuli that are pivotal for the establishment of the appropriate cellular 
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identity (Levine and Davidson 2005; Alberts 2008). Aberrant gene expression 
contributes to a number of pathological conditions, including cancer (Hanahan 
and Weinberg 2011). Control of gene expression is exerted by transcription 
factors in association/coordination with a number of epigenetic mechanisms 
regulating chromatin function and structure. By definition, epigenetics is the 
study of heritable changes in gene expression that do not involve alteration in 
DNA sequence (Jaenisch and Bird 2003; Felsenfeld 2014). To date, several 
epigenetic mechanisms have been identified, including DNA and histone 
modifications, chromatin remodelling and non-coding RNAs-mediated 
regulation (Jaenisch and Bird 2003; Piunti and Shilatifard 2016) (further 
elaborated below). Among such mechanisms, histone modifiers, in particular, 
the Polycomb group (PcG) proteins have been extensively studied in the 
context of stem cell biology (Sparmann and van Lohuizen 2006; Aloia et al. 
2013) and play key roles during neurogenesis (Hirabayashi and Gotoh 2010; 
Ma et al. 2010; Aloia et al. 2013; Yao et al. 2016) (see below). I will now 
summarise research in this area and then focus on mechanisms that are 
relevant to my thesis work.  
1.5.1 Histone modifications  
Genetic information in eukaryotes is compacted into chromatin (Fig. 1.6A). The 
basic building block of chromatin is termed the nucleosome, where four core 
histones, H2A, H2B, H3 and H4, assembly into an octamer which is wrapped 
around by a superhelix that consists of 147bp DNA (Kornberg 1974; Kornberg 
and Thomas 1974; Kouzarides 2007). This DNA-histone structural unit is 
essential for modulating and storaging genetic information. Histones are highly 
conserved from yeast to mammals and they are involved in a number of 
cellular and molecular programmes, including DNA replication, recombination, 
repair and importantly, transcription regulation (Bottomley 2004; Kouzarides 
2007; Felsenfeld 2014). Histones modulate DNA accessibility either by relaxing 
chromatin into euchromatin (less condensed, more accessible) or by promoting 
chromatin aggregation into heterochromatin (highly condensed, inaccessible) 
(Felsenfeld and Groudine 2003; Bottomley 2004; Kouzarides 2007). Notably, a 
number of covalent modifications/PTMs regulate chromatin organisation by 
modifying specific amino acids within the N-terminal tail of core histones, 
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including phosphorylation, acetylation, methylation, sumoylation, ubiquitylation, 
deamination, ADP ribosylation and proline isomerisation (Kouzarides 2007). It 
has been postulated that histone modifications affect transcription by 
modulating physical histone/DNA interaction as well as by recruiting non-
histone ‘reader’ proteins with various functions ranging from chromatin 
remodelling to further histone modifications (Li et al. 2007). Moreover, 
increasing evidence suggest that alterations of chromatin structure contribute 
to transformation and malignancy through deregulated gene expression and 
genome instability (Esteller 2007).  
Regulation of histone acetylation by histone acetyltransferases enzymes 
(HATs) and histone deacetylase enzymes (HDACs) (Marks et al. 2001; Roth et 
al. 2001) represents a well-documented example of how histone modifications 
associate with different transcriptional states. Specifically, histone lysine 
acetylation is associated with transcription activation since this modification 
neutralises the basic charge of lysine and further destabilises the structure of 
chromatin in order to promote transcription (Allfrey 1966; Tse et al. 1998; 
Zheng and Hayes 2003). Conversely, transcriptional repression is correlated 
with histone lysine deacetylation since hypoacetylation leads to reduced 
accessibility to transcription factors (Nan et al. 1998; de Ruijter et al. 2003; 
Kouzarides 2007). In addition, evidence also supports that both HATs and 
HDACs have target substrates that are non-histone proteins, including the 
transcription factors p53, E2F, TFIIE, TFIIF and GATA1 (Khochbin et al. 2001; 
Marks et al. 2001; Roth et al. 2001; de Ruijter et al. 2003). 
Another well-studied covalent modification is methylation. Histone methylation 
on specific lysine site is mediated by a number of “writers”: lysine 
methyltransferases (KMTs) and is reversibly removed by the “erasers”: lysine-
specific demethylases (KDMs) (Zhang and Reinberg 2001). Interestingly, in 
contrast to other modifications such as histone acetylation/deacetylation, 
histone methylation was long believed to be an irreversible mark until the 
discovery of lysine specific demethylase 1 (LSD1) (Shi et al. 2004), which 
facilitates the removal of mono- and di-methyl marks. Importantly, unlike other 
modifications, histone lysine methylation results in more complicated 
consequences, as lysine is susceptible to be added from one methyl group up 
to three methyl groups (Margueron and Reinberg 2011). Hence, gene 
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activation or repression can be marked by the level as well as the site of lysine 
methylation. For instance, actively transcribed genes are associated with 
trimethylation on H3K4 and H3K36 whereas repressed genes are enriched for 
trimethylation on H3K9 and H3K27 (Martin and Zhang 2005; Kouzarides 2007). 
However, the presence of active or repressive histone methylation marks is not 
simply a binary state, as evidence has shown that many genes display 
occupancy of both marks (Bernstein et al. 2006; Voigt et al. 2013). In this 
respect, the “bivalent status” of certain genomic regions is believed to be 
essential during development as it maintains the genes in a poised state, 
rendering them ready for activation if necessary. It is important to note that 
more evidence is required to establish the concept of bivalency as it has been 
challenging to prove that the two antagonist modifications are present in the 
same cell and same gene.  
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Figure 1.6: Schematic views of chromatin organisation and composition of 
Polycomb Repressive Complexes PRC1 and PRC2. 
(A) Illustration of chromatin organisation in the eukaryotic nucleus. Nucleosomes are 
the major protein components of chromatin; comprising two copies of the core 
histones: H2A, H2B, H3 and H4 to form the octamer with ~147bp DNA wrapped 
around. This highly compact organisation is key to genetic information storage and 
gene regulation. (B) Composition of PRC1. Ring1a and Ring1b are two core 
components of PRC1 and they function as E3 ubiquitin ligase to establish 
H2AK119Ub. Bmi1 has been implicated in regulation of stem cell development. (C) 
Composition of PRC2. EZH1/2 are responsible for di-/trimethylation of H3K27. 
Notably, Jarid2, Aebp2 and Pcl are newly identified PRC2 components. Adapted from 
(Margueron and Reinberg 2011; Yao et al. 2016).  
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1.5.2 Polycomb Repressive Complexes 
The Polycomb group (PcG) proteins are multiprotein complexes that exhibit 
histone methyltransferase activity (Muller et al. 2002; Blackledge et al. 2014; 
Piunti and Shilatifard 2016). The Polycomb  (Pc) was originally identified in 
Drosophila and encodes a repressor required for proper body segmentation 
(Lewis 1978). It is now well established that PcG proteins are highly conserved 
from Drosophila to mammals (Levine et al. 2002; Margueron and Reinberg 
2011; Aloia et al. 2013) and they function as “gene silencers” during 
development to maintain the repression state of key genes (Boyer et al. 2006; 
Sparmann and van Lohuizen 2006; Aloia et al. 2013). Together with their 
functional antagonist Trithorax group (TrxG) proteins, which maintain/activate 
gene expression, these two groups of proteins are essential for the 
maintenance of proper gene expression pattern during development and 
throughout adulthood (Schuettengruber et al. 2007). In mammals, there are two 
well-characterized families of PcG proteins, the Polycomb Repressive Complex 
1 (PRC1) and PRC2 (Sparmann and van Lohuizen 2006; Aloia et al. 2013). 
Moreover, another two families have been identified in Drosophila, including 
Polycomb Repressive Deubiquitinase (PR-DUB) and PHO Repressive 
Complex (PhoRC) (Klymenko et al. 2006; Scheuermann et al. 2010).  
The distinct components of PRC1 and PRC2 facilitate their role in histone 
modifications as well as in gene repression (Sparmann and van Lohuizen 
2006). The composition of PRC1 is diverse (Fig. 1.6B), with two core 
components Ring1a/b together with Bmi1, Nspc1 or Mel18 (Whitcomb et al. 
2007; Aloia et al. 2013). Ring1a and Ring1b function as E3 ubiquitin ligases 
that facilitate histone H2A monoubiquitylation at lysine 119 (H2AK119Ub) 
(Wang et al. 2004a). Other constituents, for example, Bmi1 and Mel18 are 
known to modulate enzyme activity of PRC1 (Brunk et al. 1991; Kanno et al. 
1995; Aloia et al. 2013). Notably, PRC1 can be grouped into canonical PRC1 
or non-canonical PRC1 based on the presence or absence of Cbx proteins 
(Gao et al. 2012; Aloia et al. 2013; Blackledge et al. 2014). Functionally, 
canonical PRC1 is able to bind H3K27me3 marks deposited by PRC2 via Cbx 
proteins whereas non-canonical Rybp-containing PRC1 can be recruited to 
specific unmethylated CpG island through its subunit Kdm2b (Garcia et al. 
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1999; Farcas et al. 2012; Gao et al. 2012; Hisada et al. 2012; Tavares et al. 
2012; Aloia et al. 2013; He et al. 2013; Wu et al. 2013; Blackledge et al. 2014).  
The PRC2 complex is more conserved through evolution, from Drosophila to 
mammals (Fig. 1.6C), consisting of EED, EZH1/2, SUZ12 and RbAp46/48 
subunits (Whitcomb et al. 2007; Margueron and Reinberg 2011). Notably, 
SUZ12 is required for the stability of the EZH2 catalytic subunit (Cao and 
Zhang 2004; Pasini et al. 2004). Additionally, Jarid2, Aebp2 and Pcl1/2/3 have 
been recently identified as PRC2 components, by their interaction with other 
PRC2 components as well as their capabilities to modulate PRC2 enzyme 
activity (Cao and Zhang 2004; Nekrasov et al. 2007; Peng et al. 2009; Li et al. 
2010; Margueron and Reinberg 2011).  
Gene silencing by PRC1 and PRC2 is achieved in part through their 
modifications of histones. PRC1 facilitates histone H2A monoubiquitylation at 
lysine 119 (H2AK119Ub) through ubiquitin ligases Ring1a and Ring1b, 
whereas PRC2 di- and tri-methylate lysine27 of histone 3 via EZH1 and EZH2 
(Lund and van Lohuizen 2004; Kouzarides 2007). Interestingly, a study 
suggests a progressive H3K27 methylation pattern, where H3K27me3 is 
derived from monomethylation of H3K27me2 (Zee et al. 2010). In addition, a 
recent study has shown that PRC1 (Ring1b) is able to repress gene expression 
by chromatin compaction, but independently of its enzymatic activity (Eskeland 
et al. 2010). Of note, PRC1 and PRC2 activities have been reported to be 
interdependent. Specifically, H3K27me3 deposited by PRC2 serves as a 
docking site for PRC1, suggesting a cascade model  whereby PRC2-mediated 
gene repression is amplified by PRC1 recruitment/activation (Wang et al. 
2004c). However, a recent paper suggests that PRC1-mediated H2AK119Ub is 
independent of PRC2-deposited H3K27me3 (Tavares et al. 2012). Intriguingly, 
another recent paper has reported that variant PRC1-dependent (non-
canonical PRC1) H2AK119Ub is able to recruit PRC2 and H3K27me3 
(Blackledge et al. 2014), indicating a non-canonical recruitment process as well 
as the involvement of PRC1 in H3K27me3 establishment and maintenance.  
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1.5.3 PRC1 and PRC2 in regulation of neurogenesis 
As mentioned above, PcG proteins play important roles during development 
and disease. For instance, Bmi1, a PRC1 component, was identified as an 
oncogene that promotes B- and T-cell lymphomas development together with 
c-MYC (Haupt et al. 1991; van Lohuizen et al. 1991). In addition to cancer, 
accumulating evidence suggests its role in maintenance of NSCs (Molofsky et 
al. 2003; Fasano et al. 2007; Fasano et al. 2009; He et al. 2009). It has been 
reported that Bmi1 is required for SVZ aNSC self-renewal (Molofsky et al. 
2003). Specifically, Bmi1 knockout mice lead to postnatal depletion of SVZ 
NSCs rather than more committed progenitors, and this effect is mediated by 
increased expression of the Polycomb target and cell cycle inhibitor p16Ink4a 
(Molofsky et al. 2003). Interestingly, acute reduction of Bmi1 using shRNA 
impairs proliferation of NSCs both in embryonic and adult, and this defect is 
mediated by another cell cycle inhibitor, p21Cip1 (Fasano et al. 2007). Moreover, 
Bmi1-overexpression in vitro promotes NSCs self-renewal via repression of 
p21Cip1, and cooperation with forebrain-specific transcription factor Foxg1 
underpins regulation of stemness (Fasano et al. 2009). However, constitutive 
overexpression of Bmi1 using Nestin-Bmi1-GFP mice revealed that Bmi1-
overexpression has no profound effects in NSCs proliferation and SVZ-OB 
neurogenesis in vivo, suggesting discrepancies between in vivo and in vitro 
studies (He et al. 2009). In addition, Bmi1-overexpression also induces 
oxidative stress-induced DDR and elevated γH2AX foci formation in 
neurospheres, resulting in increased apoptotic cell death (Acquati et al. 2013). 
Finally, another PRC1 component, Ring1b, has also been implicated in 
neurogenesis. Tissue specific Ring1b knockout (Ring1bf/f ;Nestin-Cre-ERT2) 
leads to prolonged neurogenic phase of NPCs, thereby delaying the astrogenic 
phase during neocortical development (Hirabayashi et al. 2009). 
PRC2 subunits have also been well documented to have roles in neural 
development. For example, EZH2 knockout or EED knockdown prolonged the 
neurogenic phase thereby delaying the onset of neurogenic to astrogenic 
transition (Hirabayashi et al. 2009). Intriguingly, EZH2 has been reported to be 
responsible for inhibition of astroglial differentiation but not neuronal 
differentiation in vivo via directly repression of glial fibrillary acidic protein 
(GFAP) promoter (Sparmann et al. 2013). In addition, this phenotype requires 
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interaction with Chd4, a NuRD complex member, suggesting the coordination 
of PcG protein and HDACs in regulation of neurogenesis (Sparmann et al. 
2013).  Moreover, Emx1-Cre driven deletion of EZH2 in cortical progenitors at 
E9.5, prior to the onset of neurogenesis, leads to accelerated neurogenesis 
and a substantially thicker cortex by E14 (Pereira et al. 2010). More 
specifically, EZH2 loss results in removal of H3K27me3 repressive mark in 
cortical progenitors, leading to gene derepression and ultimately shifting the 
balance toward differentiation rather than self-renewal (Pereira et al. 2010). A 
very recent paper has shown that EZH2 conditional inactivation in the 
cerebellar primordium results in cerebellar hypoplasia, and this is due to the 
dysregulated transcriptional programmes that mediate increased GABAergic 
neurons production at the expense of Purkinje cells (Feng et al. 2016). 
Interestingly, another recently published paper has reported that EZH2 
knockdown in chick embryo neural tubes leads to disorganised neuroepithelium 
(NE) structure and EZH2 preserves NE structure through targeting the p21Cip1 
promoter (Akizu et al. 2016). Finally, another PRC2 component, SUZ12, which 
is required for stability and activity of PRC2 (Cao and Zhang 2004; Pasini et al. 
2004), has been implicated in brain malformations (Miro et al. 2009). In 
particular, loss of one allele of SUZ12 leads to cerebellar herniation, an 
enlarged brainstem as well as a smaller occipital cortex, indicating a 
haploinsufficient role of SUZ12 in CNS development (Miro et al. 2009). 
Collectively, these studies shed light on the key contributions of PcG proteins 
to neurogenesis. However, the involvement of PcG proteins in the context of 
adult SVZ neurogenesis remains only partially understood.  
1.6 Brain cancer as a disease of aberrant neurogenesis 
Alterations of the neuro/gliogenesis process are believed to underlie neoplastic 
transformation during development as well as in the adult brain (further 
discussed below). Glioblastoma multiforme (GBM) remains the most prevalent 
and aggressive primary brain tumour in adults despite intensive research 
efforts in the last 20 years (Maher et al. 2001; Sanai et al. 2005). According to 
the World Health Organisation (WHO), GBMs are classified as grade IV 
gliomas and characterised by their highly proliferative, invasive nature 
compared to lower grade astrocytomas as well as by the presence of necrosis 
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and glomeruloid microvascular proliferation at the histological levels (Kleihues 
et al. 2002). Adult GBMs can be classified into two groups: primary GBM and 
secondary GBM (Ohgaki and Kleihues 2013). Primary GBMs develop 
predominantly in older patients without histological presence of a less 
malignant precursor lesion, whereas secondary GBMs mainly develop from 
lower grade astrocytomas in younger patients with a better prognosis (Ohgaki 
et al. 2004; Ohgaki and Kleihues 2013). The hallmarks of primary GBMs are 
loss of heterozygosity (LOH) of chromosome 10q (carrying PTEN), 
mutation/amplification of epidermal growth factor receptor (EGFR), deletion of 
p16Ink4a and overexpression of Mdm2. With regard to secondary GBMs, they 
are characterised by amplification of platelet-derived growth factor A 
(PDGFA)/platelet-derived growth factor receptor α (PDGFα), mutations in 
p53/pRb and LOH of chromosome 19q (Furnari et al. 2007; Wen and Kesari 
2008; Ohgaki and Kleihues 2013). Intriguingly, with the help of genome-wide 
analysis, two predominant molecular pathways have been identified being 
dysregulated in human GBMs: inactivation of the tumour suppressive p53 and 
pRb pathways and gain of receptor tyrosine kinase (RTK) signalling (Cancer 
Genome Atlas Research 2008; Parsons et al. 2008; Brennan et al. 2013), 
which have been associated with disruption of cell cycle regulation and 
apoptosis as well as aberrant RTK cascades (Furnari et al. 2007). Notably, a 
gain-of-function point mutation (R132H) in isocitrate dehydrogenase 1 (IDH1) 
has been identified as a specific marker for secondary GBMs, with implications 
for epigenetic modifications affecting both DNA and histones (Yan et al. 2009; 
Killock 2016).  
Importantly, integrated genomic analysis has identified several molecular 
subtypes of GBMs using gene expression-based molecular classification: 
proneural, neural, classical and mesenchymal (Verhaak et al. 2010). For 
instance, the classical subtype is characterised by loss of PTEN and 
amplification of EGFR, whereas the mesenchymal subtype is depicted by loss 
of tumour suppressor neurofibromatosis type 1 (NF1). This classification 
approach provides insight into the heterogeneity within GBMs and permits the 
better clinical assessment of GBMs.  
In addition to the characterisation of different subtypes based on molecular 
profiling, the identification of cell of origin is of crucial importance as this not 
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only fosters our understanding for the biology of tumour initiation, maintenance 
and progression but also promotes better clinical treatment strategies (Fig. 
1.7). In this respect, the term “cell of origin” refers to normal cells within the 
brain that are susceptible to oncogenic insults and subject to subsequent 
transformation into GBMs (Visvader 2011). It is now believed that cells 
harbouring NSC/neural progenitor cell (NPC) properties may serve as the cell 
of origin of adult GBMs (Holland et al. 2000; Sanai et al. 2005; Vescovi et al. 
2006; Alcantara Llaguno et al. 2009; Jacques et al. 2010; Zong et al. 2015). In 
addition to the SVZ lining the lateral ventricles and DG within the hippocampus 
(Eriksson et al. 1998; Sanai et al. 2004), NSCs have been also isolated from 
subcortical white matter of the adult human brain that are competent to give 
rise to neurons and glia both in vitro and in vivo (Nunes et al. 2003), suggesting 
that different NSC types could act as cell of origin of GBM. Of note, the 
proliferative ability and developmental plasticity render NSCs/NPCs susceptible 
to accumulating more mutations and transformation in response to oncogenic 
stimuli compared to other mature cells (Sanai et al. 2005). Most evidence 
comes from studies based on mouse models, which have provided convincing 
and insightful findings with regard to cell(s) of origin of GBM (Fig. 1.7). For 
instance, concomitant mutations of p53 and NF1 tumour suppressor genes in 
NSCs give rise to glioma and early p53 inactivation preceding or concomitant 
NF1 loss is essential for tumour formation (Zhu et al. 2005b). This is further 
corroborated using mouse models with combined mutation/deletion of the key 
tumour suppressors found dysfunctional in human GBM, including p53, pRb, 
NF1 and PTEN (Holland et al. 2000; Alcantara Llaguno et al. 2009; Jacques et 
al. 2010). These studies not only highlighted the importance of NSCs in GBM 
formation but also established the crucial genetic events underlying its 
pathogenesis.  
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Figure 1.7: Cell of origin of GBM. 
NSCs and progenitors (both neural progenitors and oligodendrocytes progenitors) are 
well established as cell of origin of GBM. This is predominantly due to their persistence 
through adulthood, which leads them to be susceptible to oncogenic transformation. 
Notably, transformation of differentiated progenies may also give rise to brain tumours 
(dashed box and arrow), this is consistent with the hypothesis that CSCs may not 
necessarily be derived from transformation of stem cells. Adapted from (Liu et al. 
2011; Friedmann-Morvinski et al. 2012; Casarosa et al. 2013).  
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However, evidence suggests that other cell types act as cell of origin of gliomas 
in addition to NSCs. One study has shown that more than 20% of high-grade 
gliomas developed far away from the NSCs niches upon concomitant 
disruption of p53, PTEN and with or without pRb inactivation in adult GFAP-
CreER mice (Chow et al. 2011), suggesting astrocytes are able to serve as the 
cell of origin of gliomas as well.  
Moreover, there is also evidence suggesting that differentiated cells can also 
serve as the cell of origin of gliomas. However, this requires them to acquire 
“stemness” properties through dedifferentiation. More specifically, in response 
to lentiviral-induced silencing of p53/NF1 or activation of Ras (H-Rasv12)/p53 
silencing, neurons and astrocytes are able to undergo dedifferentiation and 
subsequently initiate and maintain malignant gliomas (Friedmann-Morvinski et 
al. 2012). Notably, these gliomas belong to the mesenchymal subtype as 
described before (Friedmann-Morvinski et al. 2012).  
Interestingly, oligodendrocytes precursor cells (OPCs) have been reported as 
being the cell of origin of gliomas. The most striking evidence coming from a 
study using Mosaic Analysis with Double Markers (MADM) showed that 
following concurrent p53/NF1 mutations a significant aberrant growth prior to 
transformation was restricted to OPCs (but not NSCs or other lineages derived 
from NSCs), raising the possibility that OPCs act as the cell of origin of 
gliomas. Moreover, this study also suggests that OPCs outcompete NSCs with 
regard to cell of origin of gliomas in this scenario (Liu et al. 2011). 
Collectively, these studies provide important evidence delineating cell of origins 
of GBMs as well as reinforcing the complexity of GBMs.  
Another key feature of GBMs is their altered/augmented migration/invasion 
capabilities (Furnari 2007; Cuddapah 2014). In contrast to other solid tumours, 
which predominantly metastasise to distant organs, GBMs mainly infiltrate 
within the brain, with very few reports of extracranial metastases (Beauchesne 
2011; Cuddapah et al. 2014; Hamilton et al. 2014). Our understanding with 
respect to GBM invasion/migration remains limited, as genomic studies have 
failed to report genetic alterations affecting direct regulators of cell invasion in 
GBM. As a result, there are few insights into which key cell migration regulators 
underlie cell invasion in GBMs. However, it is important to note that GBM cells 
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exploit similar routes as neuroblasts and neurons, indicating potential shared 
mechanisms facilitating GBM cells to infiltrate the brain parenchyma (Arvidsson 
et al. 2002; Goings et al. 2004; Zhang et al. 2007; Faiz et al. 2015). Therefore, 
it is imperative to delineate if similar molecular mechanisms are being exploited 
by both normal cells and transformed GBM cells, further facilitating our 
understanding of GBM pathogenesis.  
1.6.1 Epigenetic alterations in brain cancer 
As mentioned above, histones are targets for various PTMs that have 
implications in altering the properties of the nucleosome as well as the 
associated factors. Importantly, the existence of histone variants, which exert 
distinct properties compared to their canonical counterparts, add more 
complexity to this scenario (Kamakaka and Biggins 2005). In mammals, 
histone variants are categorised into three groups corresponding to their 
canonical partners: H2A variants (e.g. H2A.Z, H2A.X), H2B variants and H3 
variants (e.g. CENP-A, H3.3) (Skene and Henikoff 2013; Maze et al. 2014; Zink 
and Hake 2016). In addition, there are numerous H1 variants, however, their 
biological roles remain incompletely understood (Parseghian et al. 2001; 
Kamakaka and Biggins 2005; Happel and Doenecke 2009; Terme et al. 2011; 
Maze et al. 2014; Zink and Hake 2016). Notably, the key feature of histone 
variants is their distinct incorporation pattern throughout cell cycle compared to 
canonical histones; histone variants are deposited into chromatin and their 
expression is not restricted to S phase whereas canonical histones are 
incorporated in a replication-dependent way, with significantly higher level 
during S phase (Kamakaka and Biggins 2005; Skene and Henikoff 2013). 
Intriguingly, mounting evidence has implicated mutations in the histone variant, 
H3.3, in brain cancer (Khuong-Quang et al. 2012; Schwartzentruber et al. 
2012; Sturm et al. 2012; Wu et al. 2012; Bender et al. 2013; Chan et al. 2013; 
Jones et al. 2013; Lewis et al. 2013; Venneti et al. 2013; Zhang et al. 2013). 
The H3.3 protein is encoded by the H3f3a and H3f3b genes in both mice and 
humans (Wells et al. 1987; Albig et al. 1995; Witt et al. 1997; Yuen and 
Knoepfler 2013). Importantly, H3.3 is predominantly deposited in 
transcriptionally active regions, marked by H3K4me3 (Delbarre et al. 2013; 
Yuen and Knoepfler 2013). However, evidence also suggests that H3.3 is able 
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to incorporate into telomeres and pericentric repeats, sites of heterochromatin 
that are associated with the transcription-inactive state (Drane et al. 2010; 
Lewis et al. 2010b; Szenker et al. 2011; Yuen and Knoepfler 2013; Elsasser et 
al. 2015). Incorporation of histone variants into dedicated regions relies on their 
dedicated histone chaperones (De Koning et al. 2007). Specifically, H3.3 is 
guided into euchromatin regions by histone regulator A (HIRA) (Tagami et al. 
2004) and positioning into telomeric and pericentromeric heterochromatin 
regions is directed by DAXX and α-thalassemia X-linked mental retardation 
protein (ATRX) (Drane et al. 2010; Elsaesser and Allis 2010; Goldberg et al. 
2010; Delbarre et al. 2013). Importantly, recent work from our lab has 
demonstrated that the PML-NB constituent DAXX is responsible for H3.3 
loading at regulatory elements of immediate early genes upon neuronal 
activation (Michod et al. 2012). In addition, work from David Allis’ group 
showed that H3.3 accumulates in neuronal and glial chromatin during ageing 
and the activity-dependent deposition of H3.3 is mediated by HIRA (Maze et al. 
2015). Finally, our unpublished data and existing literature have shown that the 
DAXX/ATRX complex is found in PML-NBs (Xue et al. 2003; Berube et al. 
2008; Delbarre et al. 2013), suggesting the potential involvement of PML in 
regulation of H3.3 deposition (Salomoni 2013). Of note, both ATRX and DAXX 
are found mutated in various tumours, including glioma and neuroblastoma, 
indicating the potentially crucial role of alterations of the DAXX/ATRX-H3.3 
pathway in tumour development (Heaphy et al. 2011; Jiao et al. 2011; Cheung 
et al. 2012; Jiao et al. 2012; Liu et al. 2012).  
As mentioned above, mutations in histone gene itself, particularly in H3.3, have 
been implicated in paediatric GBM (Khuong-Quang et al. 2012; 
Schwartzentruber et al. 2012; Sturm et al. 2012; Bjerke et al. 2013; Chan et al. 
2013; Jones et al. 2013; Lewis et al. 2013; Venneti et al. 2013; Zhang et al. 
2013) and other diseases (Attieh et al. 2013; Behjati et al. 2013). In this 
respect, heterozygous histone mutations in the human H3F3A gene result in 
K27M (lysine 27 to methionine) and G34R/V (glycine 34 to arginine/valine) 
mutants in N-terminal tail of H3.3 (Yuen and Knoepfler 2013). In addition, these 
two mutations are mutually exclusive in paediatric GBM (Schwartzentruber et 
al. 2012; Sturm et al. 2012) and are found in tumours arising in different CNS 
anatomical regions (Fig. 1.8) (Sturm et al. 2012; Bjerke et al. 2013; Yuen and 
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Knoepfler 2013), indicating potentially different cells of origin. Furthermore, 
patients harbouring K27M are younger than G34R/V patients 
(Schwartzentruber et al. 2012; Sturm et al. 2012), suggesting that H3.3K27M 
may contribute to tumour formation in NSCs at an earlier developmental stage 
(Chan et al. 2013). Importantly, K27M and G34R/V are found concurrently with 
other classical tumour-related mutations in gliomas. Specifically, K27M is 
associated with mutations in TP53, DAXX/ATRX, NF1, PDGFRA, KRAS, BRAF 
and FGFR1 (Khuong-Quang et al. 2012; Schwartzentruber et al. 2012; Jones 
et al. 2013; Yuen and Knoepfler 2013; Zhang et al. 2013), whilst G34R/V 
mutations are found associated with TP53, DAXX/ATRX and PDGFRA 
(Schwartzentruber et al. 2012; Yuen and Knoepfler 2013). It is thus proposed 
that H3.3K27M and H3.3G34R/V are “driver mutations” by which they function 
as “second hit” (Knudson 1971) following somatic mutations that collectively 
contribute to the onset of tumour formation (Khuong-Quang et al. 2012; 
Schwartzentruber et al. 2012; Yuen and Knoepfler 2013).  
H3.3K27M has been functionally linked to PRC2. In particular, it leads to global 
decrease of H3K27me3 level in brain tumour cells as well as in human 
embryonic kidney (HEK) cells, mouse embryonic fibroblasts (MEF) and human 
astrocytes (Chan et al. 2013; Lewis et al. 2013). More specifically, this driver 
mutation affects the enzyme activity of EZH2, the PRC2 catalytic subunit (Chan 
et al. 2013; Lewis et al. 2013). Intriguingly, though K27M impairs global level of 
H3K27me3, this effect exerts distinct enrichment levels at a set of genes with 
various biological functions (Chan et al. 2013). More specifically, one subset of 
genes (group A) with loss of H3K27me3 at promoters is associated with 
neurobiological processes (e.g. ligand-receptor interactions, synaptic 
transmission). Another subset of genes (group C) with gain of H3K27me3 at 
promoters is involved in cancer pathways (e.g. p16Ink4a). Interestingly, group A 
genes also possess higher enrichment of H3K4me3 at promoters, an active 
mark, indicating the antagonist features of H3K27me3 and H3K4me3 in gene 
expression. Moreover, group C genes are defined as bivalent genes marked by 
the high density of both H3K27me3 and H3K4me3 at promoter regions (Chan 
et al. 2013).  
The involvement of PRC2 and H3K27me3 has been well documented in a 
number of cancers. PRC2 has been implicated as an oncogene in a number of 
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different cancers. For instance, high level of EZH2 is associated with prostate 
cancer, breast cancer, lung cancer and liver cancer (Varambally et al. 2002; 
Sudo et al. 2005; Bachmann et al. 2006; Hussain et al. 2009; Kim and Roberts 
2016). This oncogenic role has been further supported by studies revealing that 
gain-of-function point mutations of EZH2 resulting increased H3K27me3 levels 
lead to lymphomagenesis (Morin et al. 2010; Sneeringer et al. 2010; McCabe 
et al. 2012; Kim and Roberts 2016). In particular, high-EZH2 expression was 
observed in CSCs purified from human breast cancer and EZH2 was required 
for their maintenance (Chang et al. 2011). Taken together, these studies shed 
light on the potential oncogenic role of PRC2/EZH2 in adult GBM. 
Interestingly, EZH2 may also bear tumour suppressive effect as loss-of-
function EZH2 mutations have been implicated in a number of cancers, 
including T cell acute lymphoblastic leukaemia (T-ALL) (Ernst et al. 2010; 
Nikoloski et al. 2010; Ntziachristos et al. 2012; Simon et al. 2012; Sashida et al. 
2014; Kim and Roberts 2016). Other PRC2 subunits have also been implicated 
as tumour suppressors. For example, mutations in SUZ12 and EED are 
associated with T-ALL and malignant peripheral nerve sheath tumours 
(MPNSTs) (Ntziachristos et al. 2012; Simon et al. 2012; Lee et al. 2014; Kim 
and Roberts 2016). This context-dependent manner provides hints with respect 
to PRC2/H3K27me3 in brain cancers. More specifically, it is known that 
H3K27me3 has a tumour suppressive role in paediatric GBM (Bender et al. 
2013; Chan et al. 2013; Lewis et al. 2013) (see above), however, in the context 
of adult GBM, like many other tumours, it can exert oncogenic effects. 
Intriguingly, this context-dependent, double-faceted property of PRC2 
resembles the role of PML in tumourigenesis.  
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Figure 1.8: Distribution of H3.3 driver mutations in the CNS. 
It is important to note that H3.3K27M mutations localise mainly to midline locations 
(red): spinal cord, thalamus, pons and brainstem. In addition, K27M patients are 
typically younger than G34R/V patients, indicating an earlier developmental onset of 
tumour growth. Moreover, K27M is associated with mutations in DAXX/ATRX, TP53, 
NF-1 PDGFRA, BRAF, KRAF and FGFR1. K27M mutation results in decreased EZH2 
enzyme activity and thus leading to a decreased global H3K27me3 level. Adapted 
from (Yuen and Knoepfler 2013). 
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1.7 PML in the central nervous system  
As mentioned earlier, our previous work has revealed an unexpected role of 
PML in regulation of corticogenesis through its ability to regulate NSCs 
proliferation (Regad et al. 2009). Specifically, this study found that PML 
expression is restricted to the NPCs/NSCs in the developing neocortex (Fig. 
1.9). Interestingly, PML loss affects radial glia cells expansion and impairs 
generation of basal progenitor, resulting in reduced neuronal output and a 
thinner cortex (Regad et al. 2009). Notably, layering of the cortex was not 
affected, suggesting that PML loss negatively influenced differentiation 
throughout corticogenesis. Mechanistically, PML, pRb and protein phosphatase 
1α (PP1α) form a nuclear complex in NPCs, whereby PML regulates pRb by 
facilitating PP1α-dependent dephosphorylation. Thus, PML loss leads to 
hyperphosphorylation of pRb and therefore abolishes its cell cycle inhibitory 
effect.  
 Previous studies had suggested an involvement of PML in the nervous system 
(Gray et al. 2004; Woulfe et al. 2004; Villagra et al. 2006; Woulfe et al. 2007; 
Regad et al. 2009). Following our report, it has been shown that PML is 
expressed in different parts of adult brain, including hippocampus, cerebellum, 
cortex and brain stem, and that germline PML knockout (KO) results in 
abnormalities in learning and spatial memory (Butler et al. 2013). More 
recently, another study has reported that PML is expressed in the 
suprachiasmatic nucleus, which is responsible in regulating circadian rhythm, 
and PML expression level shows a highly regulated pattern during circadian 
period (Miki et al. 2012). Furthermore, an in vitro study using a neuronal culture 
system (which lacks glia) has shown that PML expression level is low in 
neurons, however, neuronal stimulation leads to significant upregulation of 
PML protein levels (Korb et al. 2013). In addition, PML has been implicated in 
synaptic plasticity, given the fact that PML interacts with Arc, which is involved 
in synaptic plasticity and memory formation (Bloomer et al. 2007; Korb et al. 
2013). Another study has reported that PML activates NeuroD expression 
following formation of a complex with forkhead protein FoxO1 (Kitamura et al. 
2005), implicating a role of PML in neuronal differentiation. Importantly, a 
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previous study from our group has shown that PML regulates neurogenesis in 
the developing cortex (Regad et al. 2009). This study reveals an unexpected 
role of PML in central nervous system (CNS) stem cells and neurogenesis. 
Taken together, these studies provide evidence for the multiple and dynamic 
roles of PML in CNS stem cells, neurogenesis and normal adult brain functions.  
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Figure 1.9: Schematic illustration depicting rodent corticogenesis and PML 
expression is restricted in neural progenitor cells (NPCs) in the developing 
neocortex.  
Intermediate progenitor (IP) cells in the subventricular zone (SVZ) are derived from 
radial gilal (RG) cells located in the ventricular zone (VZ). IP cells in turn generate 
neurons that migrate radially via RG fibers (red) to the cortical plate. Notably, previous 
work from our lab has shown that PML expression is restricted in NPCs located in VZ 
during neocortex development and its expression retains confined in VZ/SVZ 
postnatally (dashed red box). A subset of outer SVZ radial glia-like (oRG) cells are 
also indicated, which are generated from RG via asymmetric divisions. Adapted from 
(Lui et al. 2011). 
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1.8 Supporting data on the effect of PML loss on adult neurogenesis  
(generated before the start of my thesis work) 
Based on our findings on the role of PML in CNS development, we 
hypothesised that PML could also play a role in regulation of adult 
neurogenesis. To address this, a number of experiments were carried out by a 
former postdoctoral researcher, Joanne Betts, to study the impact of PML loss 
on adult SVZ neurogenesis.  
1.8.1 PML is expressed in the SVZ/OB niche 
To investigate the expression of PML in adult mice (6-month old) SVZ NSCs, 
fate-mapping experiments were performed using a nucleoside analogue of 
thymidine, 5-bromo-2’-deoxyuridine (BrdU), indexing S-phase synthesis of the 
cell cycle. In brief, Edu injections were carried out intraperitoneally in PML+/- 
mice once daily for 12 consecutive days to guarantee the incorporation by 
slow-cycling type B NSCs as well as the fast-proliferating type C progenitor 
cells. Mice were subsequently sacrificed at two time points: 1-month (Fig. 
1.10A) or 1-day (Fig. 1.10B) after the last injection. The differentiated cells in 
OB and the label-retaining NSCs residing in the SVZ can be detected at the 1-
month time point, whereas the 1-day time point identifies the fast cycling type C 
cells in SVZ as well as the newly generated neuroblasts that migrate away from 
SVZ. PML was successfully detected in a subset of Edu+ and GFAP+ NSCs 
within SVZ (Fig. 1.10A), type C cells (Fig. 1.10B) and in doublecortin positive 
(DCX+) migrating neuroblasts (Fig. 1.10C). The expression of PML in SVZ 
NSCs could be recapitulated in vitro using cells extracted from SVZ 
propagating adherently (Fig. 1.10D) or as neurospheres (data not shown). 
Thus, PML expression in NSCs was confirmed both in vivo and in vitro. In 
addition, PML expression was found absent in βIII-tubulin+ (Tuj1, neuronal 
marker) and GFAP+ (glia marker) differentiated cells (Fig. 1.10E) and this 
reduced expression pattern was confirmed both at mRNA and protein levels by 
triggering NSCs into differentiation in vitro (Fig. 1.10F).  
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Figure 1.10: Supporting data of phenotypes caused by PML loss. 
These results were conducted by a previous postdoctoral researcher Joanne Betts. (A) 
PML is expressed in SVZ NSCs. Staining was carried out in coronal sections for mice 
sacrificed at 1-month time point, indexing the label-retaining NSCs in SVZ. Scale 
bar=50μm. (B) Staining of coronal sections at 1-day time point, identifying PML 
expression in type C cells as well as in (C) migrating neuroblasts. Scale bar=50μm. 
(D) PML expression in adherent NSCs in vitro. Scale bar=25μm. (E) PML expression 
is virtually absent in differentiated cell types, identified by co-staining of βIII-tubulin 
(Tuj1) and GFAP. Scale bar=20μm. (F) PML mRNA and protein is gradually 
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decreased in cells undergoing differentiation at different time points. (G) Quantification 
shows decreased number of type B cells within SVZ in PML-/- mice compared to PML+/- 
mice. Conversely, quantification reveals an increased production of type C cells in 
PML-/- mice compared to PML+/- mice. (H) Staining and quantification reveals an 
increased number of migratory neuroblasts (DCX+) entering the region of posterior 
RMS in PML-deficient mice, whereas (I) shows a decreased number of neuroblasts 
migrating to RMS region proximal to OB. (J) Staining and quantification shows a 
significant reduction of OB neurons within the granule cell layer in PML-/- mice 
compared to control mice.(K) In vitro Edu incorporation reveals a higher percentage of 
Edu+ cells upon PML loss at all time points, indicating accelerated proliferation (i) 
whereas fewer label-retaining NSCs were propagated at later passages upon PML 
loss (ii), suggesting an exhaustion of NSCs. (L) Differentiation assay shows PML loss 
results in increased induction of neuronal generation (i) but a less terminally 
differentiated phenotype in vitro. Values represent mean ± SEM (n=3; *p<0.05; 
**p<0.01; ***p<0.001, unpaired t-test).   
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1.8.2 PML loss affects adult neurogenesis 
To determine the impact of PML loss on adult neurogenesis, the 
abovementioned fate-mapping experiments were performed in PML+/- and 
PML-/- mice. At the 1-month time point, there was a significant reduction of type 
B label-retaining cells in PML-/- mice SVZ compared to PML+/- control mice (Fig. 
1.10G). Conversely, at the 1-day time point, Edu injections identified more type 
C cells in PML-/- mice SVZ than PML+/- mice (Fig. 1.10G). To determine 
whether increased production of type C cell correlated with augmented 
migrating neuroblasts, the posterior region of RMS (RMSp) and proximal region 
to the OB (RMSob) in PML+/- and PML-/- mice at 1-day time point after last Edu 
injection (labeling migratory neuroblasts) were examined. Quantification of 
DCX+ and Edu+ cells in the posterior RMS (RMSp) revealed a significantly 
increased number of migratory neuroblasts entering the RMS in PML-/- mice 
compared to PML control mice (Fig. 1.10H). In contrast, a reduced number of 
neuroblasts were found in RMS region proximal to the OB (RMSob) in PML-/- 
mice (Fig. 1.10I), indicating a defect in SVZ-RMS-OB migration in PML-
deficient mice, though the entry into differentiation was augmented. This is in 
line with the reduced number of newly generated OB neurons in PML-/- mice 
following quantification of Edu+ and NeuN+ cells (Fig.1.10J) at the 1-month 
time point.  
In vitro, the Edu incorporation assay revealed that PML-/- SVZ NSCs contained 
higher amount of Edu+ cells than PML+/- cells when normalised to total amount 
of DAPI+ cells (Fig. 1.10K,i), mimicking PML loss increased proliferation in 
vivo. Moreover, at later cell passages, a reduced number of Edu+ cells were 
revealed in PML-/- cells (Fig. 1.10K,ii), suggesting exhaustion of NSCs similar 
to in vivo. Finally, induction of NSCs differentiation and subsequent staining 
and quantification revealed that PML-/- cells more frequently entered neuronal 
differentiation (Fig. 1.10L, i), however, less terminally differentiated neurons 
were produced from PML-/- NSCs (Fig. 1.10L,ii), recapitulating the pattern in 
vivo. Taken together these results suggest that PML loss results in increased 
proliferation of progenitor cells, at the expense of NSC pool, and reduced 
neuroblast migration in RMS as well as impaired differentiation in the OB both 
in vivo and in vitro. 
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1.9 Outstanding questions and hypotheses  
Given the existing literature and previous published and unpublished work from 
our group, three main outstanding questions remain: 
1. What is the role of PML in regulation of cell migration and SVZ/OB 
neurogenesis? Unpublished work from Joanne Betts suggests that PML may 
play a role in cell migration in addition to aNSC self-renewal and progenitor 
expansion. However, evidence is needed to prove that PML loss indeed affects 
the cumulative neuronal output in the OB and as a result its size. Furthermore, 
evidence is needed to prove that migration defects could be recapitulated in 
vitro, in a NSC-intrinsic fashion.  
2. What are the molecular mechanisms underlying PML function in adult 
SVZ neurogenesis? Published work from our group shows that during 
corticogenesis PML regulates NSC expansion via regulation of the growth 
suppressor pRb. Therefore, it is possible that PML regulates aNSC migration 
through regulation of cell cycle. However, it cannot be excluded that PML 
controls migration by directly modulating pathways that are involved in cell 
migration. 
3. What is the role of PML upon neoplastic transformation? 
Unpublished work from Joanne Betts suggests PML is enriched in GBM 
belonging to the mesenchymal subtype and its expression is correlated with 
poor prognosis. Accumulating evidence supports a role of PML in maintaining 
both cancer and non-cancerous stem cells. Furthermore, NSCs serve as the 
cell of origin of GBM. One of the key features of GBM is the aggressive 
invasion through the brain parenchyma and brain cancer cells and normal 
neuroblast/NSC use the similar migratory routes. Thus it is important to 
determine the involvement of PML under neoplastic transformation to gain 
insight with respect to its role in brain tumourigenesis. 
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1.10 Aims 
1. To investigate the phenotypic changes caused by PML loss during adult SVZ 
neurogenesis  
2. To determine the molecular mechanisms underlying PML role in regulation 
of adult SVZ neurogenesis  
1.11 Potential impact 
This study has the potential to provide key insights into fundamental 
mechanisms underlying neurogenesis, in particular cell migration. Moreover, as 
alterations of neurogenesis underlie cancer development in the CNS, this work 
could have implications for our understanding of the process of neoplastic 
transformation.  
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2 Materials and Methods 
2.1 Materials 
2.1.1 Animals 
The PML-/- mice were a generous gift from P.P. Pandolfi (Beth Israel 
Deaconess Medical Center), as described previously (Regad et al. 2009), and 
the PML conditional KO (PMLF/F) mice were derived from Taconic Artemis. The 
PML RingMut mice constitutively express PML with a double mutation 
(Cys31Ala, Cys34Ala), disrupting the first zinc ion-binding site of the RING 
domain (Moravcsik et al. 2013). Mice were maintained, bred, and subjected to 
procedures under the Project Licenses 80/2325, and 70/8240, which were 
issued by the Home Office.  
2.1.2 Antibodies 
Table 3: Antibodies for immunofluorescence and western blotting	
Antibody Condition Supplier Cat.  
Bmi1 WB: 1/500 Santa Cruz sc10745 
EZH2 WB: 1/1,000 Cell Signaling 4509 
GFAP IF: 1/2,000 DAKO P0488 
H3 WB: 1/50,000 Abcam ab1791 
H3K27Ac WB: 1/2,000 Abcam ab4729 
H3K27me3 WB: 1/2,000 IF: 1/2,000 Millipore 07-449 
H3K4me3 WB: 1/2,000 Millipore 7473 
Map2 IF: 1/100 Abcam ab11267 
Nestin IF: 1/100 Millipore MAB353 
PML IF: 1/100 WB: 1/500 Millipore 5718 
SUZ12 WB: 1/500 Santa Cruz sc46264 
Tubulin WB: 1/50,000 Sigma Aldrich T5168 
Twist1 WB: 1/50 Abcam ab50887 
β-actin  WB: 1/5,000 Sigma Aldrich A5441 
βIII-tubulin  IF: 1/1,000 Covance MMS435P 
γH2AX IF: 1/500 Millipore MB5636 
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Table 4: Secondary antibodies for western blotting 
Antibody Condition Supplier Cat.  
ECL Anti-Mouse IgG WB: 1/50,000 GE Healthcare NA931V 
ECL Anti-Rabbit IgG WB: 1/50,000 GE Healthcare NA934V 
 
 
Table 5: Secondary antibodies for immunofluorescence 
Antibody Condition Supplier Cat.  
Anti-Mouse IgG Alexa Fluor 568 1/1,000 Life Technologies A11019 
Anti-Rabbit IgG Alexa Fluor 568 1/1,000 Life Technologies A11008 
 
 
Table 6: Antibodies for ChIP 
Antibody Supplier Cat.  
H3 Abcam ab1791 
H3K4me3 Millipore 7473 
H3K27me3 Millipore 07-449 
Polyclonal Rabbit anti-Mouse IgG  Dako Z0259 
 
 
2.1.3 Buffers and solutions 
Phosphate buffered saline (PBS): 137mM NaCl, 2.7mM KCl, 10mM 
Na2HPO4, 2mM KH2PO4, pH 7.4. 
 
PBS-Tween (PBS-T): PBS containing 0.1% (v/v) Tween-20. 
 
TBS: 20mM Tris-HCl pH 7.6, 150mM NaCl 
 
TBS-Tween (TBS-T): TBS containing 0.1% (v/v) Tween-20.  
 
5X Laemmli buffer: 2mM β-mercaptoethanol, 250mM Tris pH 6.8, 0.125% 
bromphenol blue, 10% SDS, 50% glycerol. 
 
1X Tris-acetate-EDTA (TAE): 1mM EDTA, 20mM acetic acid, 40mM Tris, pH 
8.0.  
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5X DNA loading dye: 10mM EDTA pH 8.0, 100mM Tris pH 8.0, 0.5% 
bromophenol blue, 50% glycerol. 
 
5X Polyethylene glycol (PEG): 50mM PEG (Sigma Aldrich, 89510), 410mM 
NaCl, 0.2% 1M Tris pH 7.5.  
 
LB Broth: 5g/L yeast extract, 10g/L NaCl, 10g/L tryptone.  
 
1X SDS-Page running buffer: 25mM Tris-HCl, 192mM glycine, 0.1% SDS 
 
1X Transfer buffer: 25mM Tris-HCl, 192mM glycine, 20% Methanol 
 
2X HEPES: 1.5mM Na2HPO4, 50mM HEPES, 280mM NaCl, adjust pH to 7.05. 
 
RIPA buffer: 0.5mM EDTA, 0.5mM MgCl2 , 50mM Tris pH 8.0, 150mM NaCl, 
1% Triton-X, 0.5% SDS, supplemented with 1:100 protease inhibitor cocktail, 
and phosphatase inhibitor (1mM NaVO4, 50mM NaF) before cell lysis.  
 
Isotonic buffer (nuclear protein extraction): 5mM MgCl2, 20mM Tris pH7.5, 
100mM NaCl, 10% glycerol, 0.2% NP-40, 0.5mM DTT, 1:500 Pimix 
 
High salt buffer (nuclear protein extraction): 0.5mM DTT, 50mM Tris pH7.5, 
600mM NaCl, 10% glycerol, 0.2% NP-40, 1:500 Pimix. 
 
8% Acrylamide gel (20ml): 9.4ml H2O, 5.3ml 30% Acrylamide mix, 5.0ml 1.5M 
Tris pH 8.8, 0.1ml 20% SDS, 0.2% APS, 12ul TEMED.   
 
10% Acrylamide gel (20ml): 7.9ml H2O, 6.7ml 30% Acrylamide mix, 5.0ml 
1.5M Tris pH 8.8, 0.1ml 20% SDS, 0.2% APS, 8ul TEMED.   
 
15% Acrylamide gel (20ml): 4.6ml H2O, 10.0ml 30% Acrylamide mix, 5.0ml 
1.5M Tris pH 8.8, 0.1ml 20% SDS, 0.2% APS, 8ul TEMED.   
 
		 75	
Cell lysis buffer (ChIP): 10mM EDTA, 50mM Tris pH 7.5, 150mM NaCl, 
1%Triton, 0.5% deoxycholate, 1% SDS. 
 
Wash buffer 1 (ChIP): 0.5mM EGTA, 10mM EDTA, 10mM Hepes pH7.5, 
0.75% Triton X-100. 
 
Wash buffer 2 (ChIP): 0.5mM EGTA, 1mM EDTA, 10mM Hepes pH7.5, 
200mM NaCl.  
 
Lysis/Sonication buffer 3: 10mM EDTA, 50mM Tris pH 7.5, 150mM NaCl, 
0.5% Deoxycholate, 1% Triton-X. 
 
PBS/BSA blocking solution: 0.25g of BSA (Sigma Aldrich, A7906) in PBS to 
a final volume of 50ml. Vortexed intensively to fully dissolve BSA. 0.22μM 
syringe filtering was required. 
 
Wash buffer A (ChIP): 1mM EDTA, 50mM Tris pH 8.0, 150mM NaCl, 0.1% 
SDS, 0.5% Deoxycholate, 1% NP40.  
 
Wash buffer B (ChIP): 1mM EDTA, 50mM Tris pH 8.0, 500mM NaCl, 0.1% 
SDS, 0.5% Deoxycholate, 1% NP40. 
 
Wash buffer C (ChIP): 50mM Tris pH 8.0, 250mM LiCl, 0.5% Deoxycholate, 
1% NP40, 1mM EDTA. 
2.1.4 Plasmids 
For knockdown studies, pGIPZ vectors were derived from the UCL Cancer 
Institute Cancer Genomic Engineering (CAGE) facility. Bmi1-overexpression, 
and FUGW vectors were derived from Addgene. The p-MIG-Cre-ERT2-GFP 
vector was a generous gift from the Hugues de Thé lab at Université Paris 
Diderot. Additionally, the pTT28-His-tagged Robo1N plasmid was a kind gift 
from Lisa Robinson, The Hospital for Sick Children. 
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2.1.5 Primers 
Primers were purchased from Invitrogen. Lyophilized primers were 
reconstituted by nuclease-free H2O into 100μM for storage in -20°C. Primers 
for qPCR were designed as intron spanning, and primers for ChIP-qPCR were 
designed using Ensemble, and validated by presence of CpG island using 
UCSC Genome Browser.  
 
Table 7: Primers for PML germline KO genotyping 
  Sequence 
Forward 1 (5'-3') TTTCAGTTTCTGCGCTGCC 
Forward 2 (5'-3') CGACCACCAAGCGAAACA  
Reverse (5'-3') TTGGACTTGCGCGTACTGTC 
 
 
 
Table 8: Primers for PML conditional KO genotyping 
  Sequence 		
Forward  (5'-3') CAAAGCCACACCATACTCATCC 
PML	F/F	
Reverse (5'-3') AAGGAGGCTCTAGGACCTAGAGG 
  	
Forward  (5'-3') CAAAGCCACACCATACTCATCC Recombination	
Reverse (5'-3') AAGGAGGCTCTAGGACCTAGAGG 
  	Forward  (5'-3') GACAAGCGTTAGTAGGCACAT 
Flippase	
Reverse (5'-3') GGCAGAAGCACGCTTATCG 
 
 
 
Table 9: Primers for PML RingMut genotyping 
  Sequence 
Forward  (5'-3') CAACTCCCAGCAACCACATGG 
Reverse (5'-3') GCCGCATGTCAGCTCAATGAC 
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Table 10: List of primers for qPCR and ChIP-qPCR 
Gene Forward (5'-3') Reverse (5'-3') 
GAPDH ACCACAGTCCATGCCATCAC TCCACCACCCTGTTGCTGTA 
Twist1 GGACAAGCTGAGCAAGATTCA CGGAGAAGGCGTAGCTGAG 
Slit1 CAAGAACATCCCACGGAACAC TCCACAGCTCCGATCTGGTT 
Slit2 CCATGTAAAAATGATGGCACCTG ATCACAGTCCTGACCCTTGAA 
Robo1 CCTTCAGACCTGATCGTCTCC TGAGCGCGGGTCATCTTTG 
Scratch1 CTCTTCGGCAGACCTCGAC CCATCGTAGACCGACGCAG 
E-Cadherin CAGCCTTCTTTTCGGAAGACT GGTAGACAGCTCCCTATGACTG 
N-Cadherin CCAGCAGATTTCAAGGTGGAC TTACAGCTACCTGCCACTTTTC 
Snail1 CACACGCTGCCTTGTGTCT GGTCAGCAAAAGCACGGTT 
Fra1 ATGTACCGAGACTACGGGGAA CTGCTGCTGTCGATGCTTG 
Zeb2 ATTGCACATCAGACTTTGAGGAA ATAATGGCCGTGTCGCTTCG 
MMP3 CGATGGACAGAGGATGTCAC GACTGGGTACATCAGAGCTTCA 
MME GGGAGGCTTTATGTGGAAGC CCGGATTTGTGCAATCAAGT 
Bmi1 AAACCAGACCACTCCTGAACA TCTTCTTCTCTTCATCTCATTTTTGA 
p16Ink4a CGTACCCCGATTCAGGTG ACCAGCGTGTCCAGGAAG 
p21Cip1 TCCACAGCGATATCCAGACA GGACATCACCAGGATTGGAC 
p57Kip2 CAGGACGAGAATCAAGAGCA GCTTGGCGAAGAAGTCGT 
Ascl1 CCCCAACTACTCCAACGACT AAGTCCATTCCCAGGAGAGC 
Ccnd2 CCCGACTCCTAAGACCCATC TGCGAAGGATGTGCTCAATG 
Promoter	 Forward (5'-3')	 Reverse (5'-3')	
Twist1 CTTGCCACTACTGCTGTCAC TGCGAACCATTCAAAACCGA 
Slit2 TGTCGGGAAGTGGAGAAGAC AACAGTAATGGTGGCCCTGA 
Robo1 GGGAGCCTGAGATGGAAAGG GTTTCCTCCCTCTCCAGCC 
 
2.2 Methods 
2.2.1 DNA extraction for genotyping 
Ear snips, or cell pellet were used as starting materials. DNA extraction was 
performed using REDExtract-N-Amp™ Tissue PCR Kit (Sigma Aldrich). For 
each tube/sample, 40μl Extraction Solution + 10μl Tissue Preparation Solution 
was mixed, and the sample was fully immersed into this reaction mix. 
Incubation was carried out using a dry water bath (LabScientific) at 50°C for 20 
mins, and a subsequent 3 mins at 95°C. The 40μl Neutralisation Solution was 
mixed by vortexing it with the 50μl reaction mix. For genotyping PCR, 4μl DNA 
was used.  
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2.2.2 DNA sequencing 
Desired plasmid DNA was prepared in an appropriate concentration together 
with defined sequencing primers following the instructions from the company 
(Source Bioscience). Data were retrieved using 4Peaks software, and 
sequence alignment was carried out by EMBOSS Needle. 
2.2.3 Genotyping  
To determine the PMLF/F/WT alleles and flippase transgene, PCR programme 
was carried out by: initial denaturation at 95°C for 5 mins; denaturation at 95°C 
for 30 secs; annealing at 60°C for 30 secs; and extension at 72°C for 1 min. 
Amplification was repeated for another 34 cycles from the denaturation step: 
final extension at 72°C for 10 mins. Expected amplicons were WT: ~170bp; 
PMLF/F: ~289bp; and flippase transgene: ~340bp. See Table 8 for primers. 
To determine the recombination upon 4-OHT treatment, PCR programme was 
carried out by: initial denaturation at 95°C for 5 mins; denaturation at 95°C for 
30 secs; annealing at 60°C for 30 secs; and extension at 72°C for 1 min 30 
secs. Amplification was repeated for another 34 cycles from the denaturation 
step: final extension at 72°C for 10 min. Expected amplicons: Recombined: 
~300bp; and PMLF/W : ~1.5Kb. See Table 8 for primers. 
To determine the PML RingMut, PCR programme was carried out by: initial 
denaturation at 95°C for 5 mins; denaturation at 95°C for 1 min; annealing at 
57°C for 1 min; and extension at 72°C for 1 min. Amplification was repeated for 
another 34 cycles from denaturation step: final extension at 72°C for 6 mins. 
Expected amplicons: WT: ~200bp; and RingMut: ~254bp. See Table 9 for 
primers. 
To determine the PML WT/KO alleles, PCR programme was carried out by: 
initial denaturation at 95°C for 10 mins; denaturation at 94°C for 1 min; and 
annealing at 59°C for 1 min. Amplification was repeated for another 34 cycles 
from denaturation step: final extension at 72°C for 1 min. Expected amplicons: 
WT: ~400bp; and KO: ~600bp. See Table 7 for primers. 
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2.2.4 Agarose gel electrophoresis 
PCR products were visualised, and separated by agarose gel electrophoresis. 
Concentration of agarose gel (Sigma Aldrich, A9539) was determined by the 
size of the amplicons, which ranged from 1% to 2%. For genotyping, samples 
were loaded directly. For other reactions, DNA was mixed with DNA loading 
dye (into 1X concentration), and electrophroresis was performed for 
approximately 25 mins at 100V. After electrophoresis using a PowerPacTM 
Power Supply (Bio-Rad), bands were visualised using a G:BOX Gel imaging 
system (Syngene). 
2.2.5 Measurement of OB size 
Briefly, the whole brain was dissected from two adult mice, and the whole brain 
was isolated carefully using dedicated surgical tools. The brains were placed 
horizontally in a 10cm petri dish, and photos were taken using a Nikon D3S 
Digital SLR camera with a Nikon AF Micro Nikkor 60mm f/2.8D macro lens. 
Quantification was achieved using ImageJ area measurement. Finally, OB size 
was determined by plotting the area of the OB over the area of the rest of the 
brain.  
2.2.6 Isolation of SVZ aNSCs  
The isolation of adult mouse NSCs/progenitors was performed as previously 
described (Pollard et al. 2006). Essentially, the olfactory bulbs, cerebellum, and 
brainstem were removed from the dissected brain, and an area encompassing 
the SVZ surrounding the lateral wall of the forebrain ventricle was dissected 
under microscope. Tissue was subsequently incubated in Accutase 
(STEMCELL Technologies) for 25 mins at 37°C, and mechanically dissociated. 
Cells were plated onto a laminin-coated petri dish/flask in NeuroCult 
Proliferation Kit (STEMCELL Technologies, 05702) medium supplemented with 
10 ng/mL of both bFGF-2, and EGF (Peptrotech).  
2.2.7 Tissue culture 
Human embryonic kidney cells (HEK 293T) were maintained in a DMEM (1X) + 
GlutaMAXTM-I medium with 10%FBS (LifeTechnologies, 31966-021). Phoenix 
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cells were maintained in an IMDM+GlutaMAXTM-I medium with 10% FBS, and 
aNSCs were cultured in a NeuroCultTM Proliferation Kit (STEMCELL 
Technologies) supplemented with 10 ng/mL of both bFGF-2, and EGF 
(Peptrotech). HEK 293T and Phoenix cells were dissociated from the petri dish 
using 1X Trypsin (Gibco), and the aNSCs were dissociated from the tissue 
culture flask using Accutase (STEMCELL Technologies, 05702). Cell number 
and size were determined by Vi-CELL XR (Beckman Coulter). All cells were 
maintained at 37°C with 5% CO2. HEK 293T and Phoenix cells were 
cryopreserved using a defined medium containing 10% DMSO, 45% 
DMEM/IMDM, and 45% FBS, and stored in -80°C for short-term storage, and in 
liquid nitrogen for long-term storage. The aNSCs were cryopreserved using a 
defined medium containing 10% DMSO with 90% NeuroCultTM Proliferation 
medium, snap frozen on dry ice, and transferred at -80°C overnight, and in 
liquid nitrogen the following day. Cells were thawed in a water bath at 37°C 
before transferring the cell suspension in a 15ml Falcon tube with a pre-
warmed medium. Cell suspension was subjected to centrifugation at 1,200 rpm 
for 4 mins, and supernatant containing DMSO was completely removed. Cell 
pellet was resuspended in a normal expansion medium, and plated onto a petri 
dish/tissue culture flask.  
2.2.8 Immunofluorescence  
A total of 60,000 cells/well were plated onto laminin-coated glass coverslips in 
a 24-well plate prior to fixation. The following day, fixation was performed in 4% 
PFA for 10 mins. The cells were washed three times in PBS, and 
permeabilised in a 0.5% Triton solution (in PBS). Blocking was subsequently 
performed in 5% goat serum (in 0.1% PBS-Tween (v/v)) for 1 hour at room 
temperature. Primary incubation was carried out by a diluting antibody (Table 
3) in blocking solution, and incubated overnight at 4°C. The following morning, 
cells were washed 3 times with 0.1% PBS-Tween, and incubated with 
secondary antibodies (in blocking solution, described in Table 5) for 1 hour 
(covered with foil). Cells were washed 3 times with PBS, and counterstained 
with Hoescht (1:10,000 in PBS) for 15 mins at room temperature (covered with 
foil), and mounted. Staining was examined under a fluorescence microscope 
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(Zeiss AxioImager A1), and at least 5 different scopes were taken for 
quantification purpose. 
2.2.9 Differentiation assay 
A total of 200,000 cells/coverslip were plated at day 0 in a normal expansion 
medium onto laminin-coated glass coverslips. The following day, the expansion 
medium was replaced with medium supplemented only with bFGF-2 
(10ng/mL), and cells were incubated for additional 3 days. A NeuroCultTM 
Differentiation Kit (STEMCELL Technologies, 05704) was subsequently 
introduced for 5 days. Cells were then fixed, and subjected to 
immunofluorescence.  
2.2.10  EdU incorporation assay in vitro 
A total of 50,000 cells were plated on top of laminin-coated coverslips in 24-
well plates, and after 24 hours, EdU (10µM) was added to the medium. After 2 
hours, cells were fixed in 4% PFA for 10 minutes. Edu was detected using a 
Click-iT® EdU Alexa Fluor® 555 Imaging Kit (Applied Biosystem) as per the 
manufacturer’s instructions. Nuclei were stained with DAPI for 15 minutes, and 
coverslips were mounted for microscopy using FluorSave™ Reagent 
(Millipore). Quantification was performed by counting Edu-positive cells over 
the number of total DAPI-positive live cells in at least 5 different 
areas/coverslips.  
2.2.11  RNA extraction 
A total of 300,000 cells per well were plated onto a 6-well plate the day before 
the experiment. Cells were harvested using Accutase, and subjected to RNA 
extraction using the RNeasy® Plus Mini Kit (QIAGEN, 74134). β-
mercaptoethanol (β-ME) was added to Buffer RLT Plus in a 1:100 (v/v) ratio 
before use. Cells were disrupted and homogenised using Buffer RLT Plus (+β-
ME), and vortexing for 30 secs. Lysates were transferred to a gDNA Eliminator 
column, and centrifugation was performed at 11,000 rpm for 30 secs to remove 
genomic DNA from lysates. A 1:1 (v/v) ratio of 70% ethanol was added to the 
flow-through, and the total mixture was transferred to an RNeasy spin column, 
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and subjected to centrifugation at 11,000 rpm for 15 secs. Column-bound total 
RNA was washed twice with Buffer RPE, first at 11,000 rpm for 15 secs, and 
once again at 11,000 rpm for 2 mins. Final elution was performed using 30μl 
RNase-free H2O, and by centrifugation at 11,000 rpm for 1 min. RNA 
concentration was determined by ND-1000 NanoDropTM Spectrophotometers 
(ThermoScientific). 
2.2.12  Reverse transcription (cDNA synthesis) 
Reverse transcription was performed using High Capacity cDNA Reverse 
Transcription Kits (Applied Biosystems). 500ng-1μg RNA was added into the 
2X reaction mix containing RT Buffer, RT Random Primers, dNTP Mix, 
MultiScribeTM Reverse Transcriptase, and RNase-free H2O in a final volume of 
20μl. The PCR programme was perform as follows: 25°C for 10 mins; 37°C for 
120 mins; and 85°C for 5 mins. cDNA was further diluted for subsequent real-
time PCR analysis.  
 
2.2.13  Real-Time PCR (qPCR) 
Real-time PCR was performed using 2X Fast SYBR Green Master Mix (Applied 
Biosystems), dedicated primers (Table 10), RNase-free H2O, and cDNA in a 
final volume of 20μl (cDNA were loaded as replicates). PCR programme was 
performed as follows: 50°C for 2 mins; 95°C for 10 mins; 95°C for 15 secs (40 
cycles); and 60°C for 1 min in a 7500 Fast Real-Time PCR System (Applied 
Biosystems). Relative abundance of gene expression was normalised to 
GAPDH mRNA, and calculation was generated using the 2-ΔΔCt method as 
previously described (Livak and Schmittgen 2001). 
2.2.14  Chromatin immunoprecipitation (ChIP) 
Chromatin pulled down by immunoprecipitation was employed to study the 
DNA-protein interaction. Protocol was adapted from original protocol by Dr 
Suzana Hadjur (UCL Cancer Institute).  
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2.2.14.1 Cell fixation and crosslinking 
A total of 5x106 cells were plated onto a T75 flask, and expanded to obtain 
sufficient starting materials. Ideally, cells were grown into 80% confluent per 
flask. Cells were collected by Accutase, and washed once with PBS. Cell 
number was determined by Vi-CELL XR (Beckman Coulter), and 12x106 cells 
were pelleted down per condition (PML+/- or PML-/-). Cell pellet was 
resuspended in a normal proliferation medium containing 1% formaldehyde 
(FA) (in total 10ml) for a fixation of 10 mins at room temperature. Fixation was 
quenched by adding 0.125M glycine (solution turned yellow) for 5 mins at room 
temperature, and rotating on a tube roller (STAR LAB). Cell pellet was 
subjected to centrifugation at 2,500 rpm for 5 mins at 4°C, and supernatant was 
removed. Cell pellet was washed twice in ice-cold PBS, and spun down at 
2,500 rpm for 5 mins at 4°C. The fixed, washed pellet could be snap frozen, 
and stored at -80°C. 
 
2.2.14.2 Preparation of nuclear extracts 
Following fixation and crosslinking, cell pellet was resuspended in a 10ml Wash 
buffer 1, and incubated by rotating on a tube roller for 10 mins at 4°C. 
Centrifugation was performed at 2,500 rpm for 5 mins at 4°C, and supernatant 
was removed. Cell nuclei were resuspended in 10ml Wash buffer 2, and 
incubated by rotating on a tube roller for 10 mins at 4°C. Centrifugation was 
performed at 2,500 rpm for 5 mins at 4°C, and supernatant was removed. Cell 
lysis was carried out using lysis/sonication buffer 3 containing 1% SDS with 
protease, and phosphatase inhibitors in a total volume of 300μl. Cell lysis was 
performed for 30 mins on ice. Meanwhile, Diagenode Bioruptor was pre-cooled 
to 4°C.  
2.2.14.3 Sonication 
Sonication was performed at 4°C, and programme was setup consisted of 15 
cycles (30 secs on, 30 secs off) on high power. Sonication was repeated 3 
times to reach 45 cycles in total. After every 15th cycle, the sonicator was 
allowed to cool down for 3 mins prior to the next round commencing. After 
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sonication, 5μl of sample was taken in a pre-chilled eppendorf tube (left on ice), 
and the remaining sample was centrifuged at 13,000 rpm for 30 mins at 4°C. 
An additional 5μl sample was taken in a pre-chilled eppendorf tube, and the 
remaining chromatin could be stored at -80°C. To check the sonication 
efficiency, de-crosslinking was performed by adding 5μl Proteinase K (BioLine 
Reagen), and 90μl 100mM Tris pH7.5. De-crosslinking mixture was incubated 
overnight at 65°C, and the following morning, the mixture was incubated with 
2μl RNase for 1 hour. DNA was purified using QIA Quick PCR Purification Kit 
(QIAGEN, 228106), as per the manufacturer’s instructions. Fragmentation 
could be visualised by running on a 2% agarose gel, and  ideally, the band 
smear should be restricted to 200bp~500bp.  
2.2.14.4 Chromatin immunoprecipitation 
Dynabeads Protein G (Life Technologies, 1004D) blocking was performed for 1 
hour in cold room using freshly prepared PBS/BSA. Chromatin and BSA-
blocked beads were incubated for 2 hours in cold room, and then overnight in 
3μg of anti-H3, anti-H3K27me3, anti-H3K4me3, and anti-IgG (see Table 6). 
The following day, sequential washing steps were performed using wash buffer 
A, wash buffer B, and wash buffer C as follows: once with wash buffer A, 
quickly inverted while on the magnet rack; twice with wash buffer A, rotating for 
10 mins on a windmill; once with wash buffer B, quickly inverted while on the 
magnet rack; an additional time with wash buffer B, rotating 10 mins on a 
windmill; once with wash buffer C, quickly inverted while on the magnet rack; 
and an additional time with wash buffer C, rotating 10 mins on a windmill. 
During the washing steps, a magnet rack was used to segregate magnetic 
beads from the wash buffers. After the washing steps were completed, protein-
DNA de-crosslinking was performed using buffer (1% SDS, 0.1M NaHCO3, 
Proteinase K) at 65°C overnight, while shaking on a Thermomixer (Eppendorf), 
which was also used during RNAse-A treatment for an additional 2 hours at 
37°C the following morning. The samples were purified using the phenol-
chloroform method. 
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2.2.14.5 ChIP-qPCR 
To determine the enrichment of relevant histone marks at the level of gene 
promoter regions, ChIP-qPCR promoter primers were designed (Table 10). 
PCR programme was performed as follows: 50°C for 2 mins; 95°C for 10 mins; 
95°C for 15 secs (40 cycles); and 60°C for 1 min on a 7500 Fast Real-Time 
PCR System (Applied Biosystems). Amplification was performed using 2X Fast 
SYBR Green Master Mix (Applied Biosystems), and calculation was carried out 
by the percentage input formula: 
100 x 2 ^ (Ctadjusted input-CtIP ) 
In the percentage input formula, input was adjusted by subtracting 6.644 
(Log2100), and the data were normalised to the enrichment of H3, and to the 
PML control cells (as 1).  
2.2.15  Total protein extraction 
Between 600,000 and 800,000 cells were plated onto a T25 flask the day 
before extraction. The following day, cells were washed once in PBS, which 
was previously collected by Accutase. The RIPA buffer was freshly prepared 
before the experiment. Cell pellet was resuspended in RIPA buffer, and 
incubated on ice for 20 mins. Sonication was performed (SONICS) twice using 
30% power for 4 secs (on ice). Lysates were subjected to centrifugation at 
13,200 rpm for 5 mins. Supernatant was collected, and transferred to a pre-
chilled eppendorf tube, and protein concentration was determined by BCA 
assay. As soon as the concentration was measured, a 5X Laemmli buffer was 
added to extracts.  
2.2.16  Nuclear protein extraction 
A total of 5X106 cells were plated onto a T75 flask with normal expansion 
medium the day before extraction. The following day, the medium was 
removed, and cells were washed once with PBS, and collected using Accutase. 
An isotonic buffer, and high salt buffer were freshly prepared prior to the 
experiment. Cell pellet was firstly lysed with isotonic buffer, and 
homogenisation was performed rigourously in an up and down motion using a 
P1000 Gilson for at least 3 cycles (10 mins on ice, 10 mins for 
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homogenisation). To assess the efficiency for homogenisation, cell lysates 
were stained with trypan blue (1:1 ratio), which enables faint blue nuclei with 
stark nuclear membrane to be observed under microscope. Nuclei were 
pelleted by centrifugation at 13,200 rpm for 20 mins at 4°C. Cytosolic 
supernatant was transferred to another fresh pre-chilled eppendorf tube, and 
the cell nuclei pellet was further lysed by high salt buffer for 30 mins on ice. 
Sonication was subsequently performed (SONICS) twice using 20% power for 
15 seconds (on ice). Lysates were subjected to centrifugation at 13,200 rpm for 
5 mins, and nuclear extract was collected, and transferred to a fresh pre-chilled 
eppedorf tube. Protein concentration was determined by BCA assay. As soon 
as the concentration was measured, a 5X Laemmli buffer was added to the 
extracts. 
2.2.17  Measurement of protein concentration 
Protein concentration was determined using a colorimetric BCA Protein Assay 
Kit (Pierce, 23225). The working solution was made by mixing 1ml BCA 
Reagent A+20μl BCA Reagent B per sample, and the 2μl protein sample was 
mixed with working solution by vortex, and subjected for incubation in a water 
bath at 37°C for 45 min. A standard curve was generated from the gradient 
BSA protein concentration (blank, 0.5, 1, 1.5, 2, 3,4, 6, 8, 10, unit: μg/μl), and 
was used to determine the desired protein concentration. The colorimetric 
readout was measured by a Spectrophotometer (Jenway, LAB070) at 562 nm.  
2.2.18  Western blotting 
Protein extracts were adjusted to equal volume using a 1X Laemmli buffer, 
which generated an equal amount and volume of protein extracts per sample. 
Based on the size of the proteins, acrylamide gel (8%, 10%, and 15%), and 
CriterionTM TGX Stain-FreeTM Precast Gels (Bio-Rad) were used to separate 
the proteins. Electrophoresis was performed in freshly prepared in an 1X SDS-
Page running buffer, and electrophoretic protein transfer was carried out using 
a wet Criterion Blotter (Bio-Rad) onto an Amersham Protran Nitrocellulose 
Blotting Membrane (GE Healthcare, 10600002) in a freshly prepare 1X 
Transfer buffer. For acrylamide gels, a 150 mins protein transfer was 
performed at 60V, and for precast gels, a 60 mins protein transfer was 
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performed at 100V with ice cubes. Protein transfer was visualised by a short 
incubation of Ponceau S (Sigma Aldrich) staining of nitrocellulose membrane, 
and blocking was performed in dried skimmed milk (5%, Marvel) with PBS-T for 
1 hour at room temperature. Primary antibody incubation (Table 3) was 
performed on a tube roller (STAR LAB) at 4°C overnight, and the following day, 
washing was performed in PBS-T 3 times for 10 mins each. Secondary 
antibody (Table 4) was performed at room temperature for 1 hour, and a 
protein of interest was subsequently detected using Pierce ECL Western 
Blotting Substrate (Thermo Scientific, 32106) with Super RX-N film (Fujifilm). 
Notably, for Twist1, SuperSignal® West Dura Extended Duration Substrate 
(Thermo Scientific, 34076) was employed.  
2.2.19  Extracellular Matrix (ECM) assay 
ECM assay was performed using BD BioCoat Matrigel Invasion Chambers (BD 
Bioscience, 354480), and Falcon Translucent Insert (BD Bioscience, 353097) 
as control inserts as per the manufacture’s instructions. Essentially, 50,000/well 
were plated in invasion and migration chambers, and 40ng/mL of both bFGF-2, 
and EGF were used as chemoattractant in the bottom wells. Cells were 
immersed in the normal culture conditions for incubation, and after 48 hours, 
cells were fixed using 100% methanol (pre-chilled in -20°C) for 2 mins, and 
stained with DAPI for 30 mins at room temperature. Images were obtained 
using a fluorescence microscope (Zeiss AxioImager A1), and quantification of 
DAPI-positive cells was undertaken using Cell Profiler with optimised pipeline. 
An invasion index was plotted as the number of DAPI-positive cells passing 
invasion chambers, divided by the number of cells passing control chambers. 
For the supernatant ECM assay, 5x106 cells were plated onto a T75 flask with 
12ml medium the day prior to the experiment to obtain sufficient materials. The 
following day, the medium from PML+/- and PML-/- cells was taken, and filtered 
through a 0.45μm cell strainer. Medium from PML-/- cells was used on top of 
PML control cells. Remaining steps were carried out as above.  
2.2.20  Plasmid DNA purification 
A JetStarTM 2.0 Plasmid Purification Kit (Genomed) was used for purification of 
plasmid DNA. Desired plasmid DNA was inoculated overnight with 200ml LB 
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medium supplemented with 100μg/ml ampicillin (Sigma Aldrich). The following 
day, bacteria were concentrated by centrifugation at 12,000g for 3 mins, and 
supernatant was removed. Pellet was lysed in Buffer E1 (supplemented with 
RNase) fully until homogeneous. Cell suspension was mixed with Buffer E2 
gently, with no vortex, until homogeneous, and incubated at room temperature 
for 5 mins. The mixture was neutralised by Buffer E3 immediately by inverting 
the tube up and down several times until homogeneous. Mixture separation 
was performed by centrifugation at 12,000g for 10 mins, and the supernatant 
was loaded onto an equilibrated column (using Buffer E4) to allow the DNA to 
be bounded by the column. Washing was performed once using Buffer E5, 
elution was subsequently performed using Buffer E6, and precipitation of DNA 
was carried out using isopropanol. Precipitate was concentrated by 
centrifugation at 12,000g for 30 mins, and supernatant was removed and pellet 
DNA was washed once with 70% ethanol at 4°C. Purified DNA pellet was air-
dried at room temperature for approximately 10 mins, and dissolved in 
nuclease-free H2O. DNA concentration was determined the following day by 
NanoDropTM Spectrophotometers (Thermo Scientific). 
 
2.2.21  Virus particle production 
Lentivirus production was achieved using HEK 293T cells, and retrovirus 
production was performed using Phoenix cells. For lentivirus, 6X106 HEK 293T 
cells were plated onto a 15cm dish with 20ml DMEM (10% FBS) at day 0. The 
following day, transfection (per plate) was carried out using solution containing 
24ug plasmid of interest, 15.6ug pCMV-HIV-1, 7.2ug pCMV-VSV-G, 100uL 
CaCl2 (2.5M), and 900uL H2O. The mixture was mixed by vortexing, and 
equilibrated for 30 mins at room temperature. Precisely 1,000uL pre-warmed 
(37°C) 2X HEPES was subsequently introduced into the DNA-calcium chloride 
mixture, mixed by pipetting up and down, and incubated for exactly 1 min. The 
transfection mixture was introduced to each HEK 293T cells plate drop by drop, 
and the plate was stirred gently. The medium was changed after 8 hours, and 
after 48 hours (from the time the medium was changed), viral supernatant was 
collected, and subjected to polyethylene glycol (PEG) precipitation.  
		 89	
For retrovirus, 2.5X106 Phoenix cells were plated onto a 10cm dish with 10ml 
IMDM (10% FBS) at day 0. The following day, transfection (per plate) was 
performed using 20ug plasmid of interest, 1.2ug packaging plasmid (SARA III 
vector, Salomoni lab), 250uL CaCl2 (1M), and H2O to a final volume of 1,000ul. 
The mixture was mixed by vortexing, and equilibrated for 30 mins at room 
temperature. 1,000uL pre-warmed (37°C) 2X HEPES was subsequently 
introduced into the DNA-calcium chloride mixture, and mixed by pipetting up 
and down, and incubated for exactly 1 min. The transfection mixture was 
introduced to each Phoenix cell plate drop by drop, and the plate was gently 
stirred. The medium was changed after 8 hours, after 36 hours (from the time 
the medium was changed), viral supernatant was collected, and subjected to 
PEG precipitation.  
2.2.21.1 PEG precipitation for virus particle concentration 
5X PEG was prepared as described previously. PEG solution was mixed well, 
and heated in a microwave. The pH level was adjusted to 7.2, and the solution 
was autoclaved, and stored in a fridge (4°C) for long-term usage. For virus 
particle precipitation, supernatant was collected and centrifuged at 3,000g for 
15 mins. Upper phase supernatant was filtered via a 0.45um PVDF filter to 
eliminate cell debris, and the supernatant was transferred to a sterile vessel, 
with 1 volume of cold 5X PEG added. The solution mix was refrigerated at 4°C 
overnight. The following day, the viral-supernatant/PEG mixture was 
centrifuged at 1,500g for 30 mins at 4°C. Upper phase supernatant was 
discarded, and residual solution was further centrifuged at 1,500g for 5 minutes 
at 4°C. The supernatant was carefully removed, and viral pellet was 
resuspended in cold PBS. Virus particles were aliquoted in PCR tubes, and 
stored at -80°C. Titration was determined by serial infection, and analysed by 
FACS (see the following paragraph). 
2.2.21.2 Virus tittering by FACS analysis 
Virus tittering was performed using HEK 293T cells, and the day prior to the 
experiment, 70,000 cells/well were plated onto a 24-well plate in a final volume 
of a 500μl medium. In total, 8 wells were needed for each virus: 6 wells were 
plated for serial dilution; and an additional 2 well were also plated, one for cell 
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counting prior to transduction, and one for untransduced control. The following 
day, 1 well was used to determine the cell number prior to transduction. Serial 
dilutions of the virus particles were performed using DMEM medium (+10% 
FBS) in eppendorf tubes, and to obtain 10-2 to 10-7 dilutions, a 2.5μl stock virus 
was added to 247.5μl medium for a final volume of 250μl (10-2 well). In next 
tube, 25μl of virus from 10-2 well was added into 225μl medium for a final 
volume of 250μl (10-3). Serial dilutions were further performed until the 10-7 
dilution was obtained. Following this process, the medium from 24-well was 
removed. Subsequently, 200μl of diluted virus particles were added to 
corresponding wells, leaving 1 well for untransduced control. Cells were 
incubated overnight at 37°C, and after 24 hours, the medium containing virus 
particles was removed, and replaced with fresh DMEM medium (+10% FBS). 
Cells were incubated at 37°C for an additional 48 hours. At 72 hours post 
transduction, GFP expression should range from around 100% to 0% when 
viewed under a fluorescent microscope. Flow cytoemetry was performed for 
the wells obtaining approximately 5% to 2% GFP+ cells. The following equation 
was used to determine the tittering of virus: 
T=(P x N) / (D x V) 
In this equation, T is the final titer of virus (TU/ml), P is the percentage of GFP+ 
cells (e.g. N = 0.2 for 20% GFP+ cells), N is the number of cells prior to 
transduction, D is the dilution factor (e.g. 10-4 = 0.0001), and V is the volume of 
virus-containing medium (200μl). 
2.2.22  Virus transduction of aNSCs 
80,000 cells/well in a 12-well plate were plated in a final volume of 500μl 
medium the day prior to transduction. Cells should be approximately 60% 
confluent, and look healthy. The medium was changed the following morning 1 
hour prior to transduction. For retrovirus transduction, 5μg/ml polybrene was 
added to the medium, and cells were transduced with virus using appropriate 
MOI (MOI1, or MOI 2) for at least 1 hour, and up to 6 hours. Virus-containing 
medium was removed and replaced with normal proliferation media. Ideally, 
viral vector carrying fluorescent reporter should be visualised under a 
fluorescent microscope 48 hours post-transduction, and based on the 
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percentage of reporter+ cells, cell sorting may be carried out. For viral vector 
containing resistance (e.g. puromycin), 72 hours post-transduction selections 
were performed.  
2.2.23  Robo1N purification 
A total of 2x106 HEK 293T cells were plated onto a 10cm petri dish with 10ml 
DMEM medium. 20μg of pTT28-His-tagged Robo1N plasmid was transfected 
to obtain sufficient starting materials. After 120 hours incubation, the medium 
was collected, and subjected to centrifugation at 4,000g for 15 mins. 
Supernatant was filtered through a 0.45μm cell strainer, and purification was 
performed using the Ni-NTA Superflow Cartridges (QIAGEN, 30760). 
Essentially, a syringe (50ml) was filled with Buffer NPI-10, and the buffer was 
expelled by air depressing. The syringe was attached to the cartridge inlet, and 
the cartridge outlet stopper was removed. The cartridge was equilibrated using 
10 column volumes of buffer. The syringe was then removed, and lysate was 
applied to the cartridge. Washing was performed by applying a fresh syringe 
with 10 column volumes of Buffer NPI-20, and the protein was eluted using 
Buffer-NPI 250, and concentrated by Amicon® Ultra Centrifugal Filters 
(Millipore). Protein concentration was determined by BSA assay, as described 
previously.  
2.2.24  Statistical analysis 
All values and graphs were expressed as mean ± SEM (standard error of the 
mean), and statistical analyses were performed using unpaired two-tailed t 
tests, unless specified (GraphPad Prism). A statistically significant difference 
was indicated by a P value of less than 0.05. 	 	
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3 Results 
3.1 PML loss results in reduced olfactory bulb size  
Based on the data that PML loss leads to impaired cell migration in SVZ-RMS-
OB route and impaired differentiation in OB (Joanne Betts), it was speculated 
that this process may affect the overall neuronal output displayed in OB. 
Therefore, the present research investigates the effect of PML loss on OB size. 
To test this effect, dissection and measurement of the whole brains were 
performed from four pairs of adult mice (6-months-old, same gender within 
each pair). OB size was measured and plotted as the ratio between the areas 
of OB and the rest of the brain using specific software solutions (see Materials 
and Methods). Interestingly, quantification revealed a significant reduction of 
OB size in PML-/- mice compared to PML+/- mice (Fig. 3.1A). Our previous work 
has demonstrated that PML loss leads to a smaller brain at birth, whilst adult 
mice display only a 10% thinning of the cortex wall, and no differences in 
overall brain size (Regad et al. 2009). Nonetheless, the present research aims 
to formally exclude the possibility that the reduced OB size was due to reduced 
overall brain size. Therefore, data were plotted as the rest of the brain, and OB-
only (Fig. 3.1B). Indeed, no difference was found in size of the rest of the brain 
between PML+/- and PML-/- mice. However, the OB size itself was significantly 
smaller in PML-/- mice than in control mice (Fig. 3.1B), indicating the difference 
from the ratio was primarily due to the difference in OB size. In addition, and as 
reported previously, the phenotypes of PML+/+ and PML+/- mice were 
undistinguishable (Regad et al. 2009). To further confirm this finding with 
regard to adult OB size, an additional four pairs of mice were used to conduct 
the measurement. As expected, no differences were found in neither in the 
ratio of OB size (Fig. 3.1C) nor the rest of brain or OB-only (Fig. 3.1D) between 
PML+/+ and PML+/- mice.  
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Figure 3.1: PML loss results in reduced olfactory bulb size. 
 (A) Representative images revealed reduced OB size in PML-/- mice. Histograms plot 
the ratio of the OB size over the rest of the brain, and the values represent mean ± 
SEM (n = 4; ***p < 0.001, paired ratio t-test), and scale bar = 5mm. (B) Although, a 
reduction in OB size had no affect on the rest of the brain (-OB) in PML-/- mice 
compared to control mice. Values represent mean ± SEM (n = 4; **p < 0.01; n.s. = 
non-significant, paired ratio t-test). (C), (D) Representative images and quantification 
revealed no difference in OB size, or in the separate measurement for the rest of the 
brain, and OB-only between PML+/+, and PML+/- mice. Values represent mean ± SEM 
(n = 4; n.s. = non- significant, paired ratio t-test). 	 	
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3.2 PML loss affects cell migration in vitro 
Subsequently, the present research investigated whether the changes in cell 
migration observed in vivo could be recapitulated in vitro. aNSCs were used as 
an in vitro model system, as this allowed investigation of the intrinsic nature of 
phenotypic changes observed in vivo, as well as studying the underlying 
molecular mechanisms. Moreover, aNSCs have been suggested to acquire 
migratory properties in response to injury (Faiz et al. 2015). Adult NSCs (6-
month) were extracted from the SVZ region, and grown in vitro as adherent 
cells (Pollard et al. 2006). These adherent NSCs could then be propagated in 
vitro with the presence of EGF and b-FGF in a defined serum-free medium 
(Conti et al. 2005; Pollard et al. 2006; Pollard et al. 2008). This in vitro system 
makes it possible to study a number of aNSC biological features and 
behaviours such as migration, proliferation, and differentiation (Reynolds and 
Weiss 1992; Palmer et al. 1995; Doetsch et al. 1999a; Laywell et al. 2000; 
Gregg and Weiss 2003). To assess the cell migration capability, extracellular 
matrix (ECM) transwell assays were employed (Fig. 3.2A). The manufacturer’s 
conditions were amended to use 4x grow factors as chemoattractant in the 
bottom chamber (see Materials and Methods). DAPI+ cells passing the ECM 
at 48 hours were captured (Fig. 3.2B,i), and subsequent quantification (Fig. 
3.2B,ii) revealed that PML-/- cells had significantly impaired migration 
compared to PML+/- control cells (Fig. 3.2C). Interestingly, a similar pattern of 
impaired migration was observed (Fig. 3.2D) in cells derived from a PML 
knock-in mutant mouse (PML RingMut), which expresses wild-type PML, but 
lacks PML-NBs (Moravcsik et al. 2013), indicating that PML promotes cell 
migration via a PML-NB-dependent mechanism. Notably, the observed 
differences in cell migration through the ECM were not due to changes in cell 
size (~13μm for both control and PML-deficient cells).  
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Figure 3.2: PML loss affects cell migration in vitro. 
(A) Schematic illustration details the conditions optimised for in vitro ECM assay. 
Importantly, the Matrigel, and control inserts were placed into separate wells based on 
experimental design. (B) (i) Representative images illustrate DAPI+ cells passing the 
ECM at the 48h time point; (ii) Representative images illustrate the quantification of 
DAPI+ cells using Cell Profiler with optimised pipeline outlining the cells. (C) ECM 
assay revealed impaired migration upon PML loss compared to PML+/- cells. Values 
represent mean ± SEM (n = 3; ***p < 0.001, unpaired t-test). (D) ECM assay revealed 
impaired migration in PML RingMut, and PML-/- cells compared to PML+/+ cells. Values 
represent mean ± SEM (n = 3; *p < 0.05; **p < 0.01, one-way ANOVA). (E) ECM 
assay using supernatants from PML-/- cells on top of PML+/- cells revealed a similar 
migration-compromised pattern as observed in PML-/- cells. Values represent mean ± 
SEM (n = 3; ***p < 0.001, unpaired t-test). 
 
However, the observed differences could not only be due to changes in 
intracellular signalling pathways controlling cell movement, but also to altered 
secretion of factors affecting cell migration in an autocrine or paracrine fashion. 
To test this hypothesis, we set up ECM assays based on incubation with 
supernatants from control or PML-deficient cells (see Materials and Methods). 
Supernatants from PML-/- cells (cultured for 24 hours before experiment) 
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severely impaired migration of PML+/- cells (Fig. 3.2E), indicating that soluble 
factors could influence the defect migration upon PML loss in an autocrine or 
paracrine fashion.  
3.3 Discussion 
Previous work from our lab has demonstrated the role of PML in embryonic 
CNS neurogenesis, with implications for regulation of neural stem/precursor 
cell fate, and cortex development and size (Regad et al. 2009) (see Fig. 1.9). 
However, the role of PML in adult neurogenesis has remained unexplored. 
Supporting data produced by Joanne Betts demonstrates that PML is 
expressed in aNSCs derived from SVZ, as well as in type C cells and migrating 
neuroblasts in RMS, although its expression gradually decreases alongside 
differentiation. This finding indicated the potential roles of PML in aCNS stem 
cells and SVZ-RMS-OB neurogenesis, in addition to its role during embryonic 
CNS development. Indeed, PML loss leads to increased proliferation of aNSCs 
both in vivo, and in vitro (Fig. 1.10G & K, i). It has also been demonstrated that 
PML interacts with pRb and p53 to control cell growth (Alcalay et al. 1998; 
Fogal et al. 2000; Guo et al. 2000; Pearson et al. 2000; Salomoni and Pandolfi 
2002; Vernier et al. 2011; Acevedo et al. 2016). In this respect, previous work 
from our lab has demonstrated that PML regulates embryonic neurogenesis 
through its ability to control phosphorylation level of pRb in NPCs (Regad et al. 
2009). Also in adult settings, phosphorylation levels of pRb were increased in 
PML-/- cells compared to PML+/- cells (Joanne Betts, Appendix 1. A). 
Interestingly, re-expression of PML-I isoform in PML-deficient cells inhibited 
pRb phosphorylation, and led to reduced proliferation (Appendix 1. B). In 
contrast, a PML mutant lacking the RING domain, and unable to form PML-
NBs had no effect. Furthermore, PP1α and pRb colocalise in PML-NBs in WT 
cells, but not in PML-deficient cells (Appendix 1. C). Finally, p53 and p21 
protein levels were decreased in PML-/- cells (Appendix 1. D), indicating that 
the observed increase in proliferation upon PML loss may also partially depend 
on p53.  
It has been demonstrated that the turnover rate of OB neurons is from at least 
10,000 cells per day to 80,000 per day (Kaplan et al. 1985; Lois and Alvarez-
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Buylla 1994). Our findings have demonstrated that PML loss reduced the 
number of migratory neuroblasts in the RMS region proximal to OB, and 
reduced the number of de novo generated, mature neurons production in OB. 
Notably, there was no difference in cell death observed by active caspase-3 
staining between PML+/- and PML-/- in RMS migration (Joanne Betts, data not 
shown), excluding the possibility that reduced migration was due to enhanced 
level of cell death. Future experiments could be performed by measuring the 
thickness of RMS, as a previous study has demonstrated that after removal of 
OB, chain migration continued along the RMS but the RMS increased in 
volume (Kirschenbaum et al. 1999). Therefore, an observation of a thicker and 
bigger RMS in PML-/- mice would be expected. 
Due to the reduction in OB size, it would be also be worthwhile investigating 
the functional consequences of this impairment. It has been demonstrated that 
the ability to discriminate between two distinct odorants is not affected by 
impairment in adult OB neurogenesis (Imayoshi et al. 2008a; Lazarini et al. 
2009). However, a number of other phenotypes have been reported, including 
the detection threshold of an odorant, short-term and long-term olfactory 
memory, and perceptual learning ability (Breton-Provencher et al. 2009; 
Moreno et al. 2009; Valley et al. 2009; Sultan et al. 2010). Therefore, it could 
be investigated if these functions are affected between PML control and PML-
deficient mice, as this research may provide more information about the 
potency of the effect of OB neurons replacement in adulthood. In addition, 
mating behaviour may also be affected in PML-/- mice, as a previous study has 
demonstrated that intact olfactory input is essential in masculine sexual 
behaviour in male mice (Rowe and Edwards 1972). Furthermore, it has also 
been reported that approximately 50% of the newborn OB neurons are 
eliminated one month after reaching the OB due to programmed cell death 
(Winner et al. 2002). Therefore, it would be interesting to also study the survival 
of newborn OB neurons and how effectively integrate into the existing circuit.   
As discussed in Introduction, a plethora of factors that regulate RMS cell 
migration in vivo have been well established, making it difficult to propose if this 
defect is due to NSC-intrinsic behaviour using a germline model in which all 
cells are PML-deficient. Therefore, the present study uses an in vitro system for 
isolation, and propagation of NSCs, which allowed the intrinsic nature of the 
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cell migration phenotype to be studied, and mechanistic studies to be 
performed (see below sections from 3.7). Notably, the impaired cell migration 
upon PML loss could be recapitulated in vitro using ECM assay. Moreover, it 
seems PML depends on intact PML-NBs to promote migration, because PML 
RingMut cells displayed a similar pattern of migration defects observed in PML-
deficient cells. Future experiments could be conducted by staining migratory 
neuroblasts (DCX+) in PML RingMut RMS in comparison to PML control, and 
PML-deficient mice to confirm this phenotype in vivo, as well as measuring the 
OB size in PML RingMut mice to confirm the phenotypic changes.  
Interestingly, the ECM assays based on the addition of supernatants from 
control, and PML-deficient cells revealed the potential involvement of soluble 
factors in regulating NSC migration in vitro, providing guidance to identify the 
underlying mechanisms. As described in the Introduction, the SVZ-RMS-OB 
migration is regulated by a summation of different factors, including cell-cell, 
and cell-ECM interactions, as well as the chemoattractant or chemorepulsive 
factors. Supernatants ECM assay from the present study suggests that soluble 
factors secreted from PML-/- aNSCs may contribute to the migration defect. 
Indeed, soluble factors have been implicated in regulating migration from SVZ 
to OB. For example, within the SVZ niche, the contact with CSF via ependymal 
cilia, and single cilium from type B1 cells is central for sensing the systemic 
factors circulating around and through CSF (Doetsch et al. 1999b; Alvarez-
Buylla and Garcia-Verdugo 2002; Bond et al. 2015). Interestingly, aberrant cilia 
formation from mutant mice leads to defective migration from SVZ to RMS 
(Sawamoto et al. 2006), suggesting that contact with the CSF, and the soluble 
factors therein, are important in mediating cell migration. Moreover, it has been 
suggested that along the journey of RMS migration, the directional migration is 
guided partially through secreted factors from the septum (opposing the 
direction of RMS migration), or OB (Hu and Rutishauser 1996; Coskun and 
Luskin 2002; Sun et al. 2010), reinforcing the contribution of secreted factors to 
cell migration in the SVZ/RMS/OB route.   
Finally, supporting data (Joanne Betts) has suggested that PML loss leads to 
increased entry into differentiation, but an impaired production of mature 
neurons in vitro (Fig. 1.10L), suggesting the phenotypic changes in response to 
PML in vivo could be caused by a combination of different mechanisms, such 
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as aberrant migration and/or altered differentiation (further discussed below 
page 106 and page 116).   
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3.4 PML loss affects expression of axon guidance regulators 
Next, the present study investigated the molecular mechanisms underlying the 
defect in cell migration. As discussed previously, ECM supernatants assay 
suggests soluble factors may be involved in migration phenotype. The long 
migratory route that cells within the SVZ-RMS-OB niche need to follow during 
differentiation requires a tight control by both intrinsic, and extrinsic factors 
(Lois and Alvarez-Buylla 1994; Mason et al. 2001; Lim and Alvarez-Buylla 
2016). OB, and other structures, such as septum, are known to secrete signals 
guiding chain migration (Hu and Rutishauser 1996; Coskun and Luskin 2002; 
Sun et al. 2010). However, an interesting study demonstrated that RMS 
migration was not affected upon removal of OB in the short-term 
(Kirschenbaum et al. 1999), indicating that gradients of factor secreted by the 
OB alone are not sufficient to support SVZ to OB migration. Notably, it has 
been reported that migrating neuroblasts secrete chemorepulsive signal Slit 
(Nguyen-Ba-Charvet et al. 2004; Kaneko and Sawamoto 2007; Eom et al. 
2010; Kaneko et al. 2010), and Slit1 is essential in regulating neuronal 
migration in adult SVZ-RMS-OB, whereas Slit1 and Slit2 are vital in the 
developing forebrain (Hu 1999; Wu et al. 1999; Nguyen-Ba-Charvet et al. 2004; 
Yeh et al. 2014).   
Therefore, a panel of genes encoding soluble factors/receptors that are known 
to regulate migration in the CNS (e.g. Slit/Robo family members) (Fig. 3.3A), 
as well as more generally genes involved in regulation of cell migration, 
including metalloproteinases (MMP3, MME), and epithelial-mesenchymal 
transition factors (Scratch 1, E-cadherin, Twist1, Snail1, N-Cadherin, Fra1, 
Zeb2) (Fig. 3.3B) were checked by qPCR. Interestingly, among these genes, 
the Slit2 gene was found to be significantly upregulated in PML-deficient cells 
compared to PML+/- cells (Fig. 3.3A), and this observation was consistent in 
independent NSC preparations. Moreover, Slit2 was found upregulated (albeit 
not statistically significant due to variations between repeats, see Appendix 6. 
A for details) in PML RingMut cells, displaying a similar pattern as observed in 
PML-/- cells (Fig. 3.3A), indicating the requirement of PML-NBs in repression of 
Slit2. In addition, Robo1, the cognate receptor of Slit2, was also found 
upregulated in PML-/- cells (Fig. 3.3C). As discussed in the Introduction, the 
high affinity binding of Slit1 to Robo inhibits RMS cell migration in the adult 
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brain (Nguyen-Ba-Charvet et al. 2004), and further discussion on the literature 
can be found below. However, though highly expressed in NSCs (not shown), 
no alterations in expression of the ligand Slit1 and its cognate receptor Robo2 
were found in either germline PML KO, or PML KI cells (Fig. 3.3C). Notably, 
the upregulation of Slit2 in PML-/- cells was also confirmed at the protein level 
(Fig. 3.3D).  
 
	
Figure 3.3: PML loss affects expression of axon guidance regulators. 
 (A) qPCR analysis demonstrated upregulation of Slit2 in PML-deficient cells, as well 
as in PML RingMut cells. Values represent mean ± SEM (n = 3; *p < 0.05; **p < 0.01, 
unpaired t-test). (B) qPCR analysis of expression pattern of EMT-related genes, and 
metalloproteinases genes. Genes were arranged from left to right based on their 
expression level (from low to high). (C) qPCR analysis revealed the expression pattern 
of Slit2 receptor, Robo1, and Slit1/Robo2 (the other ligand-receptor). A similar 
expression pattern was found in PML RingMut cells. Values represent mean ± SEM (n 
= 3; *p < 0.05, unpaired t-test). (D) Representative Western blotting (WB) analysis 
confirmed upregulation of Slit2 protein in PML-/- cells compared to PML+/- cells. Tubulin 
was used as loading control. 
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To determine whether these changes could be repeated upon acute PML loss, 
a PML conditional knockout (KO) system (PMLF/F) generated by our lab was 
used. Essentially, the PML exon3 is flanked by two loxP sites, enabling 
recombination via introduction of Cre recombinase (Fig. 3.4A). SVZ NSCs 
were isolated and propagated from PMLF/F, and control (PMLF/W) mice and cells 
were transduced with p-MIG-Cre-ERT2-GFP virus. Acute PML loss could be 
achieved by treatment with 4-hydroxytamoxifen (4-OHT), as detected by DNA 
recombination (Fig. 3.4B), and protein degradation (Fig. 3.4C). Utilising this 
system, Slit2 upregulation was confirmed in 4-OHT-treated PMLF/F;CreERT2 
cells upon acute PML loss both at mRNA (Fig. 3.4D), and protein level (Fig. 
3.4E).  
 
	
Figure 3.4: PML acute loss affects Slit2 expression. 
 (A) Schematic illustration demonstrates that exon3 of PML is flanked by two loxP 
sites, with dedicated oligos to amplify specific bands for genotyping. (B) Gel 
electrophoresis illustrates recombined band (~300bp) upon 4-hydroxytamoxifen (4-
OHT) treatment amplified by defined oligos. (C) WB analysis confirmed conditional 
deletion/disruption of PML upon 4-OHT treatment. β-Actin was used as loading 
control. (D) qPCR analysis revealed upregulation of Slit2 in response to 4-OHT 
treatment-induced acute PML loss. Values represent mean ± SEM (n = 3; *p < 0.05, 
unpaired t-test). (E) WB analysis confirmed upregulation of Slit2 upon acute PML loss. 
Tubulin was used as loading control. 
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3.5 Slit/Robo signalling is required for PML-mediated regulation of cell 
migration 
It was subsequently investigated whether PML promotes cell migration through 
repression of Slit2/Robo1 signalling. Therefore, attempts were made to knock 
down Slit2 using small interfering RNA hairpins (shRNA). All available (7) 
pGIPZ lentiviral shSlit2 clones from Cancer Institute shRNA core facility were 
produced as high-titer lentiviral supernatants, and transduced into PML+/- and 
PML-/- cell (see Materials and Methods), using a Scramble (Scrbl) sequence 
as control. Unfortunately, none effectively silenced Slit2 in PML-/- cells (Fig. 
3.5). Based on a previous study (Wu et al. 1999), I employed Robo1N, a 
truncated mutant form of Robo receptor lacking the intracellular domain that 
functions as a decoy receptor via competitive binding to Slit2 (Patel et al. 
2012), and blocking its association with Robo1 on the cell surface. I assisted 
Valeria Amodeo, a postdoctoral researcher in the lab, with experiments using 
this system.  
An ECM assay utilising recombinant Slit1 (rSlit1), and Slit2 (rSlit2) proteins was 
performed to determine whether Slit proteins affected cell migration in aNSCs, 
and if so, which ones. rSlit1 had no effect on cell migration in either PML+/-, or 
PML-/- cells (Appendix 2. A). However, rSlit2 impaired migration in PML+/- cells, 
but this effect was not further exacerbated in PML-/- cells, suggesting that PML 
works through repression of Slit2 (Appendix 2. A). To formally demonstrate 
that Slit2 was required for the effect of PML loss on cell migration, a His-tagged 
Robo1N form from transfected HEK 293T was isolated using affinity purification 
based on nickel columns (see Materials and Methods for further details). 
Robo1N successfully rescued the migration defect of PML-/- cells, and this 
effect was abolished by the addition of rSlit2 (Appendix 2. B), suggesting that 
not only is Slit2 (not Slit1) the main factor in regulating cell migration in aNSCs, 
but this repulsive effect is also mediated through its cognate receptor Robo1. 
This finding provides important insight into the novel role of Slit2 in adult CNS 
cell migration. Collectively, these data suggest that PML regulates cell 
migration via repression of Slit2/Robo1 signalling.  
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Figure 3.5: Unsuccessful Slit2 knockdown using small interfering RNA hairpins.  
qPCR analysis revealed unsuccessful Slit2 knockdown in PML-/- cells using pGIPZ 
lentiviral shRNA. C1-C7: clone 1 to clone 7 for shSlit2 (see Materials and Methods for 
more information). 
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3.6 Discussion  
As discussed previously in the Introduction (page 35; page 37), a number of 
chemotropic factors regulate adult neurogenesis, and RMS migration. The 
defect in cell migration upon PML loss could be repeated in vitro using ECM 
assay, and importantly, ECM assays based on supernatants derived from 
control or KO cells revealed the potential involvement of soluble factors in this 
respect. In the present study, the chemorepulsive glycoprotein Slit2, and its 
cognate receptor Robo1, were shown to be significantly upregulated in SVZ 
aNSCs upon PML loss. Importantly, Slit2 upregulation was confirmed in two 
different genetic models (PML germline KO and PML conditional KO), and 
mouse strains (129sv and C57BL/6), reinforcing the argument that Slit2 is 
indeed a target of PML. Slit proteins, and Robo receptors were originally 
implicated in axon guidance during development (Brose et al. 1999; Long et al. 
2004; Blockus and Chedotal 2014). In addition, when considering CNS 
neurogenesis in rodent, both Slit1 and Slit2 (Bagri et al. 2002), and both Robo1 
and Robo2 (Lopez-Bendito et al. 2007), have been involved in axonal 
pathfinding in the forebrain. Furthermore, Slit and Robo have been found to 
regulate cell migration, as well as cell proliferation in CNS both in embryonic, 
and adult neurogenesis (Hu 1999; Li et al. 1999; Wu et al. 1999; Nguyen-Ba-
Charvet et al. 2004; Andrews et al. 2006; Andrews et al. 2008; Kaneko et al. 
2010; Borrell et al. 2012; Blockus and Chedotal 2014). Interestingly, Slit1 has 
been reported to impede RMS cell migration toward the OB in the adult brain 
(Nguyen-Ba-Charvet et al. 2004), but the role of Slit2 in this context was not 
explored. The present research demonstrates that Slit2 represses cell 
migration in aNSCs, suggesting that Slit2 can be a key mediator of the cell 
migration phenotype observed in PML-deficient cells. Moreover, there may be 
a context-dependent expression manner to consider, as Slit1 has been 
observed to be expressed, and to play a role in neuroblast cells, whereas, 
based on our results, Slit2 could be NSC-specific in the adult brain. To test this 
hypothesis, ongoing experiments using established in vitro neuroblasts 
migration assay (O'Leary et al. 2015) would provide more evidence of this 
claim.  
As detailed in the Introduction (page 23 and Fig. 1.2 page 25), PML interacts 
with pRb and p53, with implications for growth and tumour suppression 
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(Salomoni and Pandolfi 2002). Moreover, it has been demonstrated that in 
embryonic neurogenesis, PML partially regulates cell fate via control of pRb 
phosphorylation in eNPCs (Regad et al. 2009). Our unpublished data reveal 
that PML loss also results in hyperphosphorylation of pRb in aNSCs, (Joanne 
Betts, Appendix 1. A). Therefore, it can be hypothesised that PML could 
regulate migration in a cell cycle-dependent manner. In addition,  as shown 
before that PML indirectly stabilises p53 protein levels (Appendix 1.D) by 
preventing Mdm2-dependent p53 degradation (Fig. 1.2), it is therefore possible 
that the migration phenotype is also dependent on p53.  
However, expression of SV40 LargeT, which inhibits both pRb, and p53 in 
PML+/-, and PML-/- cells, affects proliferation (Appendix 4. A), whilst it 
enhanced rather than decreased cell migration (Appendix 3. A, B; work 
performed by Valeria Amodeo). This finding is in line with the expression 
pattern of Slit2 upon SV40 LargeT expression, in which Slit2 expression was 
unaffected in PML+/- cells, and was augmented in PML-/- cells (Appendix 3. C). 
These data suggest that PML controls aNSCs migration through Slit2/Robo1 
independently of its role in controlling cell proliferation, and the migration 
defects upon PML loss is independent of pRb, and p53.  
To determine whether PML controls cell migration through repression of Slit2, 
gene knockdown experiments were initially performed. However, as discussed 
above, it seemed all the available pGIPZ clones failed to knock down Slit2. Due 
to limited time, additional gene silencing strategies were not employed (e.g. 
CRISPR/Cas9). A previous study utilised Robo1N, a mutant form of Robo 
receptor lacking transmembrane and intracellular domains, to competitively 
inhibit Slit/Robo signalling (Wu et al. 1999). Based on the work by Wu et al. 
(1999), and a recent study using Robo1N to disrupt Slit2/Robo1 pathway (Patel 
et al. 2012), experiments in the present study were designed employing 
Robo1N to determine if Slit2 acts downstream PML to inhibit migration. In 
support of the hypothesis stated in the present study, Robo1N rescued the 
migration in PML-deficient cells, and this effect was abolished by addition of 
rSlit2. Interestingly, no effect was observed upon addition of rSlit1, reinforcing 
the proposal that Slit2, not Slit1, underlies the migration defects upon PML loss 
in aNSCs. Notably, it was rSlit2, not rSlit1, impaired migration phenotype in 
PML control cells (Appendix. 2A), suggesting Slit2 is the target responsible for 
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migration phenotype downstream PML. However, addition of both rSlit1 and 
rSlit2 in PML-/- cells seemed to rescue migration phenotype (statistically 
significant, Appendix. 2A). If the quantification inconsistency could be ruled 
out (as no statistical significant was shown in Appendix. 2B with respect to 
rSlit2 in PML-/- cells), this could be due to a potential negative feedback loop 
between Slit family members in the context of PML loss, as excessive amount 
of Slit1 could repress Slit2 pathway, thus ameliorating migration, and forced 
addition of Slit2 in PML-/- cells could also trigger the “Slit burden” in the cell (see 
also page 140 in GBM settings).  
Ultimately, these results identify a novel axis, whereby the growth suppressor 
PML controls cell migration via repression of Slit2. Therefore, future in vivo 
work could be designed to investigate RMS migration/OB size via modulation 
of Slit2 expression/activity. A method currently being established in our lab, in 
utero or early postnatal electroporation of NSCs (Pathania et al, manuscript in 
preparation), would allow others in the lab to express Robo1N in PML-/- and 
control mice (or tamoxifen-treated PMLf/f;NestinCreERT2 mice, currently 
available in our colony), and analyse whether the phenotype could be reverted 
upon inhibition of Slit2 signalling. Because a previous study has demonstrated 
that Slit1 is the principal factor in impeding neuroblast migration (Nguyen-Ba-
Charvet et al. 2004), it would also be rational to include Robo2N to test whether 
Slit1 and Slit2 function cooperatively in these settings. Similar experiments 
could be conducted by using shRNAs against Slit1 or Slit2, or  gRNA 
sequences along with Cas9.  
It cannot be excluded that the role of Slit2/Robo1 depends on the 
developmental stage, given that one study has demonstrated Robo1 mutant 
mice displayed smaller OB size at E18.5 (Borrell et al. 2012), indicating a pro-
migratory (instead of anti-migratory) or pro-differentiation function of 
Slit2/Robo1 signalling during development. Therefore, crossing a Slit2 
conditional KO mouse line with NestinCreERT2 mice would enable researchers 
to monitor the effect of Slit2 loss at postnatal stages.  
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3.7 The EMT factor Twist1 regulates Slit2 expression downstream PML 
Mechanisms underlying PML-mediated regulation of Slit/Robo signalling were 
investigated next. Among the genes that were differentially expressed upon 
PML loss (see Fig. 3.3 A&B), the transcription factor Twist1 was upregulated in 
PML-/- cells (Fig. 3.6A), as well as in PML RingMut cells (Fig. 3.6B), whilst its 
RNA levels were almost undetectable in control cells. Further validation was 
subsequently performed using immunoblotting, which demonstrated marked 
induction of Twist1 in PML-/- cells (Fig. 3.6C), and PML RingMut cells (Fig. 
3.6D). However, in PML+/- and PML+/+ cells, Twist1 was not detected [in 
accordance to qPCR data (Ct > 35)]. It is important to note that at Twist1 was 
marginally regulated by PML at early passage (passage<3), while its RNA and 
protein levels became undetectable in control cells in later passage. Moreover, 
when compared with PML-/- cells, Twist1 expression was over-amplified in PML 
RingMut cells, leading to an induction for more than 60-fold. One can speculate 
that PML RingMut has a selection preference towards cells overexpressing 
Twist1. 
Twist1 belongs to the bHLH family of transcription factors (Imayoshi and 
Kageyama 2014), and is a master regulator of epithelial-to-mesenchymal 
transition (EMT) (Yang et al. 2004), which is a crucial process contributing to 
neural crest development as well as to the onset and progression of tumour 
spreading (metastasis) (Thiery 2002; Kalluri and Weinberg 2009; Thiery et al. 
2009) (further discussed below page 113). However, there is no existing 
literature investigating the expression, or functions of Twist1 in aNSCs. I 
investigated other genes involved in EMT, and associated either directly or 
indirectly with Twist1, including the “cadherin switch” genes E-cadherin, N-
cadherin (Wheelock et al. 2008), Scratch1 (Itoh et al. 2013), Snail, and Zeb 
(Peinado et al. 2007; Xu et al. 2009; Lamouille et al. 2014) and Fra1 (Caramel 
et al.) (Fig. 3.3B). EMT regulators interact with each other, and it is known that 
Snail1 is able to induce Twist1 (Peinado et al. 2007; Xu et al. 2009; Lamouille 
et al. 2014), and Twist1 is required to maintain EMT upon Snail1-induced EMT 
initiation (Tran et al. 2011), indicating a functional feedback loop between the 
EMT transcription factors. This is in line with the data that Snail1 was 
upregulated earlier than Twist1 upon PML loss at early passage (Fig. 3.3B). 
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Notably, although E-cadherin was found upregulated in PML-/- cells compared 
to PML+/- cells, its expression levels in general were remarkably low according 
to the Ct values (> 33). In contrast, the mesenchymal marker N-cadherin, Snail, 
and Zeb were found highly expressed, but levels were not affected by PML 
loss.  
Although Twist1 is predominantly a transcriptional repressor, and an inducer of 
cell migration, its role in the context of aNSCs had not been studied previously. 
To investigate this, gene knockdown experiments using pGIPZ vectors 
expressing shTwist1 or Scrbl shRNAs in both PML-deficient and control cells 
were performed. Upon GFP-cell sorting, it could be demonstrated that Twist1 
was successfully silenced in PML-/- cells to a considerable degree (Fig. 3.7A; 
its expression is almost undetectable in control cells). Surprisingly, Slit2 and 
Robo1 expression levels were downregulated upon Twist1 KD in PML-deficient 
cells (Fig. 3.7B), suggesting Twist1 may act as a transcriptional activator of 
Slit2 and Robo1 downstream PML loss. To further evaluate the functional 
consequences of Twist1 KD, ECM assays were performed. Interestingly, 
Twist1 KD rescued cell migration in PML-deficient cells (Fig. 3.7C), in 
accordance with the observed Slit2 and Robo1 downregulation (Fig. 3.7B).  
To investigate if Twist1 upregulation may underlie other phenotypic changes 
observed upon PML loss in addition to cell migration, cell proliferation upon 
Twist1 KD in PML-deficient cells was analysed. Quantification of Edu+ cells 
revealed that proliferation decreased to control levels in PML-/- cells upon 
Twist1 KD (Fig. 3.7D), suggesting that Twist1 acts downstream PML loss to 
positively regulate adult NSCs proliferation, as well as cell migration. Work by 
Joanne Betts and Valeria Amodeo (see Appendix 4) has demonstrated a 
correlation between increased proliferation, and induction of γH2AX+ DNA 
damage foci upon PML loss in vitro, and in vivo, as an index of replicative 
stress (further discussed below). Quantification of percentage of dense foci 
(>10 foci) revealed a decreased level of γH2AX foci formation upon Twist1 KD 
(Fig. 3.7E), which was in line with the reduction in proliferation rate. 
Furthermore, because work from Joanne Betts demonstrated that PML-
deficient cells display an intrinsic defect in differentiation (Fig. 1.10L), in vitro 
differentiation assay was subsequently employed to assess the differentiation 
pattern in the context of Twist1 KD. To this end, aNSCs were plated on laminin-
		 111	
coated coverslips supplemented with normal proliferation media at day 0. EGF 
and b-FGF were sequentially removed to trigger differentiation, and cells were 
kept in a defined differentiation media until day 8 (see Materials & Methods 
page 81). Interestingly, quantification of βIII-tubulin+ and GFAP+ cells (Fig. 
3.7F) revealed that Twist1 KD did not revert the differentiation changes 
observed in PML-deficient cells.  
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Figure 3.6: EMT factor Twist1 is expressed in aNSCs and repressed by PML.   
(A) Twist1 was found consistently upregulated in PML-/- cells, and (B) massively in 
PML RingMut cells. Values represent mean ± SEM (n = 3; *p < 0.05; **p < 0.01, 
unpaired t-test). (C) WB analysis confirmed Twist1 expression at protein level in adult 
NSCs in response to PML loss, and (D) in PML RingMut. Mouse embryonic fibroblast 
(MEF) extract was used as positive control for Twist1, and β-Actin was used as 
loading control. 
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Figure 3.7: Twist1 regulates Slit2 expression downstream PML and play a role in 
migration and proliferation phenotypes.  
(A) qPCR confirmed Twist1 knockdown (KD) in PML-/- cells. Values represent mean ± 
SEM (n = 3; **p < 0.01, unpaired t-test). (B) qPCR analysis revealed that Slit2/Robo1 
expression was affected downstream upon Twist1 KD. Values represent mean ± SEM 
(n = 3; *p < 0.05; **p < 0.01, unpaired t-test). (C) ECM assay revealed rescued 
migration capability upon Twist1 KD. Values represent mean ± SEM (n = 3; *p < 0.05; 
***p < 0.001, unpaired t-test). (D) Edu assay demonstrated impaired proliferation upon 
Twist1 KD, and phenocopying PML control cells. Values represent mean ± SEM (n = 
3; *p < 0.05; **p < 0.01, unpaired t-test). (E) Quantification of γH2AX foci revealed a 
decreased level of foci formation (> 10 foci) upon Twist1 KD. Foci formation was 
subdived into two groups: less than 3 foci or nuclei (< 3 foci), and greater than 10 foci 
or nuclei (> 10 foci). Values represent mean ± SEM (n =3). (F) Quantification of 
differentiation assay revealed cell fate specification was not affected by Twist KD. 
Values represent mean ± SEM (n = 3; ***p < 0.001, unpaired t-test). 
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3.8 Discussion 
Our findings demonstrate that Twist1 is involved in regulation of cell migration, 
and proliferation downstream PML. As previously detailed, Twist1 is the master 
regulator of EMT, a biological process that contributes to normal development, 
wound healing, tissue fibrosis, and cancer progression (Kalluri and Weinberg 
2009; Thiery et al. 2009), and its reverse process is termed mesenchymal-
epithelial transition (MET) (Kalluri and Weinberg 2009; Thiery et al. 2009). 
Essentially, the EMT programme during tumour invasion and metastasis 
involves several sequential steps, including dissociation from primary tumour 
site, spreading into the circulation system (blood vessels/lymphatic system), 
dissemination into distant organs, and establishment as a secondary tumour 
(Yang et al. 2004; Thiery et al. 2009; Hanahan and Weinberg 2011).  
EMT transition is accompanied by the downregulation or loss of epithelial 
marker genes (e.g. E-cadherin), and upregulation of mesenchymal maker 
genes (e.g. N-cadherin) (Lamouille et al. 2014), indicating the essential role of 
molecular signature in this event. Notably, one of the hallmarks of EMT is 
“cadherin switch”, by which downregulation of E-cadherin, and upregulation of 
N-cadherin foster the dissociation with epithelia, and subsequent transition into 
pro-migratory/pro-invasive mesenchymal cells (Wheelock et al. 2008; Lamouille 
et al. 2014). 
As discussed, Twist1 belongs to the family of bHLH transcription factors, some 
of which have been previously implicated in cell fate determination, and lineage 
specification in CNS stem cells (Imayoshi and Kageyama 2014). For instance, 
Ascl1 promotes neuronal differentiation during embryonic neurogenesis (Parras 
et al. 2002; Schuurmans and Guillemot 2002; Parras et al. 2004; Urban and 
Guillemot 2014). In proliferating aNSCs (from DG within SGZ), Ascl1 protein is 
destabilised by E3-uniquitin ligase Huwe1, with the latter being required for 
inducing a quiescent state in proliferating aNSCs, and thus protecting them 
from exhaustion (Urban et al. 2016). Moreover, accumulated Ascl1 promotes 
aNSCs proliferation in Huwe1 WT mice via activation of Cyclin D1/D2 (Urban et 
al. 2016).  
Twist1 was found expressed in neurons in embryonic/foetal human brain (Elias 
et al. 2005), suggesting potential involvement of Twist1 in neurogenesis. 
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However, to our knowledge, its role in CNS stem cells is unknown. Findings 
from the present study suggest that Twist1 may be involved in CNS 
neurogenesis, and that it is repressed by PML to undetectable levels. Notably, 
neural crest-derived stem cells (NCSCs) are multipotent, self-renewing cells in 
peripheral nervous system (PNS) (Binder et al. 2011). At the molecular level, 
NCSCs differ from NSCs by the expression of distinct marker genes, including 
Sox10 and p75, and can be reprogrammed through direct transdifferentiation 
from PNS to CNS stem cells (Binder et al. 2011; Weber et al. 2015). 
Interestingly, NCSCs derived from mouse palate do not induce CNS stem cell 
marker genes under reprogramming conditions, characterised by sustained 
expression of neural crest marker genes, including Twist1 (Weber et al. 2015). 
Given that PML loss activates Twist1 expression, it is plausible to speculate 
that PML may play a role in repressing NCSC fate in NSCs by inactivating 
Twist1. 
In addition to its role in promoting mesoderm development (Chen and 
Behringer 1995; Fuchtbauer 1995; Gitelman 1997; O'Rourke and Tam 2002; 
Zhao and Hoffman 2004; Figeac et al. 2007; Pan et al. 2009; Qin et al. 2012), 
increased Twist1 expression has been associated with a number of solid 
tumours (Maestro et al. 1999; Rosivatz et al. 2002; Hoek et al. 2004; Watanabe 
et al. 2004; Entz-Werle et al. 2005). In particular, Twist1 has been consistently 
implicated in triggering EMT programme in the context of tumour progression 
and metastasis (Yang et al. 2004; Elias et al. 2005; Kwok et al. 2005; Lee et al. 
2006; Puisieux et al. 2006; Ansieau et al. 2008; Luo et al. 2008; Vesuna et al. 
2008; Li et al. 2009a; Hong et al. 2011). One of the best-characterised roles of 
Twist1 in this scenario is its ability to promote cell invasion/migration, including 
in human glioma (Elias et al. 2005; Mikheeva et al. 2010). However, given the 
low-migratory state of PML-/- cells, the overexpression pattern of Twist1 upon 
PML loss doesn’t fit with its canonical role. In this respect, Twist1 KD rescued 
the migration capability in PML-/- cells. Furthermore, this finding correlated with 
reduced expression of Slit2, and Robo1, suggesting that Twist1 represses 
migration in aNSCs via induction of Slit2/Robo1.  
Generally, findings from the present study indicate that Twist1 repression in 
aNSCs is permissive for cell migration, which is contradictory to findings 
observed in other tissues. To further address if Twist1 regulates migration in 
		 116	
aNSCs via Slit2, experiments could be designed to overexpress Slit2 in PML-/-
;Twist1-KD cells, to check if Slit2 overexpression is able to impair migration 
phenotype that rescued by Twist1-KD in PML-/- cells, or to introduce Robo1N in 
PML+/-;Twist1-overexpressing cells, and study whether the effects on cell 
migration/invasion are reversed by disruption of Slit2-Robo1 pathway.  
Interestingly, Twist1 KD impaired proliferation to the level observed in PML 
controls cells, suggesting a causal link between Twist1 expression level and 
proliferation state. Indeed, one study has previously demonstrated that Twist1 
positively regulates keratinocyte proliferation, specifically, that Twist1 KD in 
primary keratinocytes impairs G1/S transition by affecting the level of c-Myc, 
Cyclin E1, and E2F1 (Srivastava et al. 2016). This function is shared by 
another bHLH member, Ascl1, which promotes NPCs expansion through direct 
regulation of cell cycle progression genes, including E2F1 (Castro et al. 2011), 
suggesting that Ascl1, like Twist1, is a positive regulator of proliferation of CNS 
stem cells via direct interaction with cell cycle genes. Interestingly, Ascl1 
expression was found upregulated (albeit marginally) in PML-/- cells (Appendix 
6. B). This finding is in line with the activation of its target, Cyclin D2 (Ccnd2) 
upon PML loss (Appendix 6. B). However, this pattern was not found upon 
PML acute loss (Appendix 6. B). Further work needs to be conducted to study 
the potential involvement of Ascl1 in the context of Twist1-KD, and their 
potential interaction in adult CNS stem cells upon PML loss.  
Finally, our data reveal a link between the increase in proliferation in aNSCs 
and γH2AX foci formation (my work and findings by Joanne Betts, 
unpublished). In addition, previous work has demonstrated that NPCs display 
replication-associated DNA damage during early development as a result of the 
enhanced replicative rate (McKinnon 2009; McKinnon 2013; Wei et al. 2016). A 
recent study demonstrated that aphidicolin-induced replication stress in aNSCs 
induce genomic instability at a set of fragile sites (Wei et al. 2016). Therefore, it 
is reasonable to propose that impaired proliferation upon Twist1 KD leads to a 
decreased level of replication stress, and thus less γH2AX foci formation. Work 
by Joanne Betts (not shown) reported that a pharmacological inhibitor of the 
ATM kinase decreased DNA damage foci in PML-deficient cells. Furthermore, 
work from Valeria Amodeo in the lab revealed that inhibition of pRb/p53 via 
expression of SV40 LargeT was sufficient to induce proliferation and DNA 
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damage foci in control cells, further suggesting that enhanced proliferation 
leads to replication stress in aNSCs (Appendix 4).  
Furthermore, there was no effect observed on in vitro differentiation upon 
Twist1 KD, indicating PML regulates differentiation through other mechanisms. 
Because cell cycle has been demonstrated to control NSC differentiation 
(Salomoni and Calegari 2010), future experiments could be conducted to 
investigate the differentiation pattern in cells expressing SV40 LargeT. 
Moreover, Slit-Robo signalling has been implicated in differentiation of cortical 
interneurons (Andrews et al. 2008), and therefore it would be interesting to 
study the effects of Slit2/Robo1 using recombinant Slit2 or Robo1N on 
differentiation, because Twist1 affects expression of Slit2 upstream.  
Ultimately, the results found in the present study suggest that PML inhibits 
Slit2/Robo1 via transcriptional repression of Twist1. However, evidence for 
Twist1 upregulation in vivo was lacking. Therefore, 
immunohistochemistry/immunofluorescence was performed in brain sections 
from PML-deficient, and control brains using different anti-Twist1 antibodies 
(commercially available, and obtained from Gongda Xue, Friedrich Miescher 
Institute, Switzerland). Unfortunately, results were not consistent due to the 
extremely low quality of all available antibodies tested. Only one experiment 
demonstrated co-staining of label-retaining NSC (Edu+) with Twist1 in the PML-
deficient SVZ, but the finding could not be reproduced (data not shown).  
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3.9 PRC1 component Bmi1 is not part of the mechanism 
The PRC1 component Bmi1 (Joanne Betts, data not shown) was one of the 
genes upregulated in PML-deficient cells, and acts cooperatively with Twist1 in 
a feedback loop fashion to induce EMT (Yang et al. 2010a). Therefore the 
present study investigated whether Bmi1 could also be involved in the 
phenotypic changes caused by PML loss in aNSCs. The initial experiments 
were carried out by knockdown of Bmi1 in PML-/- cells using shRNA to check if 
Bmi1-KD mimics phenotypes observed in PML control cells. However, none of 
the constructs were able to achieve this (data not shown).  Thus, to determine 
if Bmi1 overexpression mimics PML loss, PML+/- cells were transduced with the 
lentivirus overexpressing Bmi1, with FUGW as a control (Fasano et al. 2007). 
Bmi1-overexpression (OE) was confirmed by immunoblotting (Fig. 3.8A), and 
qPCR (Fig.3.8B). Due to findings examined the existing literature, relevant 
CDKi were then examined upon Bmi1-OE. Importantly, p16Ink4a is a well-known 
target of Bmi1, and has been identified as a regulator of G1/S transition, which 
is found deregulated in a number of cancers including brain cancer (Molofsky 
et al. 2003; Leung et al. 2004). In addition, p21Cip1 has been identified as a 
target of Bmi1 (Fasano et al. 2007), with implications in NSC self-renewal, as 
well as for the NPCs maintenance in the forebrain (Kippin et al. 2005). 
Moreover, p57Kip2, which belongs to the same Cip/Kip family as p21Cip1, acts as 
a tumour suppressor for its implications in inhibition of angiogenesis, tissue 
invasion, and metastasis, as well as in promoting cell differentiation and 
apoptosis (Kavanagh and Joseph 2011). Interestingly, increasing evidence 
suggests that p57Kip2 participates in CNS development (Itoh et al. 2007; Joseph 
et al. 2009; Jadasz et al. 2012; Furutachi et al. 2013). In particular, a recent 
study revealed that deletion of p57Kip2 triggers increased neurogenesis in the 
short-term, but leads to NSC exhaustion and impaired neurogenesis in the 
long-term (Furutachi et al. 2013), which shares a similar phenotype of PML loss. 
Surprisingly, gene expression analysis revealed that all Bmi1 target genes 
tested were upregulated instead of downregulated upon Bmi1-OE (Fig.3.8C), 
and therefore challenging the canonical role of Bmi1, at least in an aNSC 
context. Furthermore, Edu assays indicated that Bmi1 overexpression did not 
result in accelerated proliferation (Fig.3.8D), but did lead to an elevated level of 
γH2AX foci formation (Fig. 3.8E). Interestingly, induction of differentiation 
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revealed that Bmi1-OE results in an increased percentage (~15%) of βIII-
tubulin+ neurons generated, although no difference was found in astrocytic 
lineage (Fig. 3.8F), suggesting a pro-neurogenic differentiation pattern in 
response to Bmi1-OE. Therefore, these results indicate that Bmi1-OE in PML 
controls cells partially phenocopies PML loss in NSCs. Despite these 
preliminary data, we were unable to confirm Bmi1 upregulation in subsequent 
experiments performed using new aNSC preparations (Appendix 6. C; further 
discussed below).  
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Figure 3.8: Role of Bmi1 downstream PML loss is unclear. 
(A) Representative WB validation of Bmi1-overexpression (OE) in PML control cells at 
protein level. FUGW empty vector was used as control, and β-actin was used as 
loading control. (B) qPCR analysis revealed Bmi1-OE in PML control cells. Values 
represent mean ± SEM (n = 3; *p < 0.05, unpaired t-test). (C) qPCR analysis revealed 
an unexpected pattern of Bmi1 target genes. Values represent mean ± SEM (n = 3; *p 
< 0.05, unpaired t-test). (D) Edu assay demonstrated that no difference in proliferation 
was found upon Bmi1-OE. Values represent mean ± SEM (n = 3; n.s. non significant 
unpaired t-test) (E) Bmi1-OE led to elevated level of γH2AX foci formation (>10 foci). 
(F) Differentiation assay revealed Bmi1-OE results in more neuronal specification, 
while no difference was observed in astrocytic-lineage production. Values represent 
mean ± SEM (n = 3; **p < 0.01, n.s.= non significant, unpaired t-test). 
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3.10 Discussion 
As an oncogene, overexpression of Bmi1 has been reported in a number of 
different tumours, including human medulloblastomas, breast cancer, prostate 
cancer, lung cancer, and myeloid leukaemia (Vonlanthen et al. 2001; Kim et al. 
2004; Leung et al. 2004; Sawa et al. 2005). Importantly, increasing evidence 
suggests that Bmi1 contributes to the maintenance, and self-renewal of stem 
cells, in particular, neural stem cells (Lessard and Sauvageau 2003; Molofsky 
et al. 2003; Fasano et al. 2009). Moreover, a recent study proposed the 
possibility to target cancer-initiating cells self-renewal machinery by inhibiting 
Bmi-1 to achieve abrogation of their tumourigenic potential (Kreso et al. 2014). 
Because it has been proposed that brain cancers arise from multipotent neural 
stem cells (Singh et al. 2004; Sanai et al. 2005; Vescovi et al. 2006), targeting 
the subpopulation cells with “stemness” would be an effective therapeutic 
strategy. The present study assessed whether Bmi1 contributes to the 
phenotypes caused by PML loss, by overexpressing Bmi1 in control aNSCs to 
firstly determine whether it could phenocopy PML loss. Contrary to 
expectations, Edu assay revealed no effect in cell proliferation. Moreover, the 
known Bmi1 targets CDKi that have roles in neurogenesis were found 
upregulated upon Bmi1-OE. This finding is in contrast to a study, which has 
revealed increased Bmi1 (~2 fold) expression in NSCs promotes proliferation 
(Yadirgi et al. 2011). However, a recent study has demonstrated that Bmi1 
overexpression in granule cell progenitors leads to decreased proliferation 
(Behesti et al. 2013), and this decrease may due to the induction of 
compensatory mechanisms to counteract oncogenic Bmi1 overexpression. 
Given the gene expression pattern upon Bmi1-OE observed in the present 
study, where CDKi p16Ink4a, p21Cip1, and p57Kip2 were found derepressed in 
response to Bmi1-OE, it is plausible to suggest that sustained oncogenic Bmi1 
expression activates compensatory effects, partially by upregulation of CDKi to 
attenuate tumourigenic potential. In addition, elevated γH2AX foci formation 
(>10 foci) was found in cells overexpressing Bmi1 compared to control, 
mimicking the effect of PML loss (Joanne Betts, data not shown). As discussed 
previously, an increased γH2AX level may be linked to replication-induced 
stress. However, if no difference in proliferation upon Bmi1-OE is considered, 
induction of γH2AX foci may not due to the replication stress. Indeed, a study 
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has reported that Bmi1 overexpression per se leads to more γH2AX foci 
formation (Acquati et al. 2013). Additionally, although γH2AX foci can be 
established in as short as 30 minutes after DSB formation (Rogakou et al. 
1999), a study conducted by Kinner et al (2008) suggests that γH2AX foci 
remain elevated even after DSBs have been rejoined. This finding is consistent 
with a study demonstrating that after irradiation, Bmi1 was found enriched at 
chromatin, and colocalised with ATM, and γH2AX (Facchino et al. 2010). 
Similarly, additional studies are needed for instance, using ATM inhibitor, to 
demonstrate that Bmi1-OE leads to DSBs. Importantly, the differentiation assay 
conducted in the present study revealed an interesting pattern. Given that 
Bmi1-OE triggers increased neuronal production, even though preliminary, this 
finding suggests that this differentiation pattern might function as another 
counteractive mechanism to attenuate the Bmi1-induced oncogenic 
transformation. Contrary to expectations, it ultimately appears that Bmi1 
overexpression in PML control cells only partially mimics PML loss. Ideally, 
additional studies should be carried out in the context of Bmi1-knockdown in 
PML KO cells to investigate whether it phenocopies PML control cells. 
Unfortunately, gene expression analysis has revealed that in other preparations 
of aNSCs, no difference was found with regard to Bmi1 expression level 
between PML+/- and PML-/- cells (Appendix 6. C), suggesting that this pathway 
may not be a relevant downstream target of PML. Therefore, the present 
research focusses on the investigation of mechanisms underlying Twist1, and 
Slit/Robo regulation downstream PML.  
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3.11 PML regulates Twist1/Slit2/Robo1 via Polycomb Repressive 
Complex 2-mediated repression 
Findings previously discussed have demonstrated that Twist1 and Slit2/Robo1 
are part of a PML-controlled pathway for regulation of cell migration in aNSCs. 
Therefore, the question as to how PML regulates these genes is an interesting 
one to pose. Notably, experiments employing acute PML gene loss (see 
above) demonstrate that while Slit2 is upregulated 5 days after 4-OHT 
treatment (Fig. 3.9A), Twist1 was clearly induced at 14 days (Fig. 3.9B). These 
data suggest that Twist1 is not the primary regulator of Slit2, and it could be 
rather part of an amplification loop, as overexpression of Twist1 in PML+/- cells 
is sufficient to induce Slit2/Robo1 albeit at a lower extent than in PML-deficient 
cells (Fig. 3.9C). It has been reported that prolonged EZH2 depletion in GBM 
leads to upregulation of Twist1 (de Vries et al. 2015). Moreover, Slit2 has been 
reported to be repressed by EZH2 in prostate cancer (Yu et al. 2010). 
Intriguingly, Twist and Slit family members are derepressed upon cerebellar 
EZH2 deletion (Feng et al. 2016). Finally, EZH2 has been demonstrated to 
interact with PML-RARα (as well as PML itself) fusion protein (Villa et al. ; Villa 
et al. 2007). Thus, it is conceivable to hypothesise that PML could regulate 
expression of Twist1 and Slit2/Robo1 via an epigenetic mechanism involving 
PRC2.  
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Figure 3.9: A Twist1-mediated amplification loop for induction of Slit2 upon PML 
loss in aNSCs.   
(A) Slit2, not Twist1, was found upregulated upon acute loss (5-day post-4-OHT 
treatment) (n = 1). (B) Following prolonged incubation (one additional week+5-day 
post 4-OHT treatment), Twist1 was found upregulated after Slit2 upon PML loss (n = 
1). (C) Overexpression of Twist1 in PML control cells led to no induction of Slit2, and 
Robo1 (n = 1). Experiments were carried out in cultured aNSCs. Same PML 
conditional KO system was employed as described in Fig. 3.4. 
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Figure 3.10: Twist1, Slit2 and Robo1 are PRC2 targets and PML loss affects 
H3K27me3 levels at their promoters.  
(A) GSK-343 treatment revealed decreased total H3K27me3 level in PML+/- cells. 
DMSO was used as treatment control. (B) qPCR analysis revealed derepression of 
Ezh2 targets, Twist, Slit2, and Robo1 in response to GSK-343 treatment. Values 
represent mean ± SEM (n = 3; *p < 0.05; **p < 0.01, unpaired t-test). (C) ChIP-qPCR 
analysis revealed significantly less H3K27me3 enrichment at the promoter regions of 
target genes. Values represent mean ± SEM (n = 3; *p < 0.05; **p < 0.01, unpaired t-
test). (D) ChIP-qPCR analysis revealed increased H3K4me3 enrichment at the 
promoter regions of target genes. Values represent mean ± SEM, (n = 3). 
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To first establish the link between PRC2 and the genes of interest, the 
pharmacological agent GSK-343 was used, which is a highly-selective, and 
potent inhibitor of EZH2 (Verma et al. 2012). As expected, treatment of PML+/- 
cells with GSK-343 led to reduced total H3K27me3 levels compared to DMSO-
treated controls (Fig. 3.10A). Notably, Twist1, Slit2, and Robo1 were found 
upregulated after 48 hours of treatment (Fig. 3.10B). Furthermore, PML acute 
loss didn’t result in Twist1 upregulation (Fig. 3.9A), suggesting Twist1 is not 
the direct target of PML. It could be that PML loss leads to reduced PRC2 and 
H3K27me3 mark, which results in immediate de-repression of Slit2 (Fig. 
3.9A&B). Slit2 will then in turn promotes Twist1 expression, favouring cells that 
overexpress Twist1 and this is further stabilised by the reduced H3K27me3 
mark. The is in line with the data that GSK-343-induced de-repression of 
Twist1 was slower than Slit2 (Fig. 3.10A&B), indicating a positive feedback 
loop between Twsit1 and Slit2. 
Secondly, it was evaluated whether PML loss affected H3K27me3 levels at the 
promoter regions of Twist1, Slit2, and Robo1 by chromatin immunoprecipitation 
(ChIP)-qPCR using primers specific for the respective promoter regions (see 
Table 10; primers were validated using UCSC Genome Browser showing 
overlapping CpG islands, Appendix 6. D). Indeed, PML loss led to reduced 
H3K27me3 enrichment at gene promoter regions of these genes (Fig. 3.10C). 
This reduction correlated with increased levels of the Trithorax-dependent 
H3K4me3 mark (albeit not statistically significant) (Fig. 3.10D), correlating with 
the transcriptional activation of these genes.  
To provide insights into the underlying mechanisms of this effect, the 
expression levels of the two core PRC2 components, EZH2, and SUZ12 were 
analysed. As mentioned in Introduction (page 50), EZH2 is the catalytic 
component of PRC2 for establishing H3K27me3 mark and it regulates 
expression of developmental genes, whereas SUZ12 is required for the activity 
and stability of PRC2 complex (Cao and Zhang 2004; Lund and van Lohuizen 
2004; Pasini et al. 2004; Kouzarides 2007). Findings revealed that EZH2, the 
catalytic subunit of PRC2 was downregulated at the protein level in PML-/- cells 
compared to PML+/- cells (not mRNA, Appendix 6. E) (Fig. 3.11A). Although 
no difference was found at protein level (data not shown), SUZ12 mRNA was 
found downregulated upon PML loss in two genetic models (Appendix 6. E). 
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Reduced EZH2 levels are expected to lead to a global decrease in H3K27me3, 
and H3K27me3 levels were indeed reduced in PML-/- cells compared to PML+/- 
cells (Fig. 3.11A). No differences were detected with regard to global 
H3K27Ac, and H3K4me3 levels (Valeria Amodeo, Fig. 3.11B). This global 
reduction pattern of H3K27me3 was further corroborated using 
immunofluorescence (Fig. 3.11C), and by utilising PML conditional KO system 
upon acute PML loss (Fig. 3.11D). Based on previous studies reporting an 
interaction between PML and EZH2 (Villa et al. 2007), we speculate that PML 
may directly interact with EZH2 in aNSCs, and in turn affecting its stability. This 
hypothesis is currently under investigation, but initial experiments have failed to 
detect an interaction between PML, and either EZH2, or SUZ12 in human 
glioblastoma cells (Valeria Amodeo, unpublished). 
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Figure 3.11: PML loss affects PRC2 component and H3K27me3 levels 
globally.   
(A) Representative WB revealed reduced total H3K27me3 level as a result of reduced 
Ezh2 protein level in PML-/- cells compared to PML+/- cells. H3 was used as histone 
loading control. (B) WB analysis revealed that no differences were found in H3K27Ac, 
and H3K4me3 levels in PML-/- cells compared to PML+/- cells. H3 was used as histone 
loading control.  (C) Representative images of reduced H3K27me3 in PML-/- cells by 
immunofluorescence staining. (D) WB analysis demonstrated reduced H3K27me3 
upon acute PML loss in response to 4-OHT treatment. H3 was used as histone loading 
control. (E) WB revealed inhibition of JMJD3, and UTX in PML-/- cells using GSK-J1 
rescued H3K27me3 levels compared to EtOH-treated control cells. Cells were treated 
with GSK-J1 (50nM) and EtOH for 48 hours, and H3 was used as histone loading 
control. (F) qPCR analysis revealed that Slit2 expression was found reduced upon 
GSK-J1 treatment in PML-/- cells. Values represent mean ± SEM (n = 3; **p < 0.01; 
***p < 0.001; one-way ANOVA, and unpaired t-test). Note, experiments in (B), (E) and 
(F) were performed by Valeria Amodeo.  
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Based on these findings, it was investigated whether changes in H3K27me3 
are responsible for the observed transcriptional activation of the Slit2 gene. 
Therefore, together with Valeria Amodeo in the lab, the GSK-J1 compound was 
used, which inhibits both JMJD3, and UTX, the demethylases of H3K27me3 
(Kruidenier et al. 2012; Heinemann et al. 2014). GSK-J1 treatment in PML-/- 
cells increased H3K27me3 levels (Fig. 3.11E), and accordingly, significantly 
reduced Slit2 expression (Fig. 3.11F). Ultimately, these results suggest that 
PML regulates Slit2 expression through modulation of H3K27me3 levels.  
To further corroborate these findings, a paediatric GBM-associated H3.3K27M 
mutant histone variant was used, and as discussed in the Introduction, leads to 
global reduction of H3K27me3 levels by inhibiting EZH2 enzymatic activity 
(Schwartzentruber et al. 2012; Bender et al. 2013; Chan et al. 2013; Lewis et 
al. 2013). To establish this system, NSCs derived from 15-day and 6-month old 
mice were transduced, with H3.3K27M, wild type (WT) H3.3, and control GFP. 
This model was used to further study the correlation between H3K27me3 and 
Slit2. A global reduction of H3K27me3 levels was observed in H3.3K27M-
transduced NSCs in comparison to WT H3.3 and empty vector (Appendix 5. 
A). In response to reduced global H3K27me3 levels (Valeria Amodeo, 
Appendix 5. A), Slit2 was found upregulated in H3.3K27M-expressing cells 
(Valeria Amodeo, Appendix 5. B). Interestingly, this effect was also observed 
in WT H3.3 cells, suggesting that both WT and mutant H3.3 can promote Slit2 
upregulation potentially by different mechanisms (further discussed below). 
According to the effect on Slit2 expression, both WT H3.3 and H3.3K27M 
significantly impaired migration, and this effect was not further amplified in 
PML-/- cells (Valeria Amodeo, Appendix 5. C). 
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3.12 Discussion 
The present study demonstrates that the EMT master regulator Twist1, and 
axon guidance genes Slit2/Robo1 may underpin the effect of PML loss on 
aNSC migration. Although in germline PML KO cells, all these genes were 
upregulated, Twist1 appeared to be induced later than Slit2 upon acute PML 
loss (Fig. 3.9A&B), suggesting that Twist1 regulates Slit2 as part of an 
amplification loop rather than a main mechanism. Therefore, it is important to 
determine the mechanism by which PML regulates their expression levels. 
Interestingly, Twist1, and Slit2 are targets of PRC2 (Yu et al. 2010; de Vries et 
al. 2015), and PML has been demonstrated to interact with PRC2 (Villa et al. 
2007). Interestingly, a recent study reported that Twist1, and Slit family 
members are targets of EZH2 in embryonic cerebellum (Feng et al. 2016), 
reinforcing the link between PRC2 and Twist1/Slit2, and their involvement in 
CNS neurogenesis. Finally, PRC2 has been implicated in regulating CNS 
neurogenesis in the embryonic and adult brain (Hirabayashi et al. 2009; Pereira 
et al. 2010; Hwang et al. 2014; Yao and Jin 2014; Zhang et al. 2014), and 
radial neuronal migration in cerebral cortex (Zhao et al. 2015). Therefore, it is 
plausible to consider PRC2 in this respect. Indeed, all the genes investigated in 
the present study were found to be targets of PRC2, and PML loss resulted in 
decreased levels of H3K27me3 at the promoter regions of these genes, 
suggesting that PML regulates Slit2 via PRC2. In this respect, findings in the 
present study demonstrate that in PML-/- cells, EZH2 protein levels were 
reduced, which correlated with a global decrease in H3K27me3 (Fig. 3.11A). 
This finding provides an epigenetically controlled mechanism by which 
alteration of PRC2 component, and H3K27me3 downstream PML could affect 
the expression levels of transcriptional programmes that are key to regulating 
cell migration in the adult CNS. We are currently investigating the composition 
of the PRC2 complex to determine whether PML loss only affects EZH2 levels, 
or more generally the stability of the complex (Cao and Zhang 2004; Pasini et 
al. 2004). Furthermore, it would be important to study EZH2, and H3K27me3 
genome-wide in PML-deficient cells using ChIP-Seq, as this investigation could 
provide important insights into the actual impact of PML loss on their chromatin 
enrichment. Furthermore, PML has been reported to be associated with 
chromatin, although this claim is debated (P et al. 2007). In this respect, PML 
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binds matrix-associated regions in the genome. Therefore, it might also be 
informative to attempt PML qPCR or ChIP-Seq. However, availability of 
antibodies could be an issue given the potentially low affinity of PML for 
chromatin or the transient nature of these interactions. Based on preliminary 
data in the lab, PML does not seem to associate with the promoter region of 
Slit2 by using a commercially available antibody. 
Further experimental investigations are also needed with respect to the 
relationship between Twist1 and EZH2, as one study has reported a 
contradictory finding that in bone marrow-derived mesenchymal stem cells, 
Twist1 induces EZH2, in turn leading to increased H3K27me3 (Cakouros et al. 
2012). Based on our data, and existing literature, it is tempting to investigate if 
Twist1-KD/Twist1-OE affects the stability of PRC2, and in turn the levels of 
H3K27me3, which would allow determination of whether a complex feedback 
loop exists.   
More work could also be conducted using in vivo models. For instance, a 
previously described EZH2 conditional KO line could be used to assess 
whether EZH2 loss affects Slit/Robo, and phenocopies the changes caused by 
PML loss in adult neurogenesis. In addition, a study has revealed that selective 
EZH2 inhibition via ZLD1039 potently blocks H3K27me3, and this drug can be 
delivered through oral gavage in mice (Song et al. 2016). Based on this finding, 
treatment could be carried out to determine if EZH2 inhibition mimics PML loss. 
Finally, to further corroborate these findings, GSK-J1 inhibitor treatment in 
PML-deficient mice may allow us to determine if a rescue of H3K27me3 levels 
could revert phenotypic changes caused by PML loss.  
Finally, experiments based on the expression of H3.3K27M in aNSCs suggest 
that H3.3K27M-mediated inhibition of EZH2 leads to Slit2 upregulation, and 
reduced invasion. EZH2 is found highly expressed in a number of human 
cancers (Varambally et al. 2002; Bracken et al. 2003), and therefore, inhibition 
of EZH2 has been reported to exert tumour suppressive effects (Fiskus et al. 
2006; Tan et al. 2007; Wilson et al. 2010). This finding is contrary to its effect in 
paediatric tumours, in which K27M is associated with marked invasion through 
brain parenchyma. However, it was observed in the present study that Slit2 
was also induced in WT H3.3-expressing cells, which may due to the reported 
H3.3 enrichment in H3K4me3, as well as in other active marks (Loyola et al. 
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2006). Interestingly, a recent study has demonstrated that the width of 
H3K4me3 is associated with tumour suppressor activity (Chen et al. 2015). 
More specifically, broad H3K4me3 correlates with increased transcription 
elongation, and enhancer activity, including at the Slit2 locus in lung tissue 
(Chen et al. 2015). The trend of greater H3K4me3 levels at the Slit2 promoter 
in PML-deficient aNSCs suggest that this could be a mechanism contributing to 
Slit2 upregulation following a drop in H3K27me3 levels. Of note, loss of PML 
and H3.3K27M have cumulative effect on Slit2 expression, suggesting that 
Slit2 derepression in PML-/- cells is not solely due to a H3.3K27M-induced loss 
of H3K27me3. Likewise, H3.3K27M could act via a different mechanism as 
H3.3WT on Slit2 induction. Therefore, I believe it would be worth testing this 
hypothesis in future research.  	 	
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4 Discussion and Conclusions 
This project set out to determine the role of PML in regulation of adult SVZ/OB 
neurogenesis and cell migration. Control of cell cycle and cell migration 
underpins neurogenesis during development as well as in adulthood. This 
study has shown that PML loss results in reduced OB size and it affects aNSC 
migration in vitro. Our work has identified that PML controls cell migration in 
aNSCs through transcriptional control of the axon guidance gene Slit2 
independently of its ability to regulate cell cycle. My data suggest that PML 
represses Slit2 via control of the repressive mark H3K27me3. Furthermore, I 
found that the EMT factor Twist1 contributes to regulation of Slit2 downstream 
PML and PRC2, revealing a previously unknown feedback loop for control of 
cell migration in aNSCs.  
 
PML controls OB size 
The present study shows that PML loss results in reduced number of slow-
proliferating aNSC and increased entry into differentiation. However, PML loss 
impairs neuroblast migration in RMS and leads to a smaller OB size. Further 
work could be carried out in the future on the OB phenotype (see also 3.1 
Discussion). There exists a considerable degree of heterogeneity of OB 
interneuron subtypes. However, it is known that the production of diversity OB 
interneuron subtypes is not simply occurring at the time migrating neuroblasts 
entering the OB. This heterogeneity is derived from the aNSC niche itself, and 
different regions within the SVZ give rise to defined OB interneuron subtypes 
(Merkle et al. 2007; Alvarez-Buylla et al. 2008; Merkle et al. 2014). In this 
respect, our study leaves a number of specific questions unanswered: i) What 
subtype of aNSCs does PML affect? ii) If so, does it correlate to the generation 
of a specific OB neuron subtype and ultimately the OB size phenotype? To this 
end, we can utilize the mouse model of glutamate-aspartate transporter 
(GLAST) promoter (GLAST-CreERT2) (Mori et al. 2006; Ninkovic et al. 2007; 
DeCarolis et al. 2013; Benedykcinska et al. 2016) crossing to the Confetti 
multicolour Cre reporter as established recently (Calzolari et al. 2015), enabling 
us to target and follow the progeny of single aNSC in long-term. This will 
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provide us with more insight into the role of PML in regulating stem cell fate 
and lineage specification in adult CNS. 
 
A novel PML/Slit2 axis for regulation of adult neurogenesis  
Our work showed the first time that Slit2 has a role in inhibition of cell migration 
in SVZ-derived aNSCs downstream PML. In contrast, Slit1 is not regulated by 
PML and fails to affect cell migration in aNSCs. A previous study reported that 
Slit1, not Slit2, exerts chemorepulsive function in adult RMS migration 
(Nguyen-Ba-Charvet et al. 2004). However, we cannot rule out the possibility 
that Slit functions are context-dependent and cell type-specific, as the 
abovementioned study reported that Slit1 is itself expressed in type A cells 
along the RMS (Nguyen-Ba-Charvet et al. 2004). In this respect, we have not 
studied the respective levels of Slit1 and Slit2 during differentiation in our 
model system. Future experiments can be carried out to study the expression 
of Slit proteins in more committed cells along RMS in control and PML-deficient 
brains, as this will provide hints on whether a transition/switch of Slit proteins 
occurs throughout the SVZ-OB route and what is PML role in their regulation 
depending on the differentiation stage. Such experiments are being designed in 
the lab to study the expression of Slit1 and Slit2 in neuroblast cells first in vitro 
(O'Leary et al. 2015) and then in vivo. 
We showed in the present study that Slit2 binds to its cognate receptor Robo1 
to inhibit aNSC migration in a collective fashion. It is known that the Slit2-
Robo1 signalling pathway negatively regulates Cdc42 activity and cell 
cytoskeleton remodelling (Wong et al. 2001). Mechanistically, Slit2 binds to 
Robo1 receptor, which in turn activates the Slit-Robo Rho GTPase-activating 
protein 1 (srGAP1), resulting in inactivation of GTPase Cdc42, activation of 
another GTPase RhoA and ultimately decreased actin polymerization and cell 
migration (Wong et al. 2001; Yiin et al. 2009; Sit and Manser 2011). In my 
study, no difference was observed with respect to cytoskeleton following F-
actin staining between PML control cells and PML-/- cells (data not shown). 
However, further work is needed to more thoroughly examine the changes in 
cytoskeleton upon PML loss, as well as the mode of migration. Similar to the 
glial-dependent neuronal migration in the cerebral cortex, chain migration of 
neuroblasts in anterior SVZ requires nuclear-centrosome coupling (Wong et al. 
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2001; Schaar and McConnell 2005). In this respect, neuronal migration occurs 
via repetition of two key events: 1) leading process extension, and 2) 
movement of the cell body and translocation of the nucleus (Tsai and Gleeson 
2005). Interestingly, the positioning of centrosome in the leading process and 
the subsequent nuclear translocation toward the centrosome constitutes the 
key feature of migration, since alteration in these two sub-events has been 
linked to a cell migration defect (Solecki et al. 2004; Tanaka et al. 2004; 
Koizumi et al. 2006). Based on these studies, future experiments could be 
designed by measuring the distance between nucleus and centrosome to 
assess the nuclear translocation ability, as defects in nuclear translocation 
have been implicated in migration defect in adult forebrain (Koizumi et al. 
2006), and especially given that Slit-Robo-induced Cdc42 inactivation results in 
leading process shortening (Wong et al. 2001). 
Here in this study, we showed that Slit2 expression is regulated downstream 
PML/PRC2. However, it remains unclear how PML affects the expression or 
stability of PRC2. As discussed earlier, histone chaperone H3.3 interacts with 
PRC2 (see Introduction) and it has been implicated in the recruitment of PRC2 
to developmental gene promoters (Banaszynski et al. 2013). Work from our lab 
has shown that PML-interacting protein DAXX is responsible for H3.3 loading in 
CNS (Michod et al. 2012). Thus, it is plausible to speculate that PML regulates 
PRC2 via H3.3. Indeed, our unpublished work (Valeria Amodeo) shows that 
PML loss leads to increased H3.3 expression and loading at Slit2 promoter in 
aNSCs. Based on these studies and our findings, future experiments could be 
carried out by knockdown of H3.3 in PML-deficient cells to determine if it 
phenocopies PML control cells.   
In addition to controlling cell migration of aNSC downstream PML, Slit2 could 
also regulate SVZ neurogenesis via additional mechanisms. In this respect, 
Slit2 has been implicated in angiogenesis, but, like PML Slit2 exerts a dual role 
in this process. It either promotes (Kaur et al. 2008; Urbich et al. 2009; Yang et 
al. 2010b; Rama et al. 2015) or inhibits angiogenesis (Liu et al. 2006b; Jones et 
al. 2008; Jones et al. 2009). Of note, two independent studies have shown that 
aNSCs within SVZ are tightly apposed to blood vessels during homeostasis 
and regeneration, and that SVZ neurogenesis occurs near blood vessels (Shen 
et al. 2008; Tavazoie et al. 2008). Work from our group and others have 
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implicated PML in suppression of angiogenesis via multiple mechanisms 
(Bernardi et al. 2006; Dvorkina et al. 2016). Based on these studies, it would be 
tempting to speculate that PML loss could affect the vascular structure of adult 
SVZ via regulation of Slit2 expression. This could in turn affect the spatial 
organization of the aNSC niche, potentially affecting aNSC behaviour and 
generation of OB neurons? For instance, we could use whole mount staining of 
brain sections from PML+/- and PML-/- mice to determine if PML loss affects the 
SVZ vasculature.  
Another avenue for future investigation is whether PML controls neurogenesis 
and migration in the context of other brain areas. In this respect, our lab has 
generated a large body of unpublished work implicating PML in regulation of 
cerebellar postnatal neurogenesis. Specifically, a previous postdoc, in 
collaboration with Dr Simonetta Pazzaglia (Rome, Italy) has shown that PML 
loss leads to increased proliferation of cerebellar granule cell progenitors 
(GCPs) in the external granule layer (EGL) and augmented entry into 
differentiation. This is however associated with decreased overall number of 
mature granule neurons in the inner granule layer (IGL). These changes were 
recapitulated in vitro using primary GCPs, where PML loss led to increased 
proliferation and spontaneous differentiation. This phenotype is reminiscent of 
the SVZ neurogenesis alterations found in PML KO adult brains. It would be 
interesting to determine whether a similar PML/Slit axis regulates migration 
and/or differentiation in the context of cerebellum development. In this respect, 
as our findings also showed that SHH signalling was reduced in PML KO 
GCPs, it could be speculated that Slits are involved in regulation of SHH 
signalling downstream PML. Interestingly, a previous report has shown that 
Slit2 inhibits SHH expression in the ventral neural tube (Wang et al. 2013). Vice 
versa, Gata3 positively modulate the expression of Slit2 (Liu et al. 2014). 
Further work is needed to fully dissect the role of PML during cerebellar 
development.  
 
A novel role of Twist1 in regulation of adult neurogenesis 
This study has demonstrated, for the first time, that Twist1 is expressed at very 
low levels in aNSCs, but it is markedly induced by PML loss to regulate Slit2 
expression, cell migration and cell proliferation. However, in aNSCs Twist1 
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appears to inhibit cell migration, challenging its canonical role in promoting cell 
migration/invasion. Interestingly, Twist1 shares commonalities with another 
member of the bHLH family, Ascl1, which is expressed in aNSCs with respect 
to cell cycle progression and cell proliferation (see 3.8 for further discussion).  
A recent study has suggested that Twist1 is involved in regulation of 
metabolism. Specifically, Twist1 negatively regulates fatty acid metabolism 
(FAO) in mice via regulation of PGC1A target genes (Pan et al. 2009).  Of note, 
in HSCs and breast cancer cells, a PML/PPA-δ/FAO metabolism pathway has 
been shown to promote stem cell maintenance through promotion of 
asymmetric over symmetric division (Carracedo et al. 2012; Ito et al. 2012). 
Accordingly, pharmacological inhibition of FAO phenocopies PML loss, 
resulting in HSC exhaustion (Ito et al. 2012). Given that PML loss leads to 
upregulation of Twist1, one could speculate that the elevated Twist1 
expression inhibits PPA-δ/FAO pathway, thus in turn leading to stem cell 
exhaustion in the adult SVZ. We are currently assessing i) whether the 
expression of PGC1A target genes is affected in PML-deficient aNSCs, ii) if 
these changes are reverted upon Twist1 knockdown and iii) if Twist1-OE in 
control cells phenocopies PML loss. If indeed some of the PGC1A target genes 
appear to be regulated by a PML/Twist1 axis, we plan to determine whether 
PML/Twist1-mediated control fatty acid metabolism could plays a role in aCNS 
neurogenesis. Finally, it would be important to investigate whether Slit2 could 
be involved in FA metabolism as well.  
 
PML represses Slit1 (not Slit2) in neoplastic settings 
This part is mainly the work of Valeria Amodeo and Joanne Betts, in 
collaboration with Sebastian Brandner (UCL Institute of Neurology) and Chris 
Jones’ (Institute of Cancer Research, Sutton) lab. I contributed to this part 
intellectually and provided relevant cells and reagents. As discussed in the 
Introduction, it is well established that one of the key features of brain cancer 
cells is their ability to invade the brain parenchyma. Notably, brain cancer share 
migration routes with normal neuroblasts, suggesting that brain cancer 
migration has neurobiological roots (Cuddapah et al. 2014). Therefore, it was 
tempting to speculate whether a PML/Slit axis could regulate cell migration 
upon neoplastic transformation of aNSCs as well as in GBM cells derived from 
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established tumours. As mentioned in the Introduction, PML mediates induction 
of cellular senescence downstream oncogenic RAS. However, given recent 
studies reporting an oncogenic function of PML (Ito et al. 2008; Carracedo et 
al. 2012; Ito et al. 2012), it could be postulated that PML mediates RAS 
oncogenic functions as well. To determine the role of PML in the context of 
RAS-induced transformation, we utilised a H-RASV12-IRES-GFP (OncRAS) 
model described before (Bartesaghi et al. 2015). Notably, we found that i) PML 
expression was increased in response to OncRAS (Appendix 7. Fig 6B) and 
ii) PML loss impaired migration of OncRAS-transformed aNSCs (Appendix 7. 
Fig 6C). Notably, Slit1, not Slit2, was found to be the target for PML-mediated 
repression upon RAS-driven transformation (Appendix 7. Fig 6D). 
Furthermore, Slit2 was downregulated, suggesting a positive role of PML in 
regulation of Slit2 expression in neoplastic cells. To assess the involvement of 
PML in mediating RAS-driven transformation in vivo, injection of OncRas-
transformed PML+/- and PML-/- aNSCs into NOD-SCID mice was performed. 
Notably, PML loss delays RAS-driven oncogenesis in orthotopic xenografts 
(Appendix 7. Fig 6F) and impairs invasiveness into adjacent brain tissue 
(Appendix 7. Fig 6H). Given that PML/Slit axis also controls cell migration in 
neoplastic transformation (OncRAS-transformed aNSCs), we investigated the 
PML/Slit axis in GBM, as RAS/MAPK activation is believed to contribute to the 
development of a subset of GBM tumours (see Introduction). We first studied 
the expression of PML and SLIT/ROBO members in relation to known GBM 
molecular subtypes using existing datasets. Interestingly, PML was found 
highly expressed in GBM tumours belonging to the mesenchymal subtype 
(Appendix 7. Fig 7A), which is characterised by loss of the RAS inhibitor NF1 
and by an invasion/angiogenesis gene expression signature. Furthermore, 
PML expression was found inversely correlated with SLIT1 (Appendix 7. Fig 
7B), whereas it directly correlated with SLIT2 (Appendix 7. Supplementary 
Fig 6B), in accordance with the expression pattern observed in PML-deficient 
OncRAS-transformed aNSCs. Finally, PML expression directly correlated with 
tumour stage and was associated with poor prognosis (Appendix 7. Fig 7E, 
Supplementary Fig 6D&E).  
We then set out to determine whether PML regulates cell migration in primary 
GBM cells. PML was expressed at variable levels across a panel of primary 
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GBM cells (Appendix 7. Fig 7F). Notably, PML-KD in PMLHIGH G2 cells 
(Appendix 7. Fig 7G) led to reduced migration (Appendix 7. Fig 7H), which 
was associated with SLIT1 upregulation (Appendix 7. Fig 7I&L). In contrast, 
SLIT2 was downregulated upon PML-KD, suggesting that like in OncRAS-
transformed aNSCs, SLIT1 (not SLIT2) is the main target of PML in GBM. 
Conversely, overexpression of the PML-I isoform in PMLLOW G1 cells promoted 
cell migration, whilst it represses SLIT1 expression and enhanced SLIT2 
expression (Appendix 7. Fig 7N&O). Finally, the PRC2 components EZH2 and 
SUZ12 were reduced upon PML-KD (Appendix 7. Fig 7L), in accordance with 
the reduced H3K27me3 enrichment at SLIT1 promoter and decreased global 
H3K27me3 levels (Appendix 7. Fig 7K&M). In contrast, an elevated 
H3K27me3 enrichment was found at the SLIT2 promoter (Appendix 7. 
Supplementary Fig 6G), correlating its reduced expression in response to 
PML-KD. Our findings reveal a “switch” from SLIT2 to SLIT1 upon PML loss or 
PML-KD, suggesting that in neoplastic transformation, SLIT1, not SLIT2, is the 
main target of PML. This correlates with the H3K27me3 enrichment levels at 
the promoter regions of SLIT1 and SLIT2. Moreover, a similar regulation of 
PRC2 and H3K27me3 levels downstream PML was observed in GBM cells, 
whereby PML-KD impairs EZH2 and accordingly the H3K27me3 mark globally. 
There are several hypotheses that could be postulated to explain the observed 
‘switch’, but I am now discussing one in particular, which I feel to be more 
plausible. It is possible that RAS signalling could redistribute PRC2 and 
H3K27me3 from SLIT2 to SLIT1, potentially because SLIT2 might be unable to 
repress invasion in GBM and/or potentially have pro-tumourigenic functions 
such as increasing proliferation and/or promoting angiogenesis, as suggested 
in the literature (Kaur et al. 2008; Urbich et al. 2009; Yang et al. 2010b; Rama 
et al. 2015; Secq et al. 2015). In this context, PML downregulation via inhibition 
of PRC2 leads to SLIT1 derepression and inhibition of invasion. How could 
PML loss negatively affect SLIT2 expression? One could speculate that in 
GBM cells SLIT1-dependent signalling could lead to inhibition of SLIT2 
expression, as part of a negative feedback loop existing between different SLIT 
family members, which could be in place to control the ‘SLIT burden’ in the cell. 
To test this hypothesis, I could first examine whether recombinant SLIT1 
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(rSLIT1) could repress SLIT2 and whether a decoy ROBO2 receptor (assuming 
that it would not bind SLIT2) or SLIT1 KD could result in derepression of SLIT2.  
More generally, these findings suggest that contrary to paediatric brain tumours 
(Bender et al. 2013; Chan et al. 2013; Lewis et al. 2013), PRC2 and 
H3K27me3 may play an oncogenic role in adult GBM, as suggested by other 
studies. In adult settings, PML would represent a novel regulator of PRC2 
function in both normal and cancer settings. In this respect, our findings reveal 
that PML expression increases with tumour grade and positively correlates with 
poor prognosis. Moreover, experiments in orthotopic animal model show that 
PML loss delays the tumourigenesis and impairs cell migration of OncRAS-
transformed aNSCs, suggesting an oncogenic role of PML in the adult CNS. 
This challenges the canonical tumour suppressive role of PML (Gurrieri et al. 
2004), as its protein expression is lost or reduced in a number of human 
tumours from different origins. However, these findings are in line with more 
recent evidence supporting a pro-oncogenic role of PML in CML and breast 
cancer (Ito et al. 2008; Carracedo et al. 2012). For instance, PML is found 
highly expressed in CML patients, and its expression level positively correlates 
with poor prognosis (Ito et al. 2008). These studies together with our findings 
reinforce the multifaceted role of PML in tumour and its complexity as a 
context-dependent factor. It is important to note that unpublished work in our 
group (Joanne Betts) has shown that PML is highly expressed in 
medulloblastoma, a tumour of the cerebellum. It would be interesting to 
determine whether it could play a similar pro-migratory role also in this tumour, 
which is often associated with invasion and in some instances spinal 
metastasis (Quenum et al. 2012; Zivkovic et al. 2014).  
Taken together, our work uncovers a previously unknown pathway that 
underpins cell migration in both physiological and neoplastic settings. Since 
PML can be degraded by As2O3 (see discussion in the Introduction), one could 
speculate that this pathway could be targeted pharmacologically in GBM. 
However, caution should be taken as more work is needed to better 
understand the precise molecular mechanisms underlying the function of the 
PML/SLIT axis in brain cancer.  
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Appendix 
 
 
 
 
 
Appendix 1 (Joanne Betts).  (A) An increased amount of pRb phosphorylation in 
PML-/- cells compared to PML control cells. (B) PML-knock-in (KI) in PML-deficient 
cells impaired pRb phosphorylation, and proliferation. (C) PP1α, and pRb colocalise in 
PML-NBs in PML control cells, whereas this colocalisation is abolished in PML-
deficient cells. (D) WB analysis revealed reduced p53, and p21 protein levels in PML-/- 
cells. γ-irradiation (1Gy) led to increased p53, and p21 protein levels. 
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Appendix 2 (Valeria Amodeo). (A) rSlit2 impairs NSCs cell migration. Values 
represent mean ± SEM (n = 3; *p < 0.05, **p < 0.01, ***P < 0.001; ****P < 0.0001, one-
way ANOVA, and unpaired t-test). (B) ECM assay revealed that Robo1N rescues the 
migration of PML-/- cells. PML+/-, and PML-/- cells were treated with rSlit2 (100 ng/mL) 
and/or with Robo1N (200 ng/mL). Values represent mean ± SEM (n = 3; **p < 0.01; 
***p < 0.001; ****p < 0.0001, one-way ANOVA, and unpaired t-test). rSlit1, 
recombinant Slit1; rSlit2, recombinant Slit2. 
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Appendix 3 (Valeria Amodeo). (A) WB revealed successful expression of SV40 LT in 
PML control, and PML-deficient cells. β-actin was used as loading control. EV, 
pLXSN-empty vector; SV40T, pLXSN-SV40 LT. (B) ECM assay revealed that SV40 LT 
did not impede migration in aNSCs. Values represent mean ± SEM (n = 3; ****p < 
0.0001, one-way ANOVA). (C) qPCR analysis demonstrated that Slit2 expression was 
not regulated by SV40 LT in PML control cells. Values represent mean ± SEM (n = 4; 
**p < 0.01; ****p < 0.0001, one-way ANOVA, and unpaired t-test). 
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Appendix 4 (Valeria Amodeo). (A) Transduction of SV40 LargeT was sufficient to 
induce proliferation in PML+/- cells. Values represent mean ± SEM (n = 3; *p < 0.05; 
**p < 0.01, one-way ANOVA) (B) A positive correlation between increased proliferation 
upon SV40 LargeT and γH2AX foci formation. Values represent mean ± SEM (n = 3; 
*p < 0.05, two-way ANOVA). 
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Appendix 5 (in coordination with Valeria Amodeo). (A) WB analysis revealed 
reduced global levels of H3K27me3 in H3.3K27M-transduced cells (cells derived from 
6-month old animals). Note that the global reduction of H3K27me3 in PML-/- cells is not 
visible in panel A. This may be due to viral transduction and subsequent cell sorting, 
as control experiment using non-transduced cells (data not shown, Valeria Amodeo) 
was able to see the reduction as shown in Fig. 3.11A (B) Slit2 expression was found 
increased in H3.3, and H3.3K27M-transduced PML+/-, and PML-/- NSCs. Values 
represent mean ± SEM (n = 5; *p < 0.05; **p < 0.01, one-way ANOVA, and unpaired t-
test). (C) ECM assay revealed that WT H3.3, and the mutant H3.3K27M significantly 
decreased the migration ability of PML+/- cells. No further effects were observed in 
PML-/- cells. Values represent mean ± SEM (n = 3; *p < 0.05, ***p < 0.001, one-way 
ANOVA). 
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Appendix 6. (A) Three different experiments demonstrating similar patterns of Slit2 
expression in PML RingMut cells. (B) Ascl1, and its target Ccnd2 were found 
upregulated in PML germline KO cells, but not in PML conditional KO cells (n = 1). (C) 
Bmi1 was not regulated by PML in aNSCs from different preparations. (D) Schematic 
illustration displays ChIP-qPCR primers amplifying promoter regions of genes of 
interest. Primers were validated in UCSC Genome Browser based on CpG island 
overlapping. (E) Ezh2 mRNA was found not to be affected by PML loss. However, 
Suz12 mRNA was found to be downregulated. 
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Appendix 7 (PML in neoplastic settings): 
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Appendix 8 (Cell reports, under revision) 
 
  
 
 
 
 
 
 
A PML/Slit axis controls physiological cell migration and 
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